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The European Randomized Study of Screening for Prostate Cancer 13
Prostate cancer is a major public health problem in the Western world; it is the most common 
type of cancer and the second leading cause of cancer deaths in men1. In the early 1990s 
evidence emerged that prostate-specific antigen (PSA), a glycoprotein produced practically 
exclusively by the prostate gland, could be used for the early detection of prostate cancer2-4.
In Belgium and the Netherlands plans originated for conducting a randomised screening 
study in order to evaluate whether population-based screening for prostate cancer is effec-
tive in decreasing prostate cancer mortality at an acceptable price in terms of quality of life 
and costs5. Screening aims to detect prostate cancers at an early stage, when these are still 
curable. After conducting two pilot studies to test the feasibility of such a large prospective 
randomised controlled trial6, 7, in December 1993 the European Randomized Study of Screen-
ing for Prostate Cancer (ERSPC) started. In total, more than 200,000 men have been recruited 
in eight European countries. A comparable screening trial is carried out in the United States: 
the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial8. The answer to the question 
whether screening for prostate cancer reduces prostate cancer mortality will probably be 
available in 2010. In the meanwhile, the evaluation of screening algorithms and tests used is 
ongoing and will form the basis of a possible national prostate cancer screening program.
In Rotterdam, the ERSPC study centre of the Netherlands, more than 40,000 men aged 
55-75 years were randomised to either the screening or control arm of the study. Participants 
in the screening arm were screened every 4 years by means of a serum PSA measurement, a 
digital rectal examination (DRE) and a transrectal ultrasonography (TRUS).
Until May 1997, a man with a PSA level of 4.0 ng/ml or higher or an abnormal result on DRE 
or TRUS was offered a lateralised sextant biopsy. TRUS was not shown to be a valuable test for 
the early detection of prostate cancer in a screening programme9-11. The value of DRE in the 
early detection of prostate cancer remained more controversial12-16. For this reason, DRE and 
TRUS were discontinued as an indication for biopsy and simultaneously the PSA threshold 
as a biopsy indication was lowered to 3.0 ng/ml9, 14. This change resulted in an overall 10% 
decrease in the rate of biopsies and in a very similar detection rate of 4.7% using the PSA 3.0 
ng/ml cut-off instead of the 5.0% rate using PSA>4.0 ng/ml and DRE/TRUS14. At the moment, 
14 years after the ERSPC was launched, the fourth screening round is in progress.
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sCreenInG for ProstAte CAnCer
Before discussing the main subject of this thesis, the digital rectal examination, the preva-
lence of prostate cancer and prostate cancer screening in general are addressed. The benefits 
and limitations of PSA, the most important screening test, are evaluated and several sugges-
tions for improving prostate cancer screening are mentioned.
The background - latent prostate cancer
Latent prostate cancer is defined as cancer not diagnosed during lifetime but found at au-
topsy or during the examination of the complete prostate, removed as a part of a cystopros-
tatectomy specimen for the treatment of bladder cancer.
Data available in literature provide background information about the prevalence of pros-
tate cancer in the age groups concerned. The reported autopsy studies have been carried out 
over a large period of time, the first one by Franks17 was reported in 1954, the most recent 
ones by Sakr in 199318. This latter study included victims of traffic accidents and showed that 
already in the fourth and fifth decade of life small foci of prostate cancer could be discovered 
in 27% and 34% of those autopsy cases.
The prevalence of prostate cancer is strongly dependent on age and, obviously, on pre-
parative techniques. Table 1 gives a review of literature data. The number of cases autopsied 
as well as the number and percentage of prostate cancers identified are indicated in decades 
of age. The data average out to 15%, 21%, and 26% in the sixth, seventh and eight decade. 
However, it may not be acceptable to calculate these averages, considering the great differ-
ences in preparative techniques that have been applied between these either prospective or 
clinical routine studies. Probably, data reported by Franks are most reliable because the most 
extensive examination of the removed prostates has been applied. He reported prevalence 
rates of 29% to 40% for the age groups 50 to 79. Most of the tumours identified in autopsy 
series are described as well-differentiated and small. The applied methods of histological 
grading are not comparable.
Table 1: Prevalence of prostate cancer at autopsy in men age 50-79 years and in men of all ages, including ages below 50 and above 79 
(given in the column ‘total’).
Age 50-59 Age 60-69 Age 70-79 Total (all ages)
N autopsy N PC 
(%)
N 
autopsy
N PC 
(%)
N 
autopsy
N PC 
(%)
N 
autopsy
N PC 
(%)
Franks17 38 11 (29) 53 16 (30) 70 28 (40) 210 69 (38)
Edwards et al.87 31 3 (10) 54 10 (19) 48 12 (25) 173 29 (17)
Andrews et al.88 38 2 (5) 39 7 (18) 22 7 (32) 142 17 (12)
Moore89 56 9 (14) 77 18 (23) 63 13 (21) 304 51 (17)
Holund90 23 2 (9) 56 7 (13) 93 24 (26) 223 50 (22)
Totals 186 27 (15) 279 58 (21) 296 77 (26) 1,052 216 (21)
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Contrary to the age-dependence seen in table 1, Breslow and co-workers found no age-
dependence in 350 latent, focal carcinomas identified in 1,327 autopsy cases in seven differ-
ent areas of the world. The frequency of small focal lesions amounted to about 12% and did 
not vary between areas of high and low incidence of prostate cancer19.
More precise information on currently applied prognostic factors such as tumour volume 
and Gleason grading is available from series of prostates removed with radical cystoprostatec-
tomy specimens. Such data are summarised in table 2.
It can be seen that the age ranges are comparable to those of the autopsy data. Probably 
due to more careful and prospectively planned reviews of the entire prostatic specimens the 
prevalence numbers are high and are in the range of those reported by Franks. Sixty-three to 
100% of the cancers identified have been assigned Gleason scores below 7. Up to 37% have 
more aggressive features. Seventy-three to 87% of the described cases have total tumour vol-
umes of less than 0.2 or 0.5 ml, classifying them as clinically unimportant or minimal disease 
(in case of confinement to the prostate and Gleason score <7) according to Epstein20.
From these data a number of clinically relevant conclusions can be drawn. Firstly, the pros-
tate contains a large pool of cancers of which the majority can be classified as small and well-
differentiated in line with definitions of clinically insignificant or minimal disease. Secondly, 
the prevalence figures produced from autopsy studies and from prostates removed with 
radical cystoprostatectomy specimens can be compared to lifetime incidence and lifetime 
mortality data. For the US such figures applying to the year of 2005 have been estimated 
by Jemal et al.1. The lifetime risk of being diagnosed with prostate cancer amounts to 17.8% 
and the chance of dying of the disease to less than 3.5%. The number of new prostate cancer 
cases was estimated on 232,090. Prostate cancer was with 30,350 deaths the second leading 
cancer death cause in 20051. Autopsy and cystoprostatectomy prevalence figures exceed the 
lifetime risk of death from prostate cancer by at least 10-fold. 
Table 2: Prevalence and characteristics of prostate cancer incidentally found in radical cystoprostatectomy specimens (after Gosselaar et al.91).
Stamey et 
al.92
Montie et al.93 Ohori et al.94 Kabalin et 
al.95
Ward et al.*96 Montironi et 
al.97
Age (years)
Mean, median 
(range)
66, 65
(31-84)
62, 64
(34-80)
? 66, 66
(31-82)
69, 69
(44-92)
mean 61
(45-73)
Prostate cancers N 
(% of specimens)
55 (40) 72 (46) 90 (?) 25 (38) 30 (23) 55 (42)
Gleason scores
<7 % - 63 89 100 93 71
≥7 % - 37 11 - 7 29
Tumour volume 
≤0.2 ml %
74 - 83 (≤0.5 ml) 87 73 -
* case selection: PSA<2.0 prior to cystectomy
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The number of cancers diagnosed by screening exceeds the risk of dying of the disease by 
at least by a factor of 5. These data suggest that present diagnostic techniques are capable 
of diagnosing many of the cancers found in autopsy and cytoprostatectomy specimens. In 
1990, prior to the more general use of PSA-driven screening in North America and Western 
European countries, the ratio of the incidence and dying of prostate cancer was roughly 2:1. 
The changes induced by PSA- driven screening can also be visualised by comparing incidence 
and mortality in different areas of the world. Table 3 shows selected data from the Globocan 
2002 website. In Eastern Asia, where screening is still uncommon, the ratio of incidence and 
mortality still amounts to about 2:1 as used to be the case in the US and in Western Europe. 
Whether mortality decreased due to screening in a significant fashion remains to be shown 
by the ongoing randomised controlled trials of screening for prostate cancer.
Does PSA-driven screening detect clinically insignificant (autopsy) cancers?
The epidemiological and pathological data presented strongly suggest that this is indeed the 
case. Cumulative detection rates from screening studies add further evidence.
In table 4 data on detection rates resulting from systematic screening are summarised 
(cut-off date July 2007). In seven centres participating in the European Randomized Study 
of Screening for Prostate Cancer (ERSPC) men age 50–74 are randomised to a screening or 
a control group. The screening interval is 4 years except for Sweden and Belgium where the 
population is rescreened every two, respectively seven years. The detection rates reported 
relate to the number of men randomised, which is usually higher than the number of men 
who are actually screened. Also, test procedures are slightly different from centre to centre. 
All centres, however, utilised sextant biopsies, mostly lateralised, in men who had a PSA level 
above 3 or 4 ng/ml. It is important to differentiate, in this context, the cancer detection rate 
(CDR), which relates to the total number of cancers found in all men randomised or screened 
from the positive predictive value (PPV), which indicates the proportion of cancers in those 
who have a biopsy indication. The average detection rate in all ERSPC centres was 3.8% in 
200321 and has increased to 5.7% in July 2007. There is a variation in CDRs between the dif-
Table 3: Incidence and mortality of prostate cancer in different areas of the world (Globocan 2002).
Incidence Mortality Ratio
Cases (N) Crude rate Deaths (N) Crude rate Incid/mort
World 679,023 21.7 221,002 7.1 3.1
Southern Africa 4,778 19.3 2,648 10.7 1.8
Eastern Asia 29,472 3.9 14,535 1.9 2.1
Western Europe 98,083 109.2 29,382 32.7 3.3
Northern 
America
257,943 163.7 36,447 23.1 7.1
www-dep.iarc.fr
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ferent ERSPC study centres. For Rotterdam, the CDR was 8.4% in July 2007 (table 4, related to 
the number of men randomised).
In the similar PLCO trial which utilises the same age distribution but yearly screening by 
means of PSA and rectal examination (DRE) over a 5-year period, the detection rate in 2005 
was 1.4%22, 23. This CDR contrasts with the other studies mentioned in table 4, and concerns 
only the initial screening round of the PLCO. Furthermore, the biopsy rate of participants with 
an abnormal PSA level or DRE result are lower than in the ERSPC due to the study design of 
the PLCO.
The last line in table 4 refers to the placebo control arm of the Prostate Cancer Prevention 
Trial (PCPT)24. In this trial 9,459 men of age 55 or older (median age 62 years) presenting with-
out prostate cancer and a PSA value of less than 3.0 ng/ml were randomised to placebo. The 
participants were followed for seven years. Men who developed an abnormal rectal examina-
tion or a PSA value above 4.0 ng/ml were offered biopsy. This was applicable to 4,692 men 
in whom 571 cancers were detected by 1,934 biopsies. This resulted in a PPV (the number of 
cancers detected divided by the number of men biopsied*100%) of 29.5% and a very high 
CDR (the number of cancers detected divided by the number of men screened*100%) of 
12.2%. In line with the protocol, independent of their PSA or rectal examination, the remain-
ing men were recommended to undergo biopsy after a 7-year participation period in this 
study. This resulted in a total, cumulative detection rate of 24.4% in the placebo group. Next 
to the fact that this rate approaches the prevalence rate seen at autopsy, the data also show 
that the 7 year routine screening procedure missed almost exactly 50% of all cancers which 
were diagnosed by predominantly sextant biopsies in this population at the end of the seven 
year period (12.2 of 24.4%). This contrasts with the detection rate of 9.1% in the period until 
Table 4: Prevalence of prostate cancer in randomised studies. Detection rates are given (ERSPC meeting Antwerp, Belgium, October 2007).
Randomised to 
screen (excluding 
deaths before 
randomisation)
PCs detected at 1st 
screen 
N (% of men 
randomised)
PCs detected at 
follow-up screens
N
Total cancers 
detected
N (% of men 
randomised)
ERSPC: cut-off date 
July 2007
Belgium 5,188 116 (2.2) 98 214 (4.1)
Finland 31,970 658 (2.1) 832 1,429 (4.5)
Italy 7,499 98 (1.3) 75 173 (2.3)
Netherlands 21,206 1,014 (4.8) 769 1,783 (8.4)
Spain 2,416 40 (1.7) 40 80 (3.3)
Sweden 9,957 209 (2.1) 580 789 (7.9)
Switzerland 5,156 159 (3.1) 121 280 (5.4)
Total 83,392 2,294 (2.8) 2,515 4,748 (5.7)
PLCO22, 23 38,350 ± 537 (1.4) - 537 (1.4)
PCPT24* 4,692 - - 571 (12.2)
* for cause biopsies, 7-year period.
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January 2008 in the ERSPC Rotterdam. As already mentioned, the CDR of the Rotterdam study 
centre is higher compared to the average CDR of the ERSPC (table 4). Furthermore, a CDR 
concerns the number of cancers detected divided by the number of men screened. In table 
4 the denominater is formed by the number of men randomised to screen, which is usually 
higher than the number of men actually screened.
Present PSA-driven early detection measures for prostate cancer are capable of diagnosing 
a substantial proportion of those cancers found in autopsy studies. The question is if screen-
detected cancers match the properties of indolent or autopsy cancers (matching the current 
definitions20). Unfortunately, current series of prostate cancer cases treated by either radical 
prostatectomy or radiotherapy are not very suitable for comparison with autopsy series be-
cause they will usually represent a mixture of clinically and screen-detected cases.
The problem of detecting possibly indolent cancer by screening was recognised in an 
editorial by Carroll25 which urged the urological community to identify cases with a pattern 
compatible with a minimal risk of disease progression and to apply active surveillance regi-
mens to this group in order to reduce overtreatment.
PSA as an indicator for biopsy
Initial screening
Prostate-specific antigen (PSA) has been and remains one of the corner stones of early detec-
tion of prostate cancer. Catalona et al.2 used a PSA cut-off value of 4 ng/ml as a biopsy indica-
tion in a group of 1,653 men in age groups at risk. Thirty-seven cancers (2.3%) were detected. 
Sixteen of the 37 cancers would have been missed by rectal examination alone. Screening 
based on PSA identified men with prostate cancer who had a significantly increased propor-
tion of organ-confined tumours compared with those detected through evaluation for an 
abnormal DRE alone26. Catalona and co-workers13 evaluated the 4.0 ng/ml cut-off value in 
conjunction with rectal examination in a multicentre setting and found a cancer detection 
Table 5: PSA distribution and the diagnosis of prostate cancer in the first screening in 9,779 men aged 55-74 years.
PSA ng/ml Randomised to 
screen
N
Biopsied
N (% of men 
randomised)
Cancers per PSA 
range
N (% of total 
number PCs)
PPV 
%
CDR
%
0-2.9 7,808 915 (11.7) 79 (16.7) 8.6 1.0
3-3.9 702 174 (24.8) 44 (9.3) 25.3 6.3
4-10 1,063 985 (92.7) 241 (51.0) 24.5 22.7
≥10 206 193 (93.7) 109 (23.0) 56.5 52.9
Total 9,779 2,267 (23.2) 473 (100.0) 20.9 4.8
The study population was randomised to screening; the biopsy indication was PSA≥4.0 ng/ml and/or an abnormal DRE/TRUS (ERSPC 
Rotterdam).
PPV= the number of cancers detected divided by the number of men biopsied*100%
CDR= the number of cancers detected divided by the number of men screened*100%
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rate of 3.2% for DRE and 4.6% for PSA alone. Prostate cancer was detected in 10% of the men 
biopsied for an abnormal DRE and a PSA<4.0 ng/ml.
Later, lower cut-off values were used. Catalona and co-workers suggested to biopsy every-
one with a PSA>2.5 ng/ml or in case of an abnormal DRE27. Within the ERSPC a PSA value of 
3.0 ng/ml (without DRE as a screening test) nowadays is used after validation of this proce-
dure14.
Table 5 and 6 show the PSA distribution and the diagnosis of prostate cancer in respec-
tively 9,779 and 10,191 men age 55–74 who were randomised to screening according to re-
spectively the old and new protocol. Biopsy was recommended if PSA was ≥4.0 ng/ml and/or 
an abnormal DRE/TRUS (old protocol, table 5) or if PSA was ≥3.0 ng/ml (new protocol, table 6, 
DRE was not a screening tool). In the PSA range 3.0–3.9 ng/ml the old regimen missed about 
two thirds of the cancers (CDR 6.3% compared to 18.6%) compared to the new protocol.
Rescreening
Increasing evidence has recently accumulated showing that the detection characteristics 
change drastically if PSA has been used in a previous screening procedure. This has been 
documented by comparing the results of first and second round screening 4 years later in the 
ERSPC28. Figure 1 shows the relationships between the PPVs and PSA levels in the first and 
second round. As can be seen in figure 1, above the cut-off values of 3 and 4 ng/ml, which 
were used in the 21,210 men randomised to screening, PSA maintains its predictive value of 
about 20% in round 2. The rise of PPV associated with higher PSA levels in round 1 is lost in 
round 2.
A possible explanation for this finding is that an elevated PSA level in previously biopsied 
men mainly correlates with the prostatic volume. This is confirmed by observations made 
by Stamey et al.29, which show that in areas where screening has been prevalent for years, 
elevated PSA levels do not correlate with index prostate cancer volume but mainly with the 
Table 6: PSA distribution and the diagnosis of prostate cancer in the first screening in 10,191 men aged 55-74 years.
PSA ng/ml Randomised to 
screen
N
Biopsied
N (% of men 
randomised)
Cancers per PSA 
range
N (% of total 
number PCs)
PPV 
%
CDR
%
0-2.9 8,044 - -
3-3.9 724 618 (85.4) 135 (24.9) 21.8 18.6
4-10 1,172 1,021 (87.1) 285 (52.7) 27.9 24.3
≥10 251 210 (83.7) 121 (22.4) 57.6 48.2
Total 10,191 1,850 (18.2) 541 (100.0) 29.2 5.3
The study population was randomised to screening; the biopsy indication was PSA≥3.0 ng/ml (ERSPC Rotterdam).
PPV= the number of cancers detected divided by the number of men biopsied*100%
CDR= the number of cancers detected divided by the number of men screened*100%
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size of benign prostatic hyperplasia. This finding is also demonstrated within the ERSPC in a 
study of 1,040 men who underwent biopsy in second round screening for PSA values above 
3.0 ng/ml. The PPV was 19.0%. In a multivariate analysis age, PSA, DRE, family history, a previ-
ous negative biopsy, prostatic volume, and a suspicion of cancer by transrectal ultrasono-
graphy (TRUS) were included. Prostatic volume equal to or greater than the median volume 
of the population and a previous negative biopsy were significant negative predictors (for 
both: OR 0.5, 95% CI 0.3-0.7)30.
The cut-off of 3 ng/ml derives its unchanged PPV from cancers that have progressed to 
PSA levels >3 ng/ml and from those cancers that have potentially been missed in a previous 
screening round. Further details on the characteristics of PSA as a second round screening 
test are given in a paper written by Schröder et al.31. A summary is given in table 7. Obviously, 
using an absolute cut-off value in second round screening will include biopsy indications in 
all those men who have elevated PSA values because of an enlarged prostate.
Figure 1: The positive predictive value (PPV) of PSA-driven screening in relation to serum PSA in the 1st round of screening and the 2nd 4 
years later (ERSPC, section Rotterdam28).
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Table 7: PSA progression 4 years after screening (N=5,771, age 55-74, PSA round 1 <3.0 ng/ml) after Schröder et al. 200531.
round 1 round 2
Initial PSA 
distribution
N (%) PSA≥3.0
ng/ml
Biopsies PC PPV
ng/ml N (%) N (%) N %
<1.0 2,622 (45.4) 23 (0.9) 21 (91.3) 4 19.0
1.0-1.9 2,268 (39.3) 211 (9.3) 181 (85,8) 43 23.8
2.0-2.9 881 (15.3) 428 (48.6) 376 (87.9) 105 27.9
Total 5,771 662 (11.5) 578 (87.3) 152 26.3
Differences in PPVs are not significant (Fisher’s exact test).
PPV= the number of cancers detected divided by the number of men biopsied*100%
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Available data show that in men presenting with PSA values <1.0 ng/ml rescreening can 
safely be delayed by at least 8 years32.
An algorithm for detection of cancer in second round screening, which utilises prostatic 
volume as a negative predictor has been developed as the ‘prostate risk indicator’, available 
at www.uroweb.org.
At this time, it can be stated that the best way of utilising PSA in diagnosing prostate cancer 
in previously screened populations is not fully understood. However, as table 7 shows, the 
cut-off value of 3.0 ng/ml relates to PPVs of 19–28% depending on PSA 4 years earlier. The use 
of this (arbitrary) cut-off value resulted in biopsying only 10% of all 5,771 men.
More doubts about the use of PSA cut-off values in secondary screening come from data 
of the PCPT24, 33. The end of study biopsies carried out in the placebo control arm of this ran-
domised trial also offer a unique opportunity to study the test characteristics of PSA below 
the customary cut-off values of 2.5 and 3.0 ng/ml. Another important feature of this series is 
that this group of 3,820 men has been heavily prescreened by yearly PSA determinations and 
rectal examinations utilised as biopsy indications. In spite of the rigid preselection and heavy 
prescreening 15.1% of men undergoing the end of study biopsies (576 of 3,820) turned out 
to have prostate cancer.
PSA is a continuous marker
Further analysis reported by Thompson et al.33 revealed that PSA is not capable of differenti-
ating in the presence or absence of cancer. No single cut-off could be identified that simulta-
neously yielded a high relative sensitivity and relative specificity of testing. It seems that the 
role of PSA in diagnosing prostate cancer is more uncertain than ever before. The term rela-
tive sensitivity is used instead of sensitivity, which indicates the proportion of correct positive 
tests to the total number of cancers that could have been diagnosed in a given population. 
The total number of cancers remains however unknown, as the only way to determine this 
number is to investigate the radical prostatectomy specimens of all participants34.
While lowering PSA cut-off levels leads to a higher detection rate of prostate cancer, it also 
leads to an increase of the diagnosis of cancers, which might otherwise never bother their 
carrier (indolent, clinically insignificant, potentially overdiagnosed cancers)35. In addition, 
potentially aggressive cancers as defined by Gleason scores of 7 or higher cannot be identi-
fied by appropriate PSA cut-off levels. Even with PSA values below 3.0 ng/ml a considerable 
number of cancers detected have been shown to have aggressive features. The high rate of 
overdiagnosis makes strategies desirable, which identify aggressive but still curable cancers 
with an acceptable accuracy.
Introduction 25
Can PSA cut-offs be replaced by PSA kinetics?
As there is no PSA level at which prostate cancers cannot be detected and as potentially 
aggressive prostate cancers cannot be identified by appropriate PSA cut-off levels, the use of 
PSA kinetics (PSA changes over time) is being evaluated.
The increase of PSA over time can be described as PSA doubling-time (PSADT) or PSA 
velocity (PSAV), the yearly increase of PSA. Both expressions of PSA kinetics require several 
observations of serum PSA with observation periods of preferably one year, in order to com-
pensate for the biological variation of this marker36-38.
The yearly increase in PSA over time was first utilised by Carter et al.39 in a case study related 
to the Baltimore’s Longitudinal Study of Ageing (BLSA). The study compared 16 men recruited 
to a normal control group, 20 to a group of BPH cases and 18 with histologically diagnosed 
prostate cancer. Multiple PSA determinations were available for time periods between 7 and 
25 years prior to the histologic diagnosis or the exclusion of prostatic disease. The evaluation 
allowed a comparison between loco-regional and metastatic cancer and the control groups. 
Up to 5 years before diagnosis of cancer, the PSA did not differ between cancer and control 
subjects. After diagnosis of clinical disease an exponential increase of PSA velocity was no-
ticed. It was shown that a rate of change of 0.75 ng/ml/year was significantly related to the 
prostate cancer cases.
In 1994 Smith et al.40 evaluated 982 serially screened men who were initially all negative for 
cancer. Subsequently, all men had at least one PSA value >4.0 ng/ml and underwent biopsy. 
A PSA velocity cut-off point of 0.75 ng/ml/year or more maximised the prediction of cancer 
with an odds ratio of 7.20 with respect to those who had a PSAV of less than 0.75.
In a more recent study Fang et al.41 described that in 21 men with mostly clinically diag-
nosed prostate cancer mostly and 68 controls, a PSAV of 0.5 ng/ml/year was associated with 
a relative risk of prostate cancer of 6.53 with respect to those who had a lower PSAV. This 
difference in relative risk was statistically significant. Also the cumulative probability of being 
free of cancer progression correlated strongly with this cut-off point of PSAV. Later, Loeb and 
co-workers concluded that PSAV is significantly associated with detection of prostate cancer 
in men with a total PSA<4.0 ng/ml42.
These studies are unfortunately subject to verification bias. The wrong assumption is made 
that men with low PSA levels (below biopsy threshold) do not have cancer. The impact of this 
mistake has been demonstrated by Roobol43-45.
Large studies derived from second round screening in the ERSPC section Rotterdam46 and 
the PCPT47 did not confirm the value of PSAV in second round prostate cancer detection, in 
spite of attempting to imitate the selection criteria used by Fang30. The observation that PSAV 
plays no additional role was confirmed in a commentary by Etzioni and co-workers48.
Ch
ap
te
r 2
26
Why are findings with respect to the value of PSAV in diagnosing prostate cancer contradictory?
The most likely explanation lies in the fact that in second round screening most cancers are 
detected in the pre-clinical detectable phase46, the period of linear increase where controls 
cannot be differentiated from cancers as shown by Carter39, except that the pre-clinical de-
tectable phase in a screening setting is likely to be much longer. The fact that in Carter’s 
original observation PSAV increased when prostate cancer became ‘clinical’ suggests that 
PSAV may be a marker of aggressiveness rather than a diagnostic marker46.
This notion is confirmed by observations showing that high PSA velocity and short PSA 
doubling times are related to very aggressive disease49, 50. Obviously, more information with 
respect to the potential use of PSA kinetics as diagnostic tools and as parameters that may 
help to determine tumour aggressiveness prior to treatment are necessary.
Recently, Wolters et al. concluded that the use of PSAV as a biopsy indicator would miss a 
large number of clinically significant PC cases with increasing PSAV cut-offs. In their study, 
PSAV was not an independent predictor of a positive biopsy in general or significant PC on 
biopsy. Therefore, they concluded that PSAV does not improve the ERSPC screening algo-
rithm51.
Active surveillance regimens are likely to greatly benefit from increasing knowledge about 
PSA kinetics considering the fact that in the series of observational treatment of Choo et al. 
PSA doubling times vary between <2 and >50 years with a median PSADT of 7 years and 42% 
of men showing a doubling time of >10 years38.
Can we selectively identify aggressive cancers?
Considering what has been said so far it is evident that the problem in diagnosing prostate 
cancer cannot be resolved by maximising the relative sensitivity of biopsy indications. This 
would lead (as the data of the PCPT show) to the diagnosis of about half of those cancers that 
can be identified at autopsy and/or prostates removed by radical cystoprostatectomy. Every 
step in the direction of maximising cancer detection would lead to an increase in lifetime risk 
of a prostate cancer diagnosis, which was estimated by Draisma et al.52 to be in the range of 
300% (an increase from 8% to 36%).
The real problem and future task for our profession will be to identify those cancers that 
are aggressive and to make screening more selective in this respect. The PCPT data24 and 
ERSPC data53 shown in table 8 illustrate the problem. Assuming that cancers with a Gleason 
score of ≥7 will be the target of future detection strategies then, according to the PCPT data, 
67 cancers must be identified by biopsying 2,950 men. Such a procedure would have a PPV 
of 2.3%, 44 biopsies would be necessary to find one of these cases. The rate of diagnosis of 
high Gleason score cancers in the control arm of the PCPT overall amounts to 4.1% (237 of 
5,754*100%). Of the cancers found in the biopsies performed for indication (PSA≥4.0 ng/ml 
or abnormal DRE) during the 7-year study period 29.4% were classified as having Gleason 
scores of ≥7 as opposed to 15.8% in the end of study biopsies. Of all men analysed in the 
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placebo arm who underwent biopsy for indication during the 7-year period 3.2% had cancers 
with Gleason scores of 7 or higher (148/4,692*100%).
At present the selective identification of PCs with Gleason scores of ≥7 is not possible un-
less very large numbers of negative biopsies are accepted. In the ERSPC 80.5% and 68.1% of 
men had PSA values <3.0 and <2.0 ng/ml and were therefore excluded from biopsy.
A more promising approach might be to identify potentially indolent cancers and consider 
the remaining ones as potentially aggressive54.
Transrectal ultrasonography as biopsy indication
It has been recognised that the value of a TRUS of the prostate is limited as a screening test 
for prostate cancer9, 11, 55, 56. TRUS is highly investigator-dependent and mainly for this reason 
not suitable as a screening test. Furthermore, hypoechoic lesions are not specific for prostate 
cancer57. Next to hypoechoic lesions, prostate cancers may have iso-echoic or hyperechoic 
characteristics58-60. Nevertheless, TRUS is very useful in performing systematic prostate bi-
opsies. For this reason the TRUS-guided systematic prostate biopsy is the gold standard in 
obtaining prostatic tissue in men indicated for prostate biopsy.
Digital rectal examination as biopsy indication
With the common use of PSA cut-off points of 2.5, 3.0 or 4.0 ng/ml as biopsy indications, the 
domain of rectal examination has been limited to PSA values below these cut-offs. Only one 
in ten suspicious rectal examinations is likely to reveal prostate cancer at biopsy at PSA levels 
below 4.0 ng/ml13.
As already discussed, rectal examination has been eliminated as a screening test from the 
ERSPC and its limited value has been confirmed in a validation study14. Still, without rectal 
examination a certain fraction of clinically diagnosable prostate cancers will be missed and 
the question of their later detection with elevated PSA values in a state of curability is unre-
solved.
Table 8: Detection of prostate cancer in men with PSA values <4.0 ng/ml.
Thompson 
et al.24
Raaijmakers 
et al.53
PSA
ng/ml
Biopsied
N
PC
N (%)
Gleason
≥7 (%)
Biopsied
N
PC
N (%)
Gleason
≥7 (%)
≤ 0.5 486 32 (6.6) 4 (12.5) - -
0.6-1.0 791 80 (10.1) 8 (10.0) - -
1.1-2.0 998 170 (17.0) 20 (11.8) - -
2.1-3.0 482 115 (23.9) 22 (19.1) 478 75 (15.6) 6 (8.0)
3.1-4.0 193 52 (26.9) 13 (25.0) 258 51 (19.8) 12 (23.5)
Total 2,950 449 (15.2) 67 (14.9) 736 126 (17.1) 18 (14.3)
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DRE is a basic element of urological practice and will obviously continue to play this role. 
Clinicians should however realise that with low PSA values 9 of 10 biopsies indicated by rectal 
examination will be negative for prostate cancer.
Aggressiveness of cancers detected by DRE
Several studies suggest that prostate cancer detected by rectal examination may have more 
aggressive characteristics than tumours detected on the basis of elevated PSA levels only47, 
61-63.
Any pre-treatment procedure or finding that would enhance the selectivity of screening 
and help in an efficient way to differentiate between less aggressive and aggressive cancers 
should be highly welcomed and pursued. What is the evidence that DRE is helpful in this 
respect?
In the multicentre case finding study of 6,630 men older than 50 years reported by Cata-
lona et al.13 a PSA value of 4.0 ng/ml was a biopsy indication, which was met by 14.8% of the 
population. A number of 5,647 men (85.2%) had PSA levels of 0–4 ng/ml. This finding is very 
similar to data reported in table 5 for the ERSPC Rotterdam. Presumably, all cases included in 
Catalona’s series were not previously screened. In this study 481 men were biopsied indicated 
by a positive rectal examination as only biopsy indicator (8.6%). In these men 48 prostate 
cancers were detected resulting in a PPV of 10%. Of these, 3% were poorly differentiated.
During the first 4 years of the initial screening round of the ERSPC Rotterdam 86.6% of 
4,190 men had PSA values <4.0 ng/ml. Of these 3,629 men 142 (3.9%) were biopsied purely 
on the basis of an abnormal rectal examination. Seventeen cancers were found resulting in 
a PPV of 12% and a detection rate of 0.5%9. During the first round of the ERSPC Rotterdam, 
roughly half of the 21,210 men randomised to screening were screened by use of rectal ex-
amination in the PSA range 0–3.9 ng/ml. The other half was screened without rectal examina-
tion recommending biopsy in all participants with a PSA of 3.0–3.9 ng/ml. In this latter PSA 
range routine PSA-driven biopsy discovered almost three times as many prostate cancers 
as rectal examination (121 versus 43). However, the prevalence of Gleason score 7 or higher 
cancers amounted to 44% in the group screened by DRE versus 18% in the group screened 
without DRE. This difference seems to indicate selectiveness of DRE for detection of Gleason 
7 or higher cancers. However, if one relates the number of Gleason 7 or higher cancers to the 
total number of men with PSA values below 4 in both groups, detection rates of 0.75% and 
0.78% result62.
Recently, Borden et al. concluded that an abnormal DRE was significantly associated with 
an increased risk of high-grade (Gleason score ≥7) prostate cancer in a cohort of 790 referred 
men, using a multivariate logistic regression analysis that corrected, amongst others, for the 
PSA level61. Thompson et al. drew the same conclusion in a study including 5,519 men within 
the placebo arm of the PCPT47. Nevertheless, a substantial number of prostate cancers would 
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be missed using DRE as biopsy indicator, of which it is not known if these can safely be left 
undiagnosed.
Future
The best way of using PSA for diagnosing prostate cancer in the future and its role in differen-
tiating between aggressive and less aggressive tumours seems uncertain at the moment.
For the time being, arbitrary cut-off levels will remain an important option even in repeat 
screening, despite the resulting high rate of overdiagnosis of more than 50% achieved by 
systematic screening of non-clinical populations64. Utilising a PSA cut-off of 4 or 3 ng/ml will 
eliminate the need for prostatic biopsy in respectively 87% and 79% of all men in the age 
groups at risk.
An alternative for a PSA cut-off is to determine the risk of prostate cancer for an individual 
using a risk calculator65, 66 to decide whether or not to undergo a biopsy. On the website www.
uroweb.org the ‘prostate risk indicator’, based on the results of the ERSPC screening study so 
far can be viewed.
There are momentarily several ways to deal with the problem of unnecessary biopsies and 
the many malignancies that are detected by screening but would most probably not have 
caused any symptoms during a man’s lifetime if they had remained undiagnosed (overdiag-
nosis).
Firstly, screening intervals can be individualised. If a PSA test shows a value below the cut-
off level, the rescreening interval should be adapted to the first PSA value. Strong evidence 
exists that a PSA level between 0 and 1 will not necessitate a repeat screening for periods of 
8 years or longer (in men older than 55 years)32, 67.
Although several studies14, 16, 68 indicate that DRE is not useful as a screening test due to 
its limited PPV at low PSA levels, recent findings that DRE detects high-grade disease selec-
tively47, 61, 63 should be further investigated. Probably, DRE can play a role in the more selective 
detection of high-grade PCs. Another possibility would be the implementation of DRE in indi-
vidual screening algorithms (e.g. modification of the screening interval) or in a risk calculator 
as mentioned above. Investigating these applications of DRE is one of the objectives of this 
thesis.
Secondly, in order to prevent that overdiagnosis results in overtreatment, i.e. subjecting 
men to unnecessary costly and invasive treatment with the risk of important side-effects69, 
70, initial active treatment can be replaced by active surveillance. Active surveillance entails a 
strategy by which selected men are managed expectantly with the intention to apply poten-
tially curative treatment if signs of progression occur. Men who are diagnosed with prostate 
cancer and who present with ‘minimal’ or ‘indolent’ disease as defined in literature71-77 can 
safely be included into active surveillance regimens with a minimal chance of unnoticed pro-
gression to an incurable state. The Rotterdam section of the ERSPC and the Department of 
Urology of the Erasmus Medical Center in Rotterdam have initiated the prospective, observa-
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tional Prostate cancer Research International: Active Surveillance (PRIAS, www.prias-project.
org) study to validate the management of prostate cancer with active surveillance78, 79.
Thirdly, in order to prevent men from unnecessary biopsies the recently discovered pros-
tate cancer antigen 3 (PCA3) is a promising prostate cancer marker. Furthermore, urinary PSA 
has been shown to be helpful.
PCA3 is the most prostate cancer-specific gene described to date80, 81. It concerns prostate-
specific non-coding mRNA that is highly overexpressed in more than 95% of primary pros-
tate cancer specimens and prostate cancer metastases80, 81. A PCA3 gene-based urine test 
was a nalysed in men with PSA levels of 3.0 ng/ml or higher and has shown to improve the 
specificity of prostate cancer diagnosis and to reduce the number of unnecessary biopsies in 
the serum PSA grey zone between 3 and 15 ng/ml82, 83. Currently, the PCA3 urine test is be-
ing evaluated within the ERSPC Rotterdam screening arm as an indicator for prostate biopsy 
independent of the PSA value.
Recently has been shown that urinary PSA seems to be a useful marker in a prospective 
study in 170 men for the differential diagnosis of prostate cancer and BPH, especially when 
serum PSA is between 2.5 ng/ml and 10 ng/ml. Low urinary PSA and urinary/serum PSA ratios 
point toward prostate cancer. Urinary PSA threshold of >150 ng/ml may be used to decrease 
the number of prostate biopsies.
Eventually, it will hopefully be possible to determine what should be called ‘aggressive 
disease’ on the basis of pre-treatment criteria in the near future. Molecular markers may re-
solve the problem in the future but are unavailable at present for the differentiation between 
aggressive and less aggressive cancers. However, the recent discovery of the TMPRSS2-gene 
fusions to the ERG-gene in prostate cancer have been shown to allow stratification of pros-
tate cancer into distinct survival categories and to be promising in more exactly distinguish-
ing the future clinical behaviour of prostate cancers, especially in the large group Gleason 
6 and 7 cancers84. Recent reports on this subject show that a combined test for PCA3 and 
TMPRSS2:ERG expression in urine85 or a multiplex biomarker analysis in urine (including sev-
eral biomarkers among which PCA3 and TMPRSS2:ERG)86 outperformed serum PSA and PCA3 
alone for the detection of prostate cancer.
Chapter 3
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Whether screening for prostate cancer has a beneficial effect on prostate cancer mortality is 
still unclear. For the answer to this important question we have to await the final outcomes 
of the two ongoing randomised early detection trials: the ERSPC in Europe and the PLCO in 
the United States of America8.
PSA is the most commonly applied screening test in these trials, but also in daily clinical 
practice. As it is known that PSA is not a specific test for prostate cancer, but an overlap in PSA 
levels exists between men with normal prostates, benign prostate hyperplasia and localised 
PC, overdiagnosis and overtreatment have emerged as important side-effects of screening.
Basic research endeavours momentarily focus on the development of new, more specific 
markers for the detection of prostate cancer, or preferably, for the detection of aggressive, 
potential life-threatening disease. Unfortunately, such markers have not yet become avail-
able. Until that time PSA remains one of the corner stones of prostate cancer screening.
As described in chapter 1, DRE and TRUS have been omitted as screening test to indicate 
biopsy during the initial screening round of the ERSPC Rotterdam9, 14. From then on, the rea-
son for undergoing a prostate biopsy in the largest part of the trial has been based on solely 
a PSA cut-off of 3.0 ng/ml. However, in all men who underwent biopsy still a DRE and TRUS 
were performed as part of the screening procedure.
If population-based screening for prostate cancer will indeed prove to be beneficial in 
terms of prostate cancer mortality reduction, the first question that arises will be what the 
appropriate screening algorithm should be.
This thesis focuses on the role of DRE in screening for prostate cancer. It aims to evaluate 
whether the omission of the digital rectal examination in 1997 in the ERSPC Rotterdam is 
still justified several screenings later by analysing the consequences. It is essential to know 
if screening without DRE has possibly led to the detection of relatively more advanced can-
cers at subsequent screenings or more cancers presenting clinically in between subsequent 
screenings as interval cancers.
Another focus of this thesis is to investigate if DRE is valuable in other applications than as 
a sole biopsy indicator. For example, is DRE useful in predicting prostate cancer in addition 
to an elevated PSA level as biopsy indication or for selectively detecting aggressive prostate 
cancers?
Since DRE is subjective, the interobserver variability can play a role in its value as a screen-
ing test. For this reason the interobserver variability within the ERSPC Rotterdam is evalu-
ated.
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summAry
Screening for prostate cancer at low prostate-specific antigen (PSA) levels (≤4.0 ng/ml) risks 
detecting clinically insignificant cancers, which are of no threat to the man. In this review 
we evaluate the prevalence and tumour characteristics of prostate cancer detected at low 
PSA levels, comparing screening studies, cystoprostatectomy series and autopsy data. The 
favourable characteristics of tumours detectable at very low PSA levels seem to justify the 
conclusion that an unknown but sizeable proportion of the cancers found at biopsy are clini-
cally insignificant.
IntroDuCtIon
Prostate cancer is a large public health problem87; it is currently the most common neoplasm 
and the second leading cause of cancer death in Western men1. Prostate cancer is unique 
among the potentially lethal malignancies in the wide discrepancy between the high preva-
lence of histological changes recognisable as cancer and the much lower prevalence of clini-
cal disease. A common goal in research is to detect prostate cancer at an early, curable stage 
and to selectively detect those cancers which are aggressive.
‘Clinically insignificant’ prostate cancers, often called autopsy, latent, incidental or histo-
logical cancers, are thought not to be of immediate threat to the life or well-being of the 
host. Because of the slow progression of these prostate cancers, the often advanced age at 
diagnosis and comorbidity of the patient, it is not unlikely that the patient dies from other 
causes (intercurrent disease) before a prostatic tumour becomes aggressive. The estimated 
life-time risk of developing prostate cancer for a 50-year-old American man is ≈42% (based 
on autopsy data), yet the lifetime risk that he will have a clinically detected prostate cancer is 
≈9.5% and the risk that he will die from the disease is only 2.9%88, 89.
While not decisive in discriminating the malignant potential of a tumour, pathological 
features indicate which carcinomas are likely to be clinically insignificant, as such cancers 
tend to be of small volume (<0.5 ml according to Stamey et al.90), well differentiated and not 
invasive89. Epstein et al.20 classified tumours as clinically insignificant if they were <0.2 ml, 
confined to the prostate and had a Gleason score (GS) of <7.
A concern about PSA-based screening is that it might detect many clinically insignificant 
prostate cancers that would not pose a clinical threat to the patient (overdiagnosis). The opti-
mum threshold PSA value that indicates prostate biopsy remains unknown and is difficult to 
determine. The use of a higher PSA threshold risks missing an important cancer which is still 
curable, whereas the use of a lower threshold increases not only the number of unnecessary 
biopsies but also the number of clinically insignificant cases.
Ch
ap
te
r 4
40
Thompson et al.91 reported, in a side-study of the Prostate Cancer Prevention Trial (PCPT), 
the prevalence of prostate cancer among 2,950 men (median age 69.4 years, range 62–91). 
This side-study was carried out in participants in the placebo group; the selected partici-
pants, during the 7-year study period, never had a PSA value of ≥4.0 ng/ml or an abnormal 
DRE (measured and examined annually). At the end of the study all these men had a prostate 
biopsy (sextant technique). Prostate cancer was diagnosed in 15.2% of them, of whom 14.9% 
had a GS of ≥7. The prevalence of prostate cancer increased with the PSA level (from 7% at 
≤0.5 ng/ml to 27% at 3.1–4.0 ng/ml). The prevalence of high-grade cancers also increased 
with the PSA level, from 12.5% (PSA ≤0.5 ng/ml) to 25% (PSA 3.1–4.0 ng/ml). Therefore, it 
was concluded that biopsy-detected prostate cancer, including high-grade cancers, is not 
rare among men with PSA levels of ≤4.0 ng/ml and even in men with PSA values of <2.0 ng/
ml. Carter92 already suggested in an editorial that the prostate cancers found in the PCPT 
resemble autopsy cancers, with no clinical relevance.
In the following sections we discuss the question of whether systematic screening for 
prostate cancer at low PSA levels leads to the detection of clinically insignificant carcinomas, 
tumours which may normally never be diagnosed during a man’s lifetime. The aim of the 
review is to compare the prevalence and tumour characteristics of prostate cancers found at 
end of study biopsy in the PCPT at PSA levels of ≤4.0 ng/ml with those found in the European 
Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam section, and in cys-
toprostatectomy series and autopsy studies. Prostate cancers found in cystoprostatectomy 
specimens (surgery for bladder cancer) and prostate cancers found at autopsy are considered 
incidental, being without symptoms or otherwise clinically significant before detection. We 
refer to the biopsy results of the ERSPC because of their similarity at PSA levels of 2.1–4.0 
ng/ml and because of the available model predictions at 0–2.0 ng/ml. Variables of tumour 
aggressiveness of prostate cancers in the selected series are also compared.
PreVAlenCe of ProstAte CAnCers DeteCteD At low PsA leVels
We compared the positive predictive value (PPV, the number of prostate cancers divided by 
the number of men who had a biopsy in a given PSA range) or the prevalence of prostate 
cancers of the PCPT with the PPV or prevalence of the ERSPC, autopsy studies and cystopros-
tatectomy series.
Comparison of the PCPT with ERSPC
In the first round (biopsy indication for PSA≥3.0 ng/ml) of the ERSPC14, the PPV at a PSA of 
3.1–4.0 ng/ml was 21.4%, comparable with the 26.9% found in the PCPT in the same range 
(the PSA range of the data concerned14 was modified using the ERSPC database for optimum 
comparison with the PCPT). In this round of the ERSPC, 680 men had a PSA of 3.1–4.0 ng/ml, 
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of which 85.9% (584 men) had a biopsy and 125 had prostate cancer; 99% of these men had 
never had a biopsy before (first screening round) (table 1)14, 53, 55, 91.
However, at a PSA of 2.1–3.0 ng/ml the PPV in round two of the ERSPC (side study53, biopsy 
indicated at a PSA of ≥2.0 ng/ml, 94% never biopsied before, and again the PSA range was 
modified) was 16% (73/456), considerably lower than the PPV of 23.9% from the PCPT91.
For the other PSA ranges at <4.0 ng/ml, Kranse et al.55 calculated the PPV by logistic regres-
sion (estimated PPV). A shortcoming in using this estimate is that cases with an abnormal 
DRE were not excluded. They estimated an overall PPV of 3.9%, with a PPV of 7.4% and 12% 
at a PSA of 2.1–3.0 and 3.1–4.0 ng/ml, respectively (table 1). The previously mentioned data 
gave higher PPVs (16.0% and 21.4%) so Kranse et al. underestimated by about half. Correcting 
for this underestimate at a PSA of 2.1–4.0 ng/ml, a new overall PPV of 442/7,443, or 5.9%, was 
calculated, which remained lower than that of 15.2% in the PCPT (the number of participants 
per PSA group was similar in both series). If the 50% underestimate is used to correct the 
other PSA ranges (0–1.0 and 1.1–2.0 ng/ml), the overall PPV becomes 507/7,443, or 6.8%, 
which is still dissimilar to the 15.2% in the PCPT.
So, at low PSA levels (0–4.0 ng/ml), the PPV in the PCPT is considerably higher than in 
the ERSPC (15.2% and 6.8%, respectively). In only one PSA range were the PPVs comparable 
(21.4% and 26.9% at 3.1–4.0 ng/ml). The most striking difference is in the PPVs for <1.0 ng/
ml (respectively 8.7% and 1.1%) and 1.1–2.0 ng/ml (respectively 17.0% and 3.6%). This can 
at least partly be explained in that Kranse et al. used calculations based on the number of 
cancers found from an abnormal DRE. It is known that the PPV of a DRE decreases with de-
Table 1 An estimate of the number of prostate cancers in the ERSPC (if all men in the screening arm had a biopsy)55, corrected for 
underestimation at a PSA of 2.1-3.0 and 3.1-4.0 ng/ml with data of round 1 and 2 of the ERSPC. The PPV of the ERSPC is compared with that 
from the Prostate Cancer Prevention Trial (PCPT).
ERSPC14, 53 Estimated55 Corrected PCPT101
PSA 
range 
(ng/
ml)
N Bx PC CDR 
(%)
PPV 
(%)
N ePC ePPV 
(%)
cPC cPPV 
(%)
PPV (%)
0-1.0 3,045 34 1.1 34 1.1 8.8
1.1-2.0 2,663 96 3.6 96 3.6 17.0
2.1-3.0 543 456 73 13.4 16.0 1,093 81 7.4 175* 16.0 23.9
3.1-4.0 680 584 125 18.4 21.4 642 77 12.0 137** 21.4 26.9
overall 7,443 288 288/
7,443
=3.9
442 442/
7,443
=5.9
449/
2,950
=15.2
N, number of men screened; Bx, number of men biopsied; PC, number of prostate cancers found; ePC, estimated number of prostate cancers 
(if all men in screening arm were biopsied); ePPV, estimated PPV (if all men were biopsied); cPC, estimated number of prostate cancers 
after correcting for underestimation; cPPV, estimated PPV after correction for underestimation
*1093 x 0.16 (PPV ERSPC side study) = 175
**642 x 0.214 (PPV ERSPC round 1) = 137
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creasing PSA levels. Data from the first screening round of the ERSPC gave a PPV of 2.3% for 
a PSA of 0–1.0 ng/ml and 5.3% for 1.1–2.0 ng/ml56. So the underestimate here may be much 
more than half.
Another explanation is that the participants in the PCPT were older (median 69.4 years, 
range 62–91) than those in the first round of the ERSPC (PSA 3.1–4.0 ng/ml, median 65.7 
years, mean 65.5, range 55–74) and in the side-study in round two (PSA 2.1–3.0 ng/ml, me-
dian 66.2, mean 66.6, range 58.5–74). It is possible that in these very low (<2.0 ng/ml) PSA 
ranges the participants were the oldest in the PCPT. A third explanation for this difference 
could be that Thompson et al. obtained more samples per biopsy than were assumed by 
Kranse et al. in their model. However, Thompson et al. stated that there was no significant 
difference in PPV for subjects who had a sextant biopsy (84.5% of participants) and those in 
whom more samples were obtained.
Comparison of the PCPT with autopsy studies
Franks17 is often cited for his autopsy study in which he found a prevalence of 37.7% for 
incidental prostate cancer, ranging from 29% at age 50–59 years to all men of ≥90 years. At 
Table 2 Incidence of latent prostate cancers in different age groups (autopsy studies).
Cancer detected per age group, as % (n cancers/n cases assessed, unless <≈20)
Age 
group, 
years
Franks17 Hirst103 Edwards87 Andrews 
88
Moore89 Holund90 Sakr et 
al.18*
Sakr et 
al.104*
Sanchez-
Chapado 
et al.105**
10-19 0/2
20-29 0/4 0/24 0/7 8 4
30-39 0/8 0/28 0/3 30 
(7/23)
31 9
40-49 0/18 4
(1/23)
5 
(1/22)
17 
(4/23)
1/8 32 
(7/22)
37 14
50-59 29 
(11/38)
10 
(3/31)
5 
(2/38)
14 
(9/65)
9 
(2/23)
44 24
60-69 30 
(16/53)
19 
(10/54)
18 
(7/39)
23 
(18/77)
13 
(7/56)
65 32
70-79 40 
(28/70)
25 
(12/48)
32 
(7/22)
21 
(13/63)
26 
(24/93)
83 33
80-89 12/17 48 
(16/33)
3/17 29 
(7/24)
37 
(13/35)
90+ 2/2 5/6 60 
(3/5)
Totals 38 
(69/210)
54
(21/39)
17 
(29/173)
12 
(17/142)
17 
(51/304)
22 
(50/223)
26
(14/54)
N = 211 19 
(27/146)
N, no. of examined prostates
*Only Caucasian population mentioned in table
**Study in Caucasian Mediterranean men who are thought to have a lower prevalence of prostate cancer
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the time Franks studied the prostate specimens (1954) there was no uniformity in the grading 
of prostatic malignancy. Local spread of these tumours was frequent; there was infiltration 
of the capsule in 52 of the 69 cases, and generally accompanied by invasion of periprostatic 
tissues. In other autopsy studies before 1955, the incidence of prostate cancer at autopsy was 
12–54%93-96 (table 2)17, 18, 93-99. The incidence in one study95 was very high because the study 
population comprised men aged ≥80 years.
The frequency of finding small prostate cancers depends on the completeness of the 
histological examination and accurate studies require complete embedding of the gland. 
In all the cited studies a similar method was used (step sectioning) to examine the complete 
embedded prostate at intervals of 4 mm; in theory, any lesion of ≥4 mm would be detected. 
Most of the studies comprised older patients. Autopsy studies carried out more recently in-
cluded more patients in the younger groups and showed a higher prostate cancer incidence 
in younger men than did the earlier studies18, 98, 99 (table 2).
The prevalence of prostate cancer in autopsy studies (12–54%) is similar to or higher than 
the prevalence in the PCPT (15.2%), despite younger groups being included in several such 
studies. An explanation is that the whole prostate was examined in the autopsy series, com-
pared to detection by biopsy, by which a tumour can easily be missed, in the PCPT.
Table 3 Gleason score and tumour volume of prostate cancers detected in cystoprostatectomy series compared with Gleason scores 
detected in the Prostate Cancer Prevention Trial (PCPT).
Variable Montie et al.93 Kabalin et al.95 Ohori et al.94 Ward et al.96* Stamey et al.92 Thompson et 
al.101 (PCPT)
Mean, median 
(range) age, 
years
62, 64 (34-80) 66, 66 (31-82) NA** 68.5, 69 
(44-92)
66, 65 (31-84) 69.4 (median) 
(62-91)
Specimen 
derived by
CP CP CP CP CP Biopsy at end 
of study
N prostate 
cancers
72 25 90 30 55 449
Prevalence, % 46 38 NA** 23 40 15.2
GS 2-4, % 3 <7: 89 0 2.7
GS 5-6, % <6, 
29
≥6, 
17
97 93 77.7
GS, % 0 11 7 14.9
TV ≤0.2 ml, % 87 83
(≤0.5 ml)
73 74
CP, cystoprostatectomy; NA, not applicable
*PSA range ≤2.0 ng/ml
**CP specimens were used for comparison with RP specimens for pathological findings. All CP specimens used contained prostate cancer; 
patient age was not mentioned
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Comparison of the PCPT with cystoprostatectomy series
Cystoprostatectomy specimens obtained from men with a normal DRE undergoing surgery 
for bladder cancer potentially represent the closest approximation possible to an autopsy 
series for assessing incidental adenocarcinoma of the prostate. Men operated for bladder 
cancer with a normal DRE are not likely to have elevated (≥4.0 ng/ml) PSA levels; that 90% 
of men aged 50–90 years have PSA values of ≤4.0 ng/ml9, 100-102 supports this assumption. 
Therefore, the prevalence and tumour characteristics (discussed later) found in these studies 
can be compared with the PCPT results.
The prevalence of unsuspected prostate cancer in different cystoprostatectomy series was 
23–46%90, 103-106 (table 3), i.e. higher than the prevalence in the PCPT (15%), and matching that 
of autopsy-detected cancer of 30–40% in men aged 50–80 years17. Again, this difference can 
be explained in that the PCPT concerned biopsy-detected prostate cancers.
tumour ChArACterIstICs of ProstAte CAnCers DeteCteD At low PsA 
leVels
Aggressiveness
In a simplified way, prostate cancers can be classified as clinically important (i.e. threatening 
the life or well-being of the patient within his remaining life expectancy) or clinically insignifi-
cant (i.e. a latent cancer of no threat to the man). It is unclear at this time which small screen-
detected prostate cancers will progress rapidly, slowly or possibly not at all. Also, the lifetime 
risk of a clinical diagnosis is co-determined by age and comorbidity. Tumour volume (TV), 
Gleason grade and invasiveness are variables that can help to distinguish clinically important 
from insignificant prostate cancers88.
The Gleason score
In the GS the most prominent pattern of growth, ranging from 1 (well differentiated) to 5 
(undifferentiated), is combined with the second most common growth pattern as a criterion 
of overall grade. The total score, of 2–10, is obtained by adding the two most prominent 
patterns107.
In 2000, Epstein108 discussed the detection of low-grade prostate cancer on needle biopsy, 
suggesting that a GS of 2–4 should not be assigned to adenocarcinoma on needle biopsy, be-
cause this initially leads to undergrading, its reproducibility is poor and thus it can adversely 
affect patient care. This leads to the identification of three prognostic groups by biopsy, i.e. 
men with GS 6, 7 and 8–10 (all lower scores being included in 6). If reported, the biopsy GS of 
2–4 should be interpreted cautiously; GS 6 and 7 are the most prevalent scores on prostatic 
needle biopsy.
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A problem of a GS based on prostate biopsy is undergrading; this is reported in about half 
of the biopsy GS of <7109, 110. Thus patients with a biopsy GS of <7 are upgraded after examin-
ing the radical prostatectomy (RP) specimen in almost half of the cases, to a higher GS (≥7).
In the ERSPC, a biopsy GS of <7 was undergraded in 26% (Postma R, van der Kwast T. 
unpublished data); this reduction in undergrading in a screening situation is probably the 
result of a better biopsy technique and the few poorly differentiated tumours in prescreened 
populations.
When comparing biopsy GS (PCPT) with pathological GS (as in autopsy studies or cysto-
prostatectomy series) in this review, 20–50% of GS≥7 cancers should be added to biopsy-
detected prostate cancers to correct for undergrading. Verifying these estimates using suf-
ficiently many carefully studied RP specimens of PCPT cases is desirable and would resolve 
the problem of diagnosing indolent cancers.
Tumour volume
TV is an important predictor of clinical progression; the probability of histological progres-
sion, i.e. capsular penetration, seminal vesicle invasion and microscopic metastases to the 
pelvic lymph nodes, is related directly to intracapsular cancer volume90, 111, 112.
Stamey et al.113 concluded that TV was an independent predictor of progression after RP 
in a series of 379 RP specimens. However, in multivariate analyses TV appeared not to be a 
significant independent predictor of prognosis114, 115.
Prostate cancers are considered insignificant if they are confined to the prostate and have 
a TV of <0.2 ml and a GS of <7. These tumours are thought not to progress within the normal 
life expectancy of the man20, 89. In contrast, Stamey et al.90 determined a threshold TV of 0.5 ml 
for clinical insignificance. However, Stamey reconsidered this value of 0.5 ml in a recent edito-
rial, because it is not a clinical variable (it requires RP to measure the cancer). Furthermore, 
he suggested that what constitutes an insignificant cancer remains unknown, but it is likely 
to be >0.5 ml116.
Comparison of the PCPT with ERSPC
In a side-study (biopsy indication PSA≥2.0 ng/ml53) in the second round of the ERSPC53, 14.3% 
of the prostate cancers at a PSA of 2.0–3.9 ng/ml had a GS of ≥7 (GS were determined from 
the ERSPC database), which is similar to the proportion of poorly differentiated tumours in 
the PCPT (table 4)53, 91, 109, 117, 118. However, this side-study included only PSA levels of 2.0–3.9 
ng/ml, whereas the PCPT included 0–4.0 ng/ml. Specifically, in that lowest range (0–1.9 ng/
ml) fewer aggressive tumours would be expected and would therefore, if included in the 
ERSPC, lower the detection rate of 14.3%.
Hoedemaeker et al.68 showed that prostate cancers found at a PSA level of <4.0 ng/ml and 
with an abnormal DRE/TRUS had more favourable tumour characteristics in the RP specimen 
than those with a PSA of ≥4.0 ng/ml and a normal DRE/TRUS, or those at a PSA of ≥4.0 ng/ml 
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and abnormal DRE/TRUS. Despite 57% of the prostate cancers in the first group having a GS 
of 7, 43% met the criteria of minimal cancer and 21% were insignificant (in the other groups 
no insignificant prostate cancers were found). A substantial proportion of these tumours 
were detected on the basis of a false-positive DRE/TRUS, and thus by accident. These findings 
are confirmed by recent data on TVs of cancers detected at repeat screening in the ERSPC 
(biopsy indication PSA≥3.0 ng/ml, and almost half of the cancers detected had a PSA level of 
3.0–4.0119). The median TV of these cancers was 0.48 ml in the first and 0.43 ml in the second 
round. The mean volumes in both rounds also differed significantly but were much higher, 
indicating that the PSA-related volume distributions are strongly skewed ‘to the left’. This 
indicates a preponderance of low-volume cancers which are often ≤0.2 ml, which according 
to several studies are compatible with insignificant ‘autopsy cancers’20. These results indicate 
that screening at low PSA levels seems to detect more insignificant tumours, which can lead 
to overdiagnosis and overtreatment.
The distribution of a biopsy GS of ≥7 in several other studies was 6.3–11%; these prostate 
cancers were detected at a PSA of 2.0–4.0 ng/ml (table 4). Unfortunately, for a PSA of 0.0–2.0 
ng/ml no comparable series were found and therefore it is difficult to compare these results 
with the PCPT. Another problem is that in one of the cited series117, 85% of the men were 
previously screened, and in another109 only 36% of the participants had the recommended 
biopsy and no information on DRE was available.
In the series of Lodding et al.118 (biopsy indication PSA≥3.0 ng/ml, 66% normal DRE, 93% 
had the recommended biopsy) all detected tumours for which RP data were available had a 
TV of >0.2 ml and 21.4% of these tumours had a RP GS of 7 (biopsy GS of 7 in 6.3%). Based on 
RP specimens, 21.4% of these tumours were clinically important.
Table 4 Biopsy-derived Gleason score of prostate cancers detected in clinical studies at low PSA levels in comparison with Gleason scores 
detected in the Prostate Cancer Prevention Trial (PCPT).
Catalona et al.111 Catalona et al.119* Lodding et al.120 Raaijmakers et 
al.53
Thompson et 
al.101 (PCPT)
Biopsy GS 2-4, % 12.3 25 2.7
Biopsy GS 5-6, % ≤5, 13 =6, 77 79.4 68.8 85.7 77.7
Biopsy GS 7-10, % =7, 7 8-10, 4 8.2 6.3 14.3 14.9
N prostate 
cancers
224 73 32 126 449
Prevalence Retrospective 22 13.2 17.1** 15.2
Age, years 
(range)
Median 64 Mean 62 (50-90) Mean 59 (50-66) Mean 66 (55-74) Median 69 
(62-91)
PSA range, ng/ml 2.0-4.0 2.6-4.0 3.0-4.0 2.0-3.9 0.0-4.0
*Only 36% of study population underwent the recommended biopsy
**PPV, 126/736 = 0.171
Prevalence and characteristics of screen-detected PCs at low PSA levels: aggressive or insignificant 47
It is not surprising that series in which the PSA 3.0–4.0 ng/ml is included contain many 
clinically significant tumours. It is, among others, for this reason that a PSA level of 3.0 ng/ml 
has been proposed recently as the threshold value for screening16.
Comparison of the PCPT with autopsy studies
In 1980 Holund97 described the differentiation of latent prostate cancer, varying from well dif-
ferentiated to anaplastic, in six stages. In his study, 223 prostates were removed at consecu-
tive autopsies. If translated into GS groups, Holund found a similar percentage of poorly to 
undifferentiated prostate cancers as did Thompson et al.91 (16% and 14.9%, respectively, table 
591, 97, 99). Translating Holund’s grading system into GS cannot be done with any restriction, but 
it still seems useful for comparison.
Sanchez-Chapado et al.99 examined 27 prostates at autopsy and found only one prostate 
cancer with a GS of 7 (table 5). This tumour was a diffuse neoplasm extending outside the 
prostate, in an 80-year-old. As a result of the few prostates included in the study it is difficult 
to compare the results with the findings of Thompson et al.91.
Because of the period in which the reviewed studies were performed and the hetero-
geneity in study methods, it is not possible to draw any conclusions from comparing the 
PCPT GS and autopsy study results. In none of the reviewed studies was TV measured and 
only one autopsy study97 described a similar number of poorly to undifferentiated prostate 
cancers, which suggests a resemblance of prostate cancers found in the PCPT with autopsy 
tumours (that are thought to be clinically insignificant).
Table 5 Gleason score of prostate cancers detected in autopsy studies compared with Gleason scores detected in the Prostate Cancer 
Prevention Trial (PCPT).
Holund90 Sanchez-Chapado et al.105 Thompson et al. 101 (PCPT)
Age, years (range) (36-94) Mean 48.5 (20-80) Median 69.4 (62-91)
Specimen derived by autopsy autopsy End of study biopsy
N prostate cancers 50 27 449
Prevalence, % 22 18.5* 15.2
GS 2-4, % 36 37 2.7
GS 5-6, % 48 59 77.7
GS 7-10, % 16 4 14.9
*Study in Caucasian Mediterranean men who are thought to have a lower prevalence of prostate cancer
Comparison of the PCPT with cystoprostatectomy series
In the reviewed cystoprostatectomy studies (incidental prostate cancers in men with a nor-
mal DRE), high-grade cancer (GS≥7) was found in 0–11%103, 105, 106 (table 3). One study reported 
prostate cancers with a GS of ≥6 in 17% of men104. About 15% of the detected prostate cancers 
in this study were considered morphologically significant (defined as invasion or penetration 
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of the capsule and GS≥6). Notably, the study in which none of the tumours was poorly dif-
ferentiated had few subjects, by which the findings are probably distorted103.
TV was significant in 13–27% of the detected prostate cancers in the cited series90, 103, 106 
(table 3). In one series 17% of the detected cancers had a TV>0.5 ml105.
Recently, Ward et al.106 assessed the pathological characteristics of incidentally discovered 
prostate cancers at a PSA of 0–2.0 ng/ml in patients with a normal DRE. Of the 129 patients, 
30 (23%) had prostate cancer, of whom two (7%) had Gleason pattern 4 (versus 11% with 
GS≥7 at a PSA of 0–2.0 ng/ml in the PCPT). Only one patient had extraprostatic extension. 
Defining clinical significance as a GS of ≥7 and TV of >0.2 ml, only one tumour was clinically 
significant.
In summary, in only one series105 was there a similar percentage of poorly differentiated 
tumours (11%) as in the PCPT. However, these prostate cancers were mainly small and con-
fined to the prostate, and therefore resemble autopsy cancers. TV and confinement to the 
prostate of cancers in the PCPT are unknown (biopsy-detected cancers), but may be similar 
because these cancers are also unsuspected in men with no complaints or an abnormal DRE 
or PSA findings. TV was clinically significant (>0.2 ml) in 13–27% of the detected prostate 
cancers. However, it is not possible to claim clinical significance of a tumour on the basis of TV 
alone114, 115. Thus the expected number of clinically significant tumours is lower than this. Tak-
ing other tumour characteristics into account, Ward et al.106 detected, at a low PSA level, only 
one clinically significant prostate cancer, which contradicts the hypothesis that high-grade 
prostate cancers are not rare at low PSA levels.
ConClusIon
Thompson et al.91 concluded that biopsy-detected prostate cancer, including high-grade can-
cers, is not rare among men with a PSA level of ≤4.0 ng/ml and even in men with PSA values 
of <2.0 ng/ml. Because of the variability in reporting and execution of studies, it is difficult to 
compare the prevalence and aggressiveness of prostate cancers detected at low PSA levels. 
Nevertheless, the reviewed studies for which comparison was possible generally contradict 
the findings of the PCPT. The favourable characteristics of tumours detectable at very low 
PSA levels68, 103, 105, 106 seem to justify the conclusion that an unknown but sizeable proportion 
of the cancers found at routine biopsy in apparently normal men are clinically unimportant 
but compatible with autopsy cancers.
In summary, the higher prevalence of indolent cases, as compared to the significant and 
possibly life-threatening cases, put the value of screening in men with these low PSA levels 
(<3.0 ng/ml) in question. A PSA threshold of 3.0 ng/ml produced a good balance between an 
acceptable PPV of the test and detecting clinically significant tumours16.
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AbstrACt
Background
Omission of DRE/TRUS as biopsy indication results in fewer unnecessary biopsies, but may 
increase the risk of missing potentially aggressive prostate cancers. In 1997, the biopsy in-
dication within the ERSPC was changed from a PSA cut-off of 4.0 ng/ml and/or abnormal 
DRE/TRUS (group-1) to solely a PSA cut-off of 3.0 ng/ml (group-2). We estimated the effect of 
omitting DRE/TRUS by comparing the results of a rescreening 4 years after initial screening 
to the original policy.
Methods
We compared rate and characteristics of detected prostate cancers in the second round in 
men initially screened in group-1 (N=5,957) or group-2 (N=8,044). Additionally, we compared 
the rate of interval cancers after screening with and without DRE/TRUS.
Results
There was no significant difference in second round cancer detection rates (group-1, 3.0%; 
group-2, 2.7%), positive predictive values (group-1, 23.9%; group-2, 26.3%) and number of 
poorly differentiated tumours (group-1, 2.6%; group-2, 3.8%). Most prostate cancers were 
clinically confined to the prostate. Eleven interval cancers were detected in each group (0.18 
and 0.14%).
Conclusions
Omitting DRE/TRUS did not result in an increased interval cancer or prostate cancer detec-
tion. However, considering the natural history of prostate cancer, the 4-year follow-up may be 
too short to draw a definitive conclusion.
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IntroDuCtIon
The European Randomized Study of Screening for Prostate Cancer (ERSPC) aims to show 
whether prostate cancer (PC) mortality differs significantly between the screening and con-
trol arms. Its set-up also enables us to evaluate the screening tests used, such as digital rectal 
examination (DRE), transrectal ultrasound (TRUS) and prostate-specific antigen (PSA)120.
It is generally assumed that TRUS is not a valuable test for the early detection of PC in 
a screening program9-11. The value of DRE as a screening test for the early detection of PC 
remains controversial. For this reason, in May 1997 both test procedures were discontinued 
as an indication for sextant biopsy (at PSA levels <4.0 ng/ml) in the Rotterdam section of the 
ERSPC. At the same time, the PSA threshold as a biopsy indication was reduced from 4.0 to 
3.0 ng/ml9, 14.
Due to the omission of DRE/TRUS, and therefore the omission of biopsies at PSA<3.0 ng/ml, 
there is a risk of missing potentially aggressive tumours at these low PSA levels which could 
surface as interval cancers (ICs), i.e. PCs detected between the two screening rounds. Another 
possibility is that these cancers are detected at a subsequent screening when the PSA level 
has risen to a value above the threshold of 3.0, probably expressing more aggressive tumour 
characteristics. This may lead to more PC-specific deaths, and therefore can have an effect on 
the outcome of the study by decreasing a potential difference in PC-specific mortality.
The number of missed cases with potentially aggressive tumour characteristics depends 
both on the prevalence below the threshold value for biopsy, and on the effectiveness of 
the screening tests used to detect these cases. To evaluate this, we compared prognostic 
factors of tumours found in the second screening between two groups of men who had been 
initially screened either with DRE/TRUS (group-1) or without these tests (group-2). In the 
second round, both groups were biopsied if PSA was above the threshold value of 3.0 ng/
ml (PSA as the sole biopsy indication). In order to make these two screening protocols more 
comparable, only men with a PSA level <3.0 ng/ml at first screening were included. In this 
way, DRE/TRUS were the sole tests that could indicate a sextant biopsy in round 1 in group-1 
and there was no indication for biopsy in group-2.
The difference in prevalence of aggressive cancers in round 2 between men initially 
screened with or without DRE/TRUS should relate directly to the value of DRE and TRUS. The 
same applies to the rate of ICs.
mAterIAls AnD methoDs
Study population
In the Rotterdam area, all men in the age group 55-75 years were identified by the popu-
lation registry and asked to participate in a randomised screening study for PC. Men who 
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responded by returning the intake questionnaire and a signed informed consent form were 
randomised. Men randomised to the screening arm were screened by means of a serum PSA 
determination and, depending on the screening protocol, DRE and TRUS were carried out. 
Sextant biopsy was proposed if indicated. A more detailed description of the study design 
has been published previously120.
Before May 1997, the screening protocol determined that participants with a PSA≥4.0 ng/
ml and/or a suspicious DRE/TRUS finding at a low PSA value (0.0-3.9 ng/ml) were to undergo 
sextant prostate biopsy (referred to as ‘screening with DRE/TRUS’, group-1, in this paper). It 
should be noted that in November 1995 the omission of DRE/TRUS was already implemented 
for participants who presented with a PSA level <1.0 ng/ml9, 56. These participants were ex-
cluded from the present study.
After May 1997, a major protocol change was implemented in the ERSPC. Biopsies were 
taken exclusively from men with a PSA≥3.0 ng/ml. Men with a PSA<3.0 ng/ml were directly 
rescheduled for their next screening visit 4 years later (’screening without DRE/TRUS’, group-2, 
in this paper). Thus, in round 1 (1993-1999) the biopsy indication based on a PSA cut-off of 
4.0 ng/ml and/or abnormal DRE/TRUS (group-1) was changed to a PSA cut-off of 3.0 ng/ml 
as the sole biopsy indication (group-2). All men included in this study had an initial PSA<3.0 
ng/ml in order to make the screening protocols comparable. Rescreening without DRE/TRUS 
(1997-2003) was offered after 4 years in the second screening round (figure 1).
Positive predictive value (PPV, the proportion PCs/number of biopsied men), cancer detec-
tion rate (CDR, the proportion PCs in screened men), number of ICs and tumour character-
istics (clinical stage, pathological stage, Gleason score (GS)) of PCs detected at rescreening 
were compared between the initial two protocols.
Techniques
Screening entailed a determination of serum PSA concentration (Beckman-Coulter Hybritech 
Tandem-E Assay; San Diego, California). Blood samples were drawn before the other tests 
were performed. DRE and TRUS were performed by a resident urologist or an ultrasound tech-
nician. Nodularity and induration were considered abnormal on DRE. TRUS was performed 
using a Bruel & Kjaer® model 1,846 mainframe and a 7 MHz biplanar endorectal transducer, 
with the subject in the left lateral decubitus position. Hypoechoic lesions were considered 
suspicious. Lateral sextant transrectal prostate biopsy was performed, in line with the find-
ings of Eskew et al.121, using a Bard (C.R. Bard, Convington, GA) spring-loaded biopsy gun and 
an 18-gauge biopsy needle. Additional biopsies were taken from suspicious areas on TRUS. 
Palpable lesions were not a reason for an additional, lesion directed biopsy, so in the second 
round a suspicious DRE was not an indication for biopsy at all. At the time of performing DRE/
TRUS, the members of the screening team were not aware of the current PSA value (round 
1). At the second screening, the screening team knew that the PSA value was ≥3.0 ng/ml, but 
was not aware of the exact value or previous screening results.
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Pathologic examination
Biopsy specimens were histopathologically analysed by a single pathologist (TvdK). PC was 
graded according to the GS system. All radical prostatectomy (RP) specimens (n=75, second 
screening round) were fixed, totally embedded, and processed. For these tumours, a RP GS 
was determined and the tumour was staged according to the 1992 UICC TNM classifica-
tion122.
Statistical analysis
Statistical analysis was performed using the statistical package for the social sciences (SPSS 
10.1.0; SPSS Incorporated, Chicago, IL). Statistical testing was done by the Fisher’s exact two-
sided test. Statistical significance was defined as a p-value <0.05.
results
First screening round
At their first visit, all men included had a PSA<3.0 ng/ml. In this initial screening round (preva-
lence screen), 5,957 (4,249+1,708) men were screened according to the protocol with DRE/
TRUS (group-1, December 1993-April 1997), and 8,044 participants were screened according 
to the protocol without DRE/TRUS (group-2, May 1997-December 1999).
At the first screening visit, 79 PCs were detected (biopsy indication was an abnormal DRE in 
30 cases, an abnormal TRUS in 30 cases and both tests abnormal in 19 cases). These tumours 
had in 89.9% clinical stage T2 and in 10.1% T3a and a biopsy GS<7 in 77.2%, 7 in 17.7% and >7 
in 5.1%. Thirty-nine men underwent RP, of whom 82.1% had a pathologically organ confined 
tumour, 77.0% had a pathological GS<7 and 20.5% a GS=7 (1 GS missing) (figure 1, table 1).
Second screening round
After 4 years, 3,792 (64%) men from group-1 were rescreened, and 5,864 (73%) men from 
group-2. Rescreening was carried out without DRE/TRUS (December 1997-December 2003, 
table 1). The loss of participants in the second round was ascribed to old age (>74 years) 
(782 men for group-1 and 799 men for group-2), co-morbidity (147 and 214, respectively), 
death (245 and 292), removal from the Rotterdam region (242 and 315) or refusal (487 and 
560) (figure 1). Of the participants initially screened according to the protocol with DRE/TRUS 
(group-1), 183 had already dropped out before the second screening round due to rescreen-
ing after one year in a side-study (round 1a).
The mean age in years of the participants at the first screening visit was 63.4 (median 62.8) 
in group-1 and 63.1 (median 62.3) in group-2. At the second visit, the mean age in these 
groups was 65.8 (median 65.4) and 66.0 (median 65.4).
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In round 2, there was no significant difference between the two protocols in CDR (group-1, 
3.0%; group-2, 2.7%, p=0.381) and PPV (group-1, 23.9%; group-2 26.3%, p=0.399) (table 1). 
Table 2 shows that most of these cancers were clinically confined to the prostate in both 
groups (group-1, 95.6%; group-2, 96.3%). There was no significant difference in the percent-
age poorly differentiated tumours (biopsy GS>7) between the two groups (2.6% of the PCs 
detected in group-1 and 3.8% in group-2, p=0.384). Two PCs with GS=9 (clinical stage T2b and 
Figure 1: Flow chart ERSPC Rotterdam. The second screening round was carried out 4 years after the first screening visit.
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December 1993 – December 1999
Initial screening round 
December 1993 – November 1995
Biopsy indication: PSA≥4.0 ng/ml and/or 
abnormal DRE/TRUS (PSA 0-2.9 ng/ml) 
4,249 men 
+ 
November 1995 – April 1997 
Biopsy indication: PSA≥4.0 ng/ml and/or 
abnormal DRE/TRUS if PSA 1.0-2.9 ng/ml 
1,708 men 
= 5,957 men 
May 1997 – December 1999
Biopsy indication: PSA≥3.0 ng/ml (PSA 0-
2.9 ng/ml) 
8,044 men 
0 men biopsied 
915 men biopsied 
79 prostate cancers detected 
183 men dropped out (round 1a)
Egible for screening: 13,922 men 
1,089 men biopsied 
275 prostate cancers detected
December 1997 – December 2003
Biopsy indication: PSA≥3.0 ng/ml 
9,656 men 
Men who dropped out: 
Group-1                          Group-2 
 
>75 years            782             799 
Comorbidity         147             214 
Death                  245             292 
Moved                 242             315 
Refusal               487              560 
Total                 1,903           2,180 
GROUP-1 GROUP-2
 7 9
147 
245 292
242 315
487 560
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T3c) and one with GS=10 (T2a) were detected in group-2, while all 115 PCs in group-1 had a 
GS≤8. If the detected tumours were grouped into two prognostic GS categories (GS<7 and 
GS≥7), men in group-2 had in 26.3% tumours with a GS≥7, and in group-1 19.1% (p=0.19).
Radical prostatectomy
Of the 275 men diagnosed with PC at the second screening, 75 (42 in group-1 and 33 in 
group-2) underwent RP at our hospital. The surgical specimens showed organ confinement 
(pathological stage T2) in 90.5% (38/42) in group-1 and in 70.0% (23/33) in group-2 (p=0.035). 
The percentage of poorly differentiated tumours (RP GS>7) did not differ significantly be-
tween the two groups. One out of 40 RP specimens in group-1 (2.5%, 2 GS missing) and 
2/32=6.2% (1 GS missing) for group-2 had a GS>7 (p=0.290). If RP specimens were grouped 
into two prognostic GS categories (GS<7 and GS≥7), men in group-1 had in 35.0% tumours 
with a GS≥7, and in group-2 53.1% (p=0.154).There were no lymph node metastases in 93% 
in group-1 and in 88% in group-2 (p=0.692, regional lymph node stage unknown in 7% 
(group-1) and in 12% (group-2)).
Table 1: First and subsequent second screening round after 4 years. Group-1 is initially (first round) screened according to the protocol with 
DRE/TRUS , group-2 to the protocol without DRE/TRUS. All men had initially PSA values <3.0 ng/ml.
Initial screening second screening after 4 years
PSA (ng/
ml)
N men 
(%)
Bx (N) N PC PPV (%) CDR (%) N men Bx (N) N PC PPV (%) CDR (%)
Group-1: screened with Dre/trus Group-1: PsA≥3.0 ng/ml is biopsy indication
<1.0 1,708 
(28.7)
183 4 2.2 0.23 1,137 17 1 5.88 0.088
1.0 – 1.9 3,051 
(51.2)
511 45 8.8 1.47 1,967 168 38 22.62 1.93
2.0 – 2.9 1,198 
(20.1)
221 30 13.6 2.50 688 296 76 25.68 11.05
Total 5,957 
(100)
915 79 8.6 1.33 3,792 481 115 23.91 3.03
Group-2: no further screening (PsA<3.0 ng/ml) Group-2: PsA≥3.0 ng/ml is biopsy indication
< 1.0 3,580 
(44.5)
- - - - 2,659 22 5 22.73 0.19
1.0 – 1.9 3,154
(39.2)
- - - - 2,296 186 44 23.65 1.92
2.0 – 2.9 1,310 
(16.3)
- - - - 909 401 111 27.68 12.21
Total 8,044 
(100)
- - - - 5,864 608 160 26.32 2.73
PPV, positive predictive value, the proportion PCs/number of biopsied men; CDR, cancer detection rate, 
the proportion PCs/number of screened men; Bx, biopsied men; DRE, digital rectal examination; TRUS, 
transrectal ultrasound; PSA, prostate-specific antigen.
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Interval cancers
In group-1, 11 ICs were reported in 5,957 screened men (0.18%), in group-2, there were also 
11 ICs, in 8,044 men (0.14%, p=0.522) (table 3). In group-1, 11 ICs were clinically organ con-
fined, in group-2, 1 IC showed invasion of other organs (T4) and the stage was unknown in 
four cases. The biopsy GS of these tumours and the initial PSA of patients with an IC are listed 
in table 3.
DIsCussIon
As described in a previous paper, our decision to discontinue DRE and TRUS as screening 
tests and to use a PSA threshold as the sole biopsy indication was based on an investigation 
of the value of DRE in 10,523 consecutive men in the screening arm16, 7,055 of whom were 
found to have a PSA value <4.0 ng/ml. At these PSA levels, DRE should be useful, whereas 
the PSA value is so low that it was considered not to discriminate between a man with can-
cer or without. However, in the referred study the PPV (average 12.8% at PSA 0-3.9 ng/ml) 
Table 2: Second screening round: clinical stage and biopsy Gleason score of the screen detected prostate cancers (N=115 for screening with 
DRE/TRUS and N=160 for screening without DRE/TRUS). The screening group with DRE/TRUS consisted of 3,792 men, the screening group 
without DRE/TRUS of 5,864 men.
Screening regimen in the first screening round
Dre/trus no Dre/trus
Clinical stage N prostate cancers 
(% of total N prostate 
cancers)
% of men screened N prostate cancers 
(% of total N prostate 
cancers)
% of men screened
T1c 66 (57.4) 1.7 99 (61.9) 1.7
T2a 27 (23.5) 0.71 40 (25.0) 0.68
T2b 11 (9.6) 0.29 9 (5.6) 0.15
T2c 6 (5.2) 0.16 6 (3.8) 0.10
T3a 4 (3.5) 0.11 4 (2.5) 0.068
T3b - - 1 (0.6) 0.017
T3c 1 (0.9) 0.03 1 (0.6) 0.017
Total 115 (100.0) 115/3,792 = 3.0 160 (100.0) 160/5,867 = 2.7
Confined to prostate 110 (95.6) 2.9 154 (96.3) 2.6
Biopsy Gleason score N prostate cancers 
(% of total N prostate 
cancers)*
% of men screened N prostate cancers 
(% of total N prostate 
cancers)*
% of men screened
<7 93 (80.9) 2.5 118 (73.8) 2.0
7 19 (16.5) 0.50 36 (22.5) 0.61
>7 3 (2.6) 0.079 6 (3.8) 0.10
Total 115 (100.0) 115/3,792 = 3.0 160 (100.0) 160/5,867 = 2.7
*p=0.384 (Fisher’s exact 2-sided)
Screening for PC without DRE and TRUS: results after four years in the ERSPC Rotterdam 59
and sensitivity (14-39%, calculated by using the estimated underlying prevalence of PC) of 
DRE were low. If DRE had been omitted at a PSA<3.0 ng/ml, 47 of the 473 cancers actually 
detected (9.9%) would have been missed16. Conversely, another study on PC detection at low 
PSA levels (PSA<4.0 ng/ml) estimated that if every man with PSA 3.0-3.9 ng/ml (N=734) had 
a biopsy (instead of only the men with an abnormal DRE/TRUS), 43 (48.3%) more PCs would 
have been detected15. In addition, it was demonstrated that a substantial proportion of the 
tumours at PSA≤4.0 ng/ml were detected on the basis of a false-positive DRE/TRUS, and thus 
by accident68, 123. These findings were confirmed by another study62, that demonstrated the 
inefficiency of DRE at low PSA levels (<3.0 ng/ml) by comparing the same two protocols as 
we do in our current study: 289 DREs were necessary to find one clinically significant PC (tu-
mour not confined to the prostate, tumour volume ≥0.5 ml or Gleason pattern 4 or 5); and 96 
DREs were needed to diagnose one PC irrespective of tumour characteristics. Nevertheless, 
in the 3.0-3.9 ng/ml PSA range, an abnormal DRE detected significantly more biopsy GS 7-10 
cancers than PSA-based screening62.
On the basis of a validation study in 7,943 men in the screening arm carried out previ-
ously14, the new screening regimen in the ERSPC was considered justified. By using the new 
Table 3: Clinical stage and biopsy Gleason score of the interval cancers in the group initially screened with DRE/TRUS (N=11) and without 
DRE/TRUS (N=11).
Screening regimen in the first screening round
Interval Cancers Dre/trus no Dre/trus
Clinical stage N (% of men screened) N (% of men screened)
T1a 3 2
T1b 1 -
T1c 6 2
T2b 1 1
T2c - 1
T4x - 1
unknown - 4
Total 11 (11/5,957 = 0.18) 11 (11/8,044 = 0.14)
Biopsy Gleason score N (% of men screened) N (% of men screened)
<7 5 3
7 1 1
unknown 5 7
Total 11 (0.18) 11 (0.14)
PSA in first round (ng/ml) N (% of men screened) N (% of men screened)
<1.0 - 1
1.0 – 1.9 6 3
2.0 – 2.9 5 7
Total 11 (0.18) 11 (0.14)
PSA, prostate-specific antigen
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protocol, the CDR remained similar (CDR 5.0 and 4.7 at PSA cut-off of ≥4.0 and ≥3.0 ng/ml, 
respectively) while the PPV became higher in PSA range 3.0-3.9 ng/ml (from 6.4% in the old 
protocol to 18% in the new one). At the same time, the number of men who had to undergo a 
biopsy decreased14. In the validation study, PCs detected with the new regimen had a similar 
distribution of GS, but a larger proportion of confined disease14.
In contrast, in a multicentre clinical trial, Catalona et al.13 concluded that DRE in conjunction 
with PSA enhanced early PC detection (biopsy indication PSA≥4.0 ng/ml and/or suspicious 
DRE). DRE in men with PSA values ≤4.0 ng/ml had a PPV of 10.0%, which is similar to our 
study (PPV of DRE/TRUS of 8.6% at PSA<3.0 ng/ml, table 1). In another series12, they found 
an overall PPV of suspicious DRE of 13%. This means that approximately eight biopsies are 
necessary to find one PC. The majority of DRE-detected cancers had features of clinically im-
portant and potentially curable disease, which are strong arguments in favour of performing 
DRE (in patients with PSA>1.0 ng/ml and ≤4.0 ng/ml) together with PSA testing in screening 
programs12.
Recently, Han et al.124 evaluated 235 PCs of men diagnosed by a suspicious DRE and a PSA 
level <2.6 ng/ml, who underwent an RP. They found that 1/3 of these men had a tumour with 
GS≥7 or pathologic T3 stage, with a high risk of progression following RP. The actuarial 5- and 
10-year biochemical progression-free survivals (PSA<0.3 ng/ml) were 86% and 59% for this 
high-risk group, in contrast with 97% and 90% for the low risk group (GS<7 and pathologic 
T2). On the basis of these findings they suggested that DRE and serum PSA level should both 
be incorporated into in prostate screening programs so as to salvage men with higher grade 
or higher stage tumours. The PPV going with these data is not given, leaving unclear how 
many biopsies were needed to find one cancer. Also, it remains undetermined how many of 
these cancers progress to a higher PSA value and might still be curable after a next screen.
Our present study aims at further elucidation of the value of DRE in detecting preferably 
poorly differentiated PCs by using data derived from the second screening round.
Screening without DRE/TRUS (biopsy indication PSA≥3.0 ng/ml) resulted 4 years later in 
a PC detection rate similar to that in the group initially screened with DRE/TRUS (table 1). 
Clinical stage and differentiation grade did not differ in a statistically significant way between 
these protocols. Neither the GS of the 75 RP specimens differed significantly. In contrast, 
pathological stage of these 75 specimens showed more extraprostatic extension (T3 or 
more) in the group initially screened without DRE/TRUS (group-2, p=0.035). Although this 
conclusion is based on a small number of RP specimens and the difference is just significant 
(p=0.035), this is an observation to which we have to pay attention during further follow-up.
The rate of ICs is an important parameter to determine the sensitivity of the screening pro-
cedure125. The number of ICs was identical in the two groups (N=11). Also the percentage ICs 
of those at risk in group-1 and 2 (0.18 and 0.14%) was comparable. As far as we can judge on 
the basis of these low numbers, IC characteristics seemed to remain similar after the protocol 
change in this study, although one IC had a T4 clinical stage in group-2.
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Even if a high risk group existed amongst the cancers found by DRE at low PSA levels (<2.6 
ng/ml) as described by Han et al.124, PSA-based screening should find these tumours in a con-
secutive screening round when the PSA has risen to a level higher than the threshold value 
for biopsy. If these aggressive tumours were missed in the first round of this study due to the 
omission of DRE/TRUS, we would find aggressive, poorly differentiated PCs in the second 
round or many PCs would be clinically detected between the two screening rounds, as ICs.
However, we did find three PCs with a biopsy GS≥9 in group-2 (round 2). Such highly de-
differentiated tumours should not be missed in a screening program. If we assume that these 
PCs had a palpable or visible lesion in round 1, 8,044 men had had to undergo DRE/TRUS at 
that time. A screening program will never be able to find all cancers in a group, but intends to 
find a balance between the number of detected, clinically significant cancers and the burden 
to the screened individual. A trade-off has to be made between finding all PCs examining 
8,000 more men by DRE/TRUS and biopsy those with an abnormal result, or to miss these 
three cancers, bothering fewer men with invasive tests.
Due to the omission of DRE/TRUS, we may have missed PCs in group-2 in the first screening 
round, which we did find in group-1 (79 PCs in round 1). These 79 PCs were mainly confined 
to the prostate and had a GS<7, and were therefore curable. There are three possibilities for 
the PCs we missed after the protocol change. Firstly, they were detected 4 years later in the 
subsequent screening, which is acceptable because most cancers we detected in the second 
round were still curable. Secondly, they were detected as ICs. This is not likely, because we 
detected an equal number and proportion of ICs in both groups. Based on this finding, a 
screening interval of 4 years seems plausible, because group-2 did not reveal more ICs or 
screen-detected PCs in the second round. Also the omission of DRE in favour of lowering the 
PSA cut-off level seems justified. Thirdly, they remain undetected in spite of our follow-up of 
4 years.
ConClusIons
Omitting DRE and TRUS in the screening protocol did not result in an increased interval 
cancer rate or an increased prostate cancer detection after 4 years. Screening without DRE/
TRUS did not lead to the detection of more aggressive prostate cancers after 4 years (similar 
tumour characteristics were seen in both groups). So far, the interval cancers also seem to 
have similar tumour characteristics in both protocols. Therefore, the risk of screening without 
DRE/TRUS seems acceptable. However, considering the naturally slow growth of prostate 
cancer, the 4-year follow-up in this study may be too short to draw a definitive conclusion. A 
conclusive evaluation of the omission of DRE/TRUS will be possible only after the conclusion 
of the randomised study.
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AbstrACt
Objectives
To compare tumour characteristics of screen-detected prostate cancers either by digital rec-
tal examination (DRE) or by prostate-specific antigen (PSA) as biopsy indication at low PSA.
Methods
Two populations with PSA between 2.0-3.9 ng/ml were studied. Group-1 was biopsied if 
DRE was suspicious (1st screening-round, N=1,877). In group-2 all men were offered biopsy, 
regardless of DRE result (side-study in 2nd screening-round, N=801). We compared cancer 
detection rates and tumour characteristics.
Results
In group-1 abnormal DRE prompted biopsy in 253 (13.5%) men (236 (93.3%) actually bi-
opsied). Forty-nine prostate cancers were detected, resulting in a cancer detection rate of 
49/1,877=2.6%. In group-2 we found 120 cancers in 666 (83.1%) men actually biopsied, can-
cer detection rate=120/801=15.0%. Of all cancers detected, organ confinement (clinical T2) 
was found in 77.5% (group-1) and 96.6% (group-2; of which 99 T1c). Of all prostate cancers 
46.9% in group-1 and 15.0% in group-2 had biopsy Gleason score ≥7. In the latter, 15.2% 
of T1cs were classified as Gleason score ≥7. Considering only prostate cancers with organ 
confinement or Gleason score ≥7 for each group, cancer detection rates amounted to 2.0% 
versus 14.5% and 1.2% versus 2.3% for group-1 and group-2, respectively.
Conclusions
PSA-based screening detected a considerable amount (15.2%) of potentially aggressive tu-
mours as T1cs, but in addition large numbers of possibly insignificant cancers (T1c, Gleason 
score 6) were diagnosed. DRE seemed to detect more selectively high-grade cancers, but also 
missed many of these. Considering both populations and the need to detect aggressive but 
confined cancers, PSA as biopsy indication outperformed DRE at the price of more biopsies 
(13.5% versus 100% if all would comply).
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IntroDuCtIon
Screening for prostate cancer (PC) has become common in Western Europe and the United 
States. In the United States, approximately 75% of the men aged 50 years or older underwent 
a prostate-specific antigen (PSA) test at least once126, 127.
In screening and early detection programs for PC, the value of digital rectal examination 
(DRE) remains controversial due to its variable performance and subjectivity. The current use 
of PSA cut-off points such as 2.6117, 128, 3.014, 62 or 4.0 ng/ml129 as a biopsy indication, limits the 
domain of DRE to PSA levels below these points. It has been shown that at PSA levels <4.0 
ng/ml, approximately nine out of ten biopsies indicated by a suspicious DRE are negative 
for the diagnosis of PC13, 16. The PSA range <2.0 ng/ml is mainly credit to this large number 
of cancer-negative prostate biopsies. Schröder et al. found that DRE had a low predictive 
value in men with low PSA levels. Performance of DRE was strongly dependent on PSA levels 
and was poorest when the PSA level was less than 3.0 ng/ml, an area that is considered the 
domain of DRE16. As a consequence of this low predictive value and of the favourable charac-
teristics of most detected PCs, rectal examination has been omitted as a screening test from 
the European Randomized Study of Screening for Prostate Cancer (ERSPC)9, 14, 55.
However, a protocol change which permits the missing of potentially life threatening can-
cers, here defined as cancers with Gleason score (GS) 7 or higher, must be carefully monitored. 
In the current study we compared the characteristics of cancers detected either by a suspi-
cious DRE or by PSA-based screening in the PSA range 2.0-3.9 ng/ml. In this way, the value of 
DRE at low PSA levels (the range of interest) can be evaluated. Are potentially aggressive PCs 
more efficiently detected at a curable stage by DRE-based screening or screening based on 
a PSA cut-off? The answer to this question may help to elucidate the controversy about the 
value of DRE at low PSA levels.
methoDs
Study population
In the Rotterdam area all men in the age group 55-75 years were identified by the population 
registry and asked to participate in a randomised screening study for PC. Men who responded 
by returning the intake questionnaire and a signed informed consent form were randomised 
(N=42,376). The total screening cohort of ERSPC (section Rotterdam) consisted of 21,210 men 
(aged 55-74 years), of whom 19,970 men were actually screened. These men were screened 
by means of a serum PSA determination and, depending on the screening protocol, a DRE 
and transrectal ultrasound (TRUS). Sextant biopsy was proposed if indicated. A more detailed 
description of study characteristics has been published elsewhere120.
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In the current study we investigated two different study populations of the screening co-
hort, both in men that presented with PSA levels between 2.0-3.9 ng/ml. The first group was 
biopsied in case of a suspicious DRE (group-1, N=1,877). In the 2nd group all men were offered 
biopsy, regardless of the DRE result (group-2, N=801). The result of TRUS as a screening test 
was not considered in this study. For group-1 we used data of the first screening round with a 
screening protocol based on both the PSA value and DRE result (biopsy indication if PSA≥4.0 
ng/ml and/or DRE abnormal, December 1993-April 1997) (figure 1). For group-2 we used data 
of a side-study performed in the second screening round. During this side-study, biopsy was 
recommended in all men with a PSA value of 2.0 ng/ml or higher (April 2001-August 2002). 
At the first screen, 4 years earlier, these men had had a biopsy indication if their PSA was ≥3.0 
ng/ml. Participants in group-2 who had formerly been biopsied in the first screening round 
(N=85) were excluded from our study population.
We compared cancer detection rate (CDR, the proportion PCs in screened men), positive 
predictive value (PPV, the proportion PCs/number of biopsied men) and tumour characteris-
tics between the two groups.
Techniques
PSA values were assessed (Beckman Coulter-Hybritech; San Diego, California) before the oth-
er tests were performed. DRE was performed by a trained physician. Nodularity and indura-
tion were considered abnormal. TRUS-guided lateral sextant transrectal prostate biopsy was 
performed, in line with the findings of Eskew et al.121, using a Bard (C.R. Bard, Convington, GA) 
spring-loaded biopsy gun and an 18-G biopsy needle. According to the biopsy protocol, no 
additional, lesion-directed biopsy core was taken in case of an abnormal DRE. TRUS was also 
used to assess the prostatic volume. The TNM 1992 system was used for clinical staging of the 
detected carcinomas. Clinical stage, based on DRE, was defined by the screening physician.
Pathological examination
Biopsy specimens were histopathologically analysed by a single pathologist (TvdK). PCs were 
graded according to the GS system.
The ERSPC was approved by the institutional board of the Erasmus MC, University Medical 
Center and by a national board (required by Dutch law for population screening studies).
results
Group-1: screening on the basis of an abnormal DRE
Of the 1,900 men with a PSA value between 2.0 and 3.9 ng/ml, a DRE result was available in 
1,877 men (98.8%). Consequently, group-1 consisted of 1,877 men. These participants had a 
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mean age of 64.9 years (median 65.0). Their mean PSA value was 2.8 ng/ml (median 2.7). Of 
1,837 (97.9%) participants the prostatic volume was assessed. Mean prostatic volume was 
39.8 ml (median 37.3). Two hundred and fifty-three (13.5%) men had an abnormal DRE of 
whom 236 (236/253=93.3%) were actually biopsied. The reason for cancelling biopsy was 
refusal after PSA determination (N=10) and due to medication (N=7). Forty-nine PCs were 
detected (figure 1). The PPV was 20.8% (49/236) and the CDR was 2.6% (49/1,877). To detect 
1 PC, it was necessary to biopsy 5 men (table 1); 10 biopsies were needed to detect 1 PC with 
GS≥7. Organ confinement (clinical stage T2, based on DRE) was found in 38 PCs (77.5%), 10 
PCs (20.4%) had clinical stage T3 and one (2.0%) had T4. Moderately to poorly differentiated 
tumours (GS≥7) were found by DRE in 46.9% (23/49) (table 2). Initial treatment in this group 
was radical prostatectomy (RP) in 38.8% (N=19; organ confinement in 89.5%, GS≥7 in 52.9%), 
radiotherapy (RT) in 46.9% and watchful waiting (WaWa) in 14.3%.
Group-2: screening on the basis of PSA cut-off (≥2.0 ng/ml)
In the second screening round, in a side-study during the limited period of 16 months, 886 
men presented with a PSA between 2.0-3.9 ng/ml. Eighty-five men (9.6%) were excluded 
from this study because they had undergone a prior biopsy in the first screening round (all 
had had a benign biopsy result). Group-2 consisted therefore of 801 men with a PSA value 
Figure 1. Two groups of screened men, biopsied either if they had an abnormal DRE or if they had a PSA value ≥2.0 ng/ml. All included 
men presented with a PSA value between 2.0 and 3.9 ng/ml.
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CDR (cancer detection rate) = number of detected cancers divided by number of men screened. 
PPV (positive predictive value) = number of detected cancers divided by the number of men biopsied. DRE, 
digital rectal examination; PSA, prostate-specific antigen. 
Group-1: 1,877 men 
DRE-based screening 
(1st screening round, 
December 1993-April 1997) 
PSA 2.0-3.9 ng/ml 
253 (13.5%) men had an 
abnormal DRE; 236 (93.3%) 
men were actually biopsied 
49 prostate cancers 
detected (CDR = 2.6%, PPV = 
20.8%) 
 
Group-2: 801 men 
PSA≥2.0 ng/ml is biopsy 
indication 
(2nd screening round, April 
2001-August 2002) 
PSA 2.0-3.9 ng/ml 
801 men (100%) had biopsy 
indication; 666 (83.1%) men 
were actually biopsied 
120 prostate cancers 
detected (CDR = 15.0%, PPV 
= 18.0%) 
 
CDR (cancer detection rate) = number of detected cancers divided by number of men screened
PPV (positive predictive value) = number of detected cancers divided by the number of men biopsied
DRE, digital rectal examination; PSA, prostate-specific antigen
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between 2.0 and 3.9 ng/ml, who did have a PSA<3.0 ng/ml 4 years before in 98%. The mean 
age of these men was 66.6 years (median 66.5). Their mean PSA value was 2.7 ng/ml (median 
2.6). Mean prostatic volume was 40.9 ml (median 39.8; prostatic volume was assessed in 664 
(99.7%) men). Six hundred sixty-six of the 801 men (83.1%) were actually biopsied. The rea-
sons for not complying with biopsy recommendations were refusal after PSA determination 
Table 1: Comparison of two groups of men with a PSA value of 2.0-3.9 ng/ml, screened by lateralised sextant biopsy with either an 
abnormal DRE or a PSA≥2.0 ng/ml as a biopsy indication.
Comparison of men screened by means of DRE or PSA in the PSA range 2.0-3.9 ng/ml
DRE is biopsy indication (group-1) PSA≥2.0 is biopsy indication (group-2)
N men screened 1,877 801
N men with biopsy indication 253 (253/1,877 = 13.5%) 801 (801/801 = 100%)
N men biopsied 236 (236/253 = 93.3%) 666 (666/801 = 83.1%)
N PCs 49 120
PPV 20.8% (49/236) 18.0% (120/666)
CDR 2.6% (49/1,877) 15.0% (120/801)
No. of Bx needed to find 1 PC 4.8 5.6
PPV, positive predictive value, the proportion PCs/number of biopsied men; CDR, cancer detection rate, the proportion PCs/number of 
screened men; DRE, digital rectal examination; PSA, prostate-specific antigen
Table 2: Tumour characteristics of prostate cancers at PSA values 2.0-3.9 ng/ml. Biopsy indication was based on DRE (group-1) or PSA 
threshold value ≥2.0 ng/ml (group-2). The last column is hypothetical; the number of screened men in group-2 is multiplied by factor 
2.343 for better comparison with group-1.
Biopsy indication Abnormal DRE
(group-1)
PSA≥2.0 ng/ml
(group-2)
Group-2 multiplied 
by 2.343
N men screened 1,877 801 1,877
Mean age in years (median) 64.9 (65.0) 66.6 (66.5)
Mean TRUS volume in ml 
(median)
39.8 (37.3) 40.9 (39.8)
N PCs (%) 49 (100) 120 (100) 281
Clinical stage (%)*
T1c - 99 (82.5) 232
T2 38 (77.6) 17 (14.2) 40
T3 10 (20.4) 4 (3.3) 19
T4 1 (2.0) - -
Organ confined tumours (%) 38 (77.6) 116 (96.6) 272
Gleason score (%)
<7 26 (53.1) 102 (85.0) 239
7 15 (30.6) 15 (12.5) 35
>7 8 (16.3) 3 (2.5) 7
DRE, digital rectal examination; PSA, prostate-specific antigen; PC, prostate cancer; TRUS, transrectal ultrasound
*The clinical stage was based on DRE
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(N=124), or medication which could not be discontinued (N=11). In the biopsied group 120 
cancers were detected (PPV=18.0% (120/666), CDR 15.0% (120/801)). To detect 1 PC, it was 
necessary to biopsy 6 men (table 1); 37 biopsies were needed to detect 1 PC with GS≥7. 
Organ confinement was found in 116 PCs (96.6%), of which 99 (82.5%) were T1c cancers. PSA-
based screening detected 18 (15.0%) moderately to poorly differentiated tumours (GS≥7). Of 
the 99 detected T1c cancers, 15 (15.2%) were classified as GS≥7 (13 GS=7, 1 GS=8, 1 GS=10) 
(table 2). RP was the initial treatment in 39 (32.5%, N=39; organ confinement in 86.1%, GS≥7 
in 38.9%) cases, RT in 38 (31.7%) and WaWa in 41 (34.1%). Information on initial treatment was 
missing in two (1.7%) cases.
Considering the detection of organ confined PC for the two screened populations, DRE-
based screening had a detection rate of 2.0% (38/1,877, group-1) and PSA-based screening 
14.5% (116/801, group-2). Detection of moderately to poorly differentiated PCs, cancers with 
a GS of ≥7, amounted to 1.2% (23/1,877, group-1) versus 2.3% (18/801, group-2). Results have 
been summarised in table 2.
In order to evaluate the detection frequency of potentially aggressive PCs, that is PCs with 
GS≥7, per PSA level, the studied PSA range was split into 2.0-2.9 and 3.0-3.9 ng/ml for both 
group-1 and 2 (table 3). To selectively find GS≥7 cancers in these two PSA ranges, it was nec-
essary to biopsy 16 men in group-1 and 31 men in group-2 to find one PC at PSA 2.0-2.9 ng/
Table 3: Tumour characteristics of prostate cancers at PSA values 2.0-2.9 ng/ml compared to values of 3.0-3.9 ng/ml. Biopsy indication was 
based on DRE (group-1) or PSA threshold value ≥2.0 ng/ml (group-2). The last column represents the entire PSA range (2.0-3.9 ng/ml).
GrouP-1 PSA 2.0-2.9 ng/ml PSA 3.0-3.9 ng/ml PsA 2.0-3.9 ng/ml
N men (%) 1,184 (63.1) 693 (36.9) 1,877 (100)
N men biopsied (%) 129 (54.7) 107 (45.3) 236 (100)
N PCs (%) 15 (30.6) 34 (69.4) 49 (100)
Gleason score (%)
<7 7 (26.9) 19 (73.1) 26 (100)
≥7 8 (34.8) 15 (65.2) 23 (100)
PPV % GS≥7 PCs 6.2 (8/129) 14.0 (15/107) 9.8 (23/236)
CDR % GS≥7 PCs 0.7 (8/1,184) 2.2 (15/693) 1.2 (23/1,877)
GrouP-2
N men (%) 547 (68.3) 254 (31.7) 801 (100)
N men biopsied (%) 455 (68.3) 211 (31.7) 666 (100)
N PCs (%) 73 (60.8) 47 (39.2) 120 (100)
Gleason score (%)
<7 67 (65.7) 35 (34.3) 102 (100)
≥7 6 (33.3) 12 (66.7) 18 (100)
PPV % GS≥7 PCs 1.3 (6/455) 5.7 (12/211) 2.7 (18/666)
CDR % GS≥7 PCs 1.1 (6/547) 4.7 (12/254) 2.3 (18/801)
PSA, prostate-specific antigen; PC, prostate cancer; DRE, digital rectal examination; PPV, positive predictive value, the proportion PCs/
number of biopsied men; CDR, cancer detection rate, the proportion PCs/number of screened men
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ml. Seven men in group-1 and 18 men in group-2 had to be biopsied to find one PC in range 
3.0-3.9 ng/ml. The PPV and CDR for both groups and PSA ranges are depicted in table 3.
DIsCussIon
Due to its poor performance, especially at low PSA levels, DRE has been omitted from the 
ERSPC9, 14, 16, 55. The subsequent screening protocol, based on a PSA cut-off value slightly 
increased the PPV14. However, a certain fraction of clinically diagnosable tumours may be 
missed with using a PSA cut-off value. It is uncertain if PSA-based screening will detect these 
cancers at a still curable stage at the moment that the PSA has risen above the threshold 
value. In the current study, we compared DRE-based screening versus screening with a PSA 
cut-off value as the sole biopsy indication. The value of TRUS was not studied because it 
had been previously shown that this is not a valuable test for the early detection of PC in a 
screening program9-11.
The proportion of men with a biopsy indication that was actually biopsied, was higher in 
group-1 than in group-2 (93.3% versus 83.1%). One reason to keep using DRE as a screening 
test is a higher compliance rate for biopsy than men who were screened by PSA cut-off. Of 
all men who did not undergo the recommended biopsy, men with an abnormal DRE (N=253) 
refused in 4.0% (group-1). This is in contrast to the men in which only PSA cut-off 2.0 ng/
ml was used (group-2, N=801), in which 15.5% refused biopsy. The number of detected PCs 
in biopsied men (PPV) was comparable in both groups, (20.8% for group-1 and 18.0% for 
group-2). The number of PCs detected per screened group (CDR) was higher in group-2 which 
was expected, because in the PSA-based protocol all men had a biopsy indication (in spite of 
the lower percentage men actually biopsied in this group). If the studied PSA range was split 
into PSA 2.0-2.9 and 3.0-3.9 ng/ml, it appeared that, although low numbers, more potentially 
aggressive tumours were detected in the latter PSA range in both groups. Furthermore, CDR 
of GS≥7 tumours in that range in group-2 was twice the CDR of group-1 (table 3). More men 
were treated by watchful waiting in group-2 (34.1% versus 14.3%). Ninety percent of these 
men had a T1c PC.
To make a better comparison between group-1 and 2, we multiplied the number of par-
ticipants in group-2 by 2.343. In that hypothetical case, group-1 and group-2 consisted both 
of 1,877 men (table 2). This results in a comparable number of T2 and T3 cases (T2, 38 in 
group-1 versus 40 in group-2; T3,11 versus 19) but an additional 232 T1c cancers when using 
the PSA-based screening algorithm. The detection rate of highly differentiated PC (GS<7) was 
much higher in group-2 (239 compared to 26), therefore one can conclude that PSA-based 
screening led to overdiagnosis (large number of possibly indolent PCs, that is T1c cancers 
with favourable GS). At the same time, however, PSA-based screening detected twice the 
number of GS=7 cancers, which cannot not be ignored. The question is if the detection of 
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more of these potentially aggressive cases outweighs the diagnosis of a considerable number 
possibly indolent PCs. The answer to this question cannot result from our data. Lowering the 
PSA cut-off to 2.0 ng/ml may have identified the aggressive cancers in group-2 at the expense 
of detecting a large proportion of cancers to be classified as indolent and a considerable 
amount of additional biopsy sessions with the coinciding stress and costs. On the other hand, 
DRE-based screening (group-1) missed a considerable amount clinical significant, potentially 
aggressive tumours. Although a guideline in how to handle screening at low PSA levels in 
daily practice is obviously needed, it is not possible to draw one straight-forward conclusion 
in using DRE or a low PSA cut-off value. This study demonstrated the need of a more selective 
screening test to selectively detect those cancers in low PSA ranges with aggressive tumour 
characteristics.
Due to the used selection criteria, only few radical prostatectomy specimens were avail-
able for evaluation (N=19 in group-1 and N=39 in group-2). With such low numbers con-
clusions are not allowed to be drawn without the interference of the component chance. 
Therefore we used the biopsy GS data. A problem of a GS based on prostate biopsy is the 
possible discordance with the GS after examination of the radical prostatectomy specimen. 
Upgrading as well as undergrading of biopsy GS after radical prostatectomy occurs in con-
siderable cases109, 110. Our contemporary data and the following studies must be compared in 
this context.
Compared to our biopsy results, Kravchick et al. reported higher numbers of moderately 
to poorly differentiated disease on biopsy (GS≥7) in the PSA 2.0-4.0 ng/ml range. A total of 
171 men underwent biopsy (recommended if PSA was 2.0-4.0 ng/ml). Mean age was lower 
(63.3 years) and prostatic volume was higher (50.5 cm3) than in our study group. The mean 
number of biopsy cores was 10 in contrast to our sextant biopsies130. In this group 39 PCs 
were detected, which represented a CDR of 22.8%, compared to 15.0% in our group-2. Of 
these tumours, 69.2% had biopsy GS<7 (compared to 85.0% in our study). Consequently, 
30.8% of the PCs had by biopsy a GS≥7, which is double the percentage we found (15%). An 
explanation for finding more PCs with a higher GS are likely to be the differences in the study 
population (unscreened versus prescreened men) and the larger number of biopsy cores 
taken (a mean of 10 cores in comparison to 6 cores in our study) through which undergrad-
ing could be less.
In 555 men (PSA 2-4 ng/ml) Catalona et al. detected 235 men with PC, in which in 224 men 
a biopsy GS was known (6 and 10 core biopsies). Ninety percent had a GS<7, 7% had GS=7 
and 4% had GS>7. These findings are similar with ours (85% biopsy GS<7, 12.5% GS=7 and 
2.5% GS>7) although it is not clear if men in Catalona’s study had a normal or abnormal DRE. 
Of these men, 137 underwent RP, of which 79% had GS<7, 18% had GS=7 and 3% had GS>7. 
The percent of pathological GS≥7 was higher than that identified by biopsy. Thus, as would 
be expected, some cancers were upgraded based on the prostatectomy specimen109. In con-
trast, Catalona et al. concluded in another study that more than 80% of cancers, detected 
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in a population of men with normal DRE and PSA between 2.6-4.0 ng/ml, were considered 
significant tumours and thus were worth finding117. However, they defined significant PC as 
any cancer involving more than 1% of the total prostatic volume or having a GS=7 or higher 
in the prostatectomy specimen. The mean prostatic volume of their participants with PC was 
33.7 cm3; their cut-off volume can than be estimated at approximately 0.3 cm3, which is lower 
than the commonly applied90 0.5 cm3 and would explain in part the higher rate of significant 
PC in their study. In a third study128, this group found supportive evidence for a lower PSA 
cut-off (2.6-4.0 ng/ml) to detect a significantly higher percentage of organ-confined tumours 
(88% versus 63% at PSA 4.1-10.0 ng/ml) without detecting more clinically insignificant (11.9% 
versus 11.5%; organ confined, tumour volume <0.2 cm3, GS<720) or clinically unimportant 
cancers (23.8% versus 26.9%; organ confined, tumour volume <0.5 cm3, GS<7105), based on 
radical prostatectomy specimens)128. This paper does however not mention if the selected 
population is screened before in the biennial screening program of the study.
In our current study we compared men screened in the first screening round (group-1) to 
men screened in the second round (group-2). This comparison is biased by the different char-
acteristics of an unscreened and prescreened group of men. Formerly biopsied men (N=85; 
all had had a benign biopsy result) were excluded. Ninety-eight percent of the men in our 
study group-2 had a PSA value <3.0 ng/ml in the first screening round. While the biopsy in-
dication in the first round was PSA≥3.0 ng/ml, it is unlikely that a large proportion of cancers 
were detected that could bias the results in group-2.
Apart from a possible selection bias, the participants in group-2 were 1 year and a half 
older than men in group-1. As PC incidence rises with rising age97-99, it is possible that a small 
part of the higher cancer detection can be attributed to the higher age in group-2. Prostatic 
volume was comparable in our group-1 and 2 (mean volume 39.8 and 40.9 ml), so prostatic 
volume did not play an important role as a negative predictor for finding prostate cancer30. 
In group-1 13.5% (253/1,877) had an abnormal DRE result. Of all men in group-2 who al-
ready agreed to undergo a biopsy, 12.0% (80/666) had an abnormal DRE result. Thus, the 
rate of abnormal DREs is comparable in both groups (assuming that the men who refused to 
undergo a biopsy in group-2 are normally distributed in having a normal or abnormal DRE 
result). Although only 21 men with an abnormal DRE had PC in group-2, and comparison with 
group-1 is difficult, the distribution of GS shows the same trend (the number of men with 
GS<7 is the largest).
To our knowledge, it is unfortunately not possible to relate our data to those of the Prostate 
Cancer Prevention Trial on the basis of the information in available publications at this mo-
ment24, 33, 91.
Screening for PC at low PSA range: the impact of DRE on tumour incidence and tumour characteristics 73
ConClusIons
Considering the populations and the need to detect aggressive but confined cancers, PSA 
as a biopsy indication outperformed DRE in the PSA range 2.0-3.9 ng/ml at the price of more 
biopsies (13.5% versus 100% if all would comply) and subsequently the diagnosis of a large 
number of T1c cancers with a Gleason score of 6, generally regarded as clinically insignificant. 
However, PSA-based screening also revealed a considerable amount (15.2%) of potentially 
aggressive tumours that were present as T1c cancers. A new screening test that selectively 
and preferably objectively detects potentially aggressive prostate cancers is needed, espe-
cially at low PSA ranges, which represent the majority of men in this age range.
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AbstrACt
Background
The value of digital rectal examination (DRE) as screening test for prostate cancer is contro-
versial in the current prostate-specific antigen (PSA) era.
Objectives
To determine 1) the additional value of a suspicious DRE for the detection of prostate cancer 
in men with an elevated PSA level in subsequent screenings and 2) the tumour characteristics 
of prostate cancers detected in men with a suspicious DRE.
Design, setting and participants
Within the screening study, from 1997-2006 men aged 55-75 years were invited for an every 
4-year PSA determination. A PSA level ≥3.0 ng/ml prompted a DRE and a transrectal ultra-
sound (TRUS)-guided, lateralised sextant biopsy. Throughout the three screenings of the 
ERSPC, Rotterdam, 5,040 biopsy sessions were evaluated.
Measurements
We determined the positive predictive values (PPVs) of a suspicious DRE and normal DRE, 
which entailed, respectively, the proportion of prostate cancers detected in men with a suspi-
cious DRE or normal DRE divided by, respectively, all biopsied men with a suspicious DRE or 
normal DRE.
Results and limitations
At initial screening, the PPV of a suspicious DRE, in conjunction with an elevated PSA level, to 
detect prostate cancer was 48.6% compared to 22.4% for men with a normal DRE. Both PPVs 
decreased in consecutive screens: respectively, 29.9% versus 17.1% (screen 2) and 21.2% ver-
sus 18.2% (screen 3). Respectively, 71.0% (p<0.001), 68.8% (<0.001) and 85.7% (p=0.002) of 
all prostate cancers with a Gleason score >7 were detected in men with a suspicious DRE at 
screens 1, 2 and 3. A limitation is that only biopsied men were evaluated.
Conclusions
At initial and subsequent screenings, the chance of having cancer at biopsy was higher in 
men with a suspicious DRE compared to men with normal DRE (to a lesser extent in subse-
quent screenings), and the combination of a PSA≥3.0 ng/ml with a suspicious DRE resulted in 
detecting significantly more PCs with Gleason score >7. DRE may be useful in more selective 
screening procedures to decrease unnecessary biopsies and overdiagnosis.
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IntroDuCtIon
Prostate cancer (PC) screening is performed widely throughout the United States, and the 
incidence of PC is increasing131. Early detection has, however, not yet been shown to re-
duce prostate-specific mortality and, therefore, PC screening is being tested in two large 
randomised trials21, 129. Before the prostate-specific antigen (PSA) era, the only tool for early 
detection of PC was the digital rectal examination (DRE). DRE is subjective132, and many men 
who are destined to die of PC never develop a palpable abnormality133. After implementation 
of PSA as a screening test, disease detection subsequently increased dramatically134, 135. At 
present, serum PSA testing is used primarily to screen for PC, although it is known not to be a 
specific test. There is a considerable overlap among PSA levels in men with normal prostates, 
benign prostate hyperplasia, and localised PC. PSA-based PC screening has resulted in more 
frequent detection of small volume, low-grade, and organ-confined cancers (stage shift)136, 
137. Many of these cancers have the histological characteristics of autopsy tumours, that is, 
tumours that have not become symptomatic during life138. Concerns have been risen about 
the possibility of overdiagnosis and overtreatment of PCs, of which the detection and sub-
sequent treatment is unlikely to benefit patients64, 136, 139. In an attempt to avoid unnecessary 
biopsies and overdiagnosis, nomograms were developed140-143. In addition, the prediction of 
a screen-detected, possible indolent PC is conceivable using a new nomogram54.
The number of men who undergo prostate biopsy increases, because screening for PC be-
comes more common and because of the trend to lower the PSA cut-off value for biopsy144. 
A question that arises is if it is still useful to perform DRE in prescreened men in whom these 
small and possibly insignificant tumours are detected more frequently. The objectives of 
this study were to determine the positive predictive value (PPV) of an abnormal DRE for the 
detection of PC in men biopsied because of a PSA level ≥3.0 ng/ml within the European Ran-
domized study of Screening for Prostate Cancer (ERSPC), Rotterdam. We aimed to answer 
the following questions: 1) what is the additional value of an abnormal DRE next to a PSA 
level ≥3.0 ng/ml as an indication for biopsy, and 2) does DRE have an additional effect in the 
selective identification of more hazardous prostate cancers, that is, tumours with a Gleason 
score >7?
mAterIAls AnD methoDs
Study population
In the screening arm of the ERSPC, Rotterdam, men aged 55-75 years were invited for every 
4-year PSA determination, and a PSA level ≥3.0 ng/ml prompted a transrectal ultrasound 
(TRUS)-guided lateralised sextant biopsy (May 1997 to October 2006). All men underwent a 
DRE prior to biopsy. When biopsy results were benign, participants were re-invited 4 years 
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later. A detailed description of the study design has been published previously21. In the cur-
rent study 5,040 biopsy sessions throughout three screens were evaluated for the presence 
of PC in relation to the DRE result. Because a previous negative biopsy is a negative predictor 
for detecting PC30, 55, men with and without a previous biopsy were evaluated separately for 
PPVs of PSA and DRE and tumour characteristics in screens 2 and 3 (figure 1).
Predictive value: definitions
The study cohort consisted of men who were biopsied. The PPV to find PC in men with a 
normal DRE and an elevated PSA level (≥3.0) was defined as the proportion PCs found in 
men with a normal DRE divided by the total number of men biopsied with an elevated PSA 
and a normal DRE (PPVnDRE). The additional predictive value of a suspicious DRE (i.e., in men 
with a PSA level ≥3.0 and a suspicious DRE) for finding PC entailed the proportion of PCs 
found in men with a suspicious DRE divided by the total number of men with a suspicious 
DRE (PPVsDRE). The overall PPV of this screening procedure was the combination of PPVnDRE and 
PPVsDRE: PPVoverall = proportion PCs detected divided by the total number of biopsied men.
Techniques
Screening entailed determination of serum PSA concentration (Beckman-Coulter Hybritech 
Tandem-E Assay, CA, USA). TRUS was performed using a Bruel-Kjaer model 1,846 mainframe 
and a 7-MHz biplanar endorectal transducer, with the subject in the left lateral decubitus 
position. Nodularity and induration were considered abnormal on DRE, and a hypoechoic le-
sion was considered suspicious on TRUS. Lateral sextant transrectal prostate biopsy121, 145 was 
performed, using a Bard spring-loaded biopsy gun (Convington, GA, USA) and an 18-gauge 
biopsy needle. An additional biopsy was taken in case of a suspicious area on TRUS. Clinical 
stage was based on DRE.
Pathologic examination
Biopsy specimens were analysed histopathologically by a uropathologist, and PC was graded 
according to the Gleason score (GS) system107, 108. A potentially aggressive PC was defined as 
having a GS>7.
Statistical analyses
Chi-square tests were used to test the relationship of the outcome of DRE and the GS of PCs 
that were detected.
The ERSPC was approved by the institutional board of the Erasmus MC, University Medical 
Center in Rotterdam and by the Minister of Health.
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results
Predictive values
Throughout three screens, 5,040 biopsy sessions were evaluated for the presence of PC in 
relation to the DRE result. The number of men that were biopsied because of a PSA value ≥3.0 
ng/ml was 1,849 (18.0% of all men who underwent a PSA test), 2,220 (17.7%), and 971 (17.3%) 
for screens 1, 2 and 3, respectively. As a result of these biopsy sessions, respectively, 541 
Figure 1: Flow charts. Number of men screened and biopsied and number of cancers detected and their Gleason scores are displayed for 
screens 1, 2 and 3.
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(5.3% of all men who underwent a PSA test), 441 (3.5%), and 185 (3.3%) PCs were detected 
at subsequent screenings. Of the participants biopsied at screen 2, 43.2% (958 of 2,220) had 
undergone an earlier biopsy (with benign result). For participants biopsied at screen 3, this 
proportion was 67.1% (652 of 971). At the initial screening, 26.3% of the participants who 
were biopsied had an abnormal DRE; this proportion was 21.6% and 28.2%, for screens 2 and 
3, respectively. The predictive value of an abnormal DRE (PPVsDRE) was 48.6% compared to the 
PPV to find PC in men with a normal DRE (PPVnDRE) of 22.4% at initial screening. Throughout 
the consecutive screens the PPVsDRE remained higher than the PPVnDRE, although both PPVs 
decreased in screens 2 and 3 (table 1).
No previous biopsy
In men biopsied for the first time at screen 2 or screen 3, the proportion of participants with 
an abnormal DRE was 20.8% (screen 2) and 27.0% (screen 3). The PPV of an abnormal DRE 
(PPVsDRE) was 39.5% at screen 2 and 38.4% at screen 3, lower but in the range of the PPVsDRE of 
48.6% at initial screening. The PPV for men with a normal DRE (PPVnDRE) amounted to 22.1% for 
screen 2 and 24.9% for screen 3, values comparable to the PPVnDRE of 22.4% at initial screening 
(table 2).
Previous biopsy
In this group, 22.5% and 28.8% respectively, had a suspicious DRE in screen 2 and screen 3. 
PPVsDRE as well as the PPVnDRE decreased at the second and third screening (table 2).
Table 1: Overall positive predictive value in men with an abnormal or normal DRE, biopsied as indicated by a PSA value of ≥3.0 ng/ml in 
three subsequent screening visits.
Screening visit 1 Screening visit 2 Screening visit 3
N biopsied 1,849 2,220 971
N PCs 541 441 185
N abnormal DRE (%) 486 (26.3) 479 (21.6) 274 (28.2)
PCs found 236 143 58
PPVsDRE 236/486=48.6% 143/479=29.9% 58/274=21.2%
N normal DRE (%) 1,363 (73.7) 1,741 (78.4) 697 (71.8)
PCs found 305 298 127
PPVnDRE 305/1,363=22.4% 298/1,741=17.1% 127/697=18.2%
PPVoverall was 541/1,849=29.3% for the first, 19.9% for the second and 19.1% for the third screening round; DRE, digital rectal examination; 
PC, prostate cancer; PPV, positive predictive value.
PPVnDRE = proportion PCs in men with normal DRE/ total number of biopsied men with normal DRE
PPVsDRE = proportion PCs in men with abnormal DRE/ total number of biopsied men with abnormal DRE
PPVoverall = proportion PCs detected/ total number of biopsied men
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Tumour characteristics
Men with or without a previous biopsy were taken together for the evaluation of tumour 
characteristics, as there was no obvious difference (data not shown). Of the cancers that 
were palpable on DRE, 71% were organ-confined at initial screening. At the second and third 
screenings, this proportion was 92% and 93%, respectively. Potentially aggressive PCs (GS>7) 
were statistically significantly more often detected in men who had an abnormal DRE. This 
was seen throughout all three consecutive screens (table 3). Of all potentially aggressive PCs, 
71.0%, 68.8% and 85.7% respectively, were detected in men with an abnormal DRE in the 
consecutive screens.
DIsCussIon
The proportion of men undergoing a prostate biopsy (for PSA level ≥3.0 ng/ml) that had an 
abnormal DRE was comparable in the three screenings (table 1). Having a suspicious DRE led 
to a greater chance of having PC at initial screening: the PPV of an abnormal DRE was twice 
that of a normal DRE. Although both predictive values decreased in subsequent screenings, 
the chance for finding PC remained higher in men with an abnormal DRE in screen 2 and 
screen 3. A factor possibly influencing the chance of finding PC is prostatic volume55. Because 
we used lateralised sextant biopsies instead of volume-adjusted biopsy schemes146, some 
cancers might have been missed, specifically in larger prostates. The mean prostate volume 
became larger in the later screens (49.6, 52.6 and 55.8 ml, respectively). A larger prostate 
results in a higher PSA level and, therefore, in indication for a biopsy if the PSA threshold of 
3.0 is exceeded. Because these PSA elevations are mostly associated with benign prostate 
hyperplasia, the indication for a biopsy remains in each consecutive screening, which results 
Table 2: The positive predictive value in men screened in screening rounds 2 and 3; men previously biopsied at an earlier screening visit 
(with benign result) were compared to men not previously biopsied.
Screening visit 2 Screening visit 3
Previous Bx No previous Bx Previous Bx No previous Bx
N biopsied 958 1,262 652 319
N PCs 116 325 94 91
N abnormal DRE (%) 216 (22.5) 263 (20.8) 188 (28.8) 86 (27.0)
PCs found 39 104 25 33
PPVsDRE 39/216=18.1% 104/263=39.5% 25/188=13.3% 33/86=38.4%
N normal DRE (%) 742 (77.5) 999 (79.2) 464 (71.2) 233 (73.0)
PCs found 77 221 69 58
PPVnDRE 77/742=10.4% 221/999=22.1% 69/464=14.9% 58/233=24.9%
Bx, biopsy; PC, prostate cancer; DRE, digital rectal examination
PPVnDRE = proportion PCs in men with normal DRE/ total number of biopsied men with normal DRE
PPVsDRE = proportion PCs in men with abnormal DRE/ total number of biopsied men with abnormal DRE
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in a lower PPV. At screen 2 and screen 3, some participants were biopsied for the second or 
third time. This is likely to be a major reason for the lower PPVs, as we know that having had 
a previous negative biopsy is associated with a lower chance of detecting cancer in consecu-
tive screens30. To analyse this further, we evaluated men with and without a previous biopsy 
separately in screens 2 and 3.
In men without a previous biopsy, an abnormal DRE still predicted a greater chance to have 
PC than a normal DRE in screens 2 and 3 (table 2). Although the PPVsDRE at screens 2 and 3 was 
somewhat lower than at initial screening, DRE was valuable in predicting the presence or 
absence of cancer in addition to the chance based on an elevated PSA level.
In men previously biopsied, both the PPVnDRE and the PPVsDRE decreased dramatically, es-
pecially at screen 3. The proportion of men with an abnormal DRE was comparable in men 
with and without a previous biopsy. As the PPV in men with an abnormal DRE decreased in 
men previously biopsied, apparently the nodus or induration that was palpated became less 
specific for the presence of PC. As mentioned previously, one explanation for this observa-
tion is related to the prostate volume. In men with a previous negative biopsy, the prostate 
Tables 3A, B and C: Biopsy Gleason score of detected prostate cancers in men with an abnormal or normal DRE in screens 1, 2 and 3, 
respectively. Participants who were biopsied previously and participants who were not were taken together in tables 3B and 3C.
Table 3A
sCreenInG VIsIt 1
DRE Biopsy Gleason score 
<7 (%)
Biopsy Gleason score 
=7 (%)
Biopsy Gleason score 
>7 (%)
Total
Normal 233 (65.6) 63 (40.6) 9 (29.0) 305
Abnormal 122 (34.4) 92 (59.4) 22 (71.0) 236
Total 355 (100) 155 (100) 31 (100) 541
Chi-square test p<0.001
Table 3B
sCreenInG VIsIt 2
DRE Biopsy Gleason score 
<7 (%)
Biopsy Gleason score 
=7 (%)
Biopsy Gleason score 
>7 (%)
Total
Normal 249 (72.6) 44 (53.7) 5 (31.2)) 298
Abnormal 94 (27.4) 38 (46.3) 11 (68.8) 143
Total 343 (100) 82 (100) 16 (100) 441
Chi-square test p<0.001
Table 3C
sCreenInG VIsIt 3
DRE Biopsy Gleason score 
<7 (%)
Biopsy Gleason score 
=7 (%)
Biopsy Gleason score 
>7 (%)
Total
Normal 112 (72.7) 14 (58.3) 1 (14.3) 127
Abnormal 42 (27.3) 10 (41.7) 6 (85.7) 58
Total 154 (100) 24 (100) 7 (100) 185
Chi-square test p=0.002
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volume was greater than in men not previously biopsied (61.8 versus 45.5 ml in screen 2 and 
60.3 versus 46.7 ml in screen 3). Another possible explanation is the fact that men screened at 
repeat visits represent a selective cohort. After all, a considerable number of PCs have already 
been detected at initial screening. It is known from previous ERSPC studies that PCs found 
at repeat screening are in general smaller tumours, which might be missed by DRE more 
frequently35, 147. Consistent with our finding, Lopez-Corona et al.148 concluded in a cohort of 
343 men with a previous negative biopsy, DRE was not a statistically significant predictor in 
their nomogram for a positive repeat prostate biopsy. In contrast, Eggener et al.149, using a 
multivariate analysis to identify predictors of subsequent PC in men with an initially negative 
biopsy, concluded that men with an initial PSA value of 2.6-4.0 ng/ml, an abnormal DRE and a 
negative previous biopsy had almost twice the risk for subsequent diagnosis of PC compared 
to the men with a normal DRE. However, the PPV of an abnormal DRE in this group was 18%, 
comparable with our PPVsDRE in previously biopsied men (table 2).
A limitation of the current study is that the value of DRE is not addressed in the total 
screened population, since we evaluated only biopsied men. The value of DRE could only 
be verified in men who underwent biopsy (i.e., men with a PSA level ≥3.0), which is the gold 
standard for defining if PC is present. Furthermore, we did not correct for the influence of a 
lesion-directed biopsy core in case of a hypoechoic lesion on TRUS. The proportion of men 
with an additional biopsy core was larger in men with a suspicious DRE in all screening rounds 
(respectively, 51% versus 15%, screen 1; 39% versus 11%, screen 2; 16% versus 7%, screen 3). 
Intuitively, biopsy of a suspect area on TRUS would lead to detecting more PCs. However, 
a recent study showed that the value of an additional biopsy core is poor, since only 3.5% 
of the visible cancers were detected solely by the 7th biopsy core150. Another limitation is 
that, compared to more extensive biopsy schemes, the lateralised sextant biopsy technique 
misses PCs. However, a stage shift to more favourable tumour characteristics at subsequent 
screens35, 151 and a low interval cancer rate125, 152 was shown, which suggest, with the follow-up 
time available, that lateralised sextant technique does not miss a considerable number of 
potentially aggressive cancers.
Throughout three consecutive screens, there was a statistically significantly more frequent 
detection of potentially aggressive PCs (GS>7) in men who had an abnormal DRE. This is 
in line with the findings of other large PC screening studies, indicating that an abnormal 
DRE is associated with having high-grade (GS≥7) disease47, 61, 63. When looking separately at 
participants who were previously biopsied and those who were not, an abnormal DRE was 
still associated with a greater chance of finding a potentially aggressive PC. In men with one 
previous benign biopsy result versus men with two previous biopsies (data not shown), the 
same trend was seen. However, DRE as a screening tool is not reconsidered within the ERSPC, 
Rotterdam. An evaluation four years after the omission of DRE showed that this did not result 
in an increased interval cancer rate or PC detection at subsequent screening153. Preliminary 
third-round data indicate similar findings. Furthermore, most men undergoing population-
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based screening for prostate cancer will have serum PSA levels <3.0 ng/ml, leading to an 
eminent financial and logistic burden. In addition, the very low PPV of <10% in the PSA range 
<3.0 ng/ml16 and the resulting rate of 90% biopsies (unnecessary) seems unacceptable both 
clinically and in terms of future health care policy.
An increasing number of men are screened for the presence of PC, and the population of 
men with a previous negative biopsy is growing. We know already that having a previous 
cancer-negative biopsy30 lowers the risk of detecting PC at later screens. This study showed 
that in men with a previous biopsy, a PSA level ≥3.0, and a normal DRE, the chance to find PC 
was relatively low (10.4% and 14.9% in screen 2 and screen 3 respectively). These non-palpa-
ble PCs had a GS<7 (potentially indolent) in 91% (round 2) and 88% (round 3) of the cases. 
The potentially aggressive PCs found in this group amounted to 0.3% of all PCs detected in 
screens 2 and 3. In this setting, DRE can be used for a more selective biopsy strategy. It may 
be justified to postpone biopsy to a later screening in men with a previous negative biopsy, 
an elevated PSA level, and a normal DRE in order to lower the risk of overdiagnosis (the detec-
tion of potentially indolent PCs) and to reduce the number of unnecessary biopsies. The ap-
plication of DRE could have prevented approximately 70% (table 2) of the men in this cohort 
with a previous biopsy from having another biopsy after 4 years. At the same time, using this 
strategy will result in missing T1c PCs with a GS<7. At later rescreenings these cancers could, 
however, most probably be detected because of the consistently elevated PSA levels in these 
men, conversion to a suspicious DRE, or on the basis of new markers. Recently published data 
on an active surveillance policy of cancers with clinical stage ≤T2 and a biopsy GS< 7 suggest 
that this delay in detection is not causing harm78. However, for a definitive answer we need 
to wait for the conclusive outcomes of the ERSPC and PLCO21, 129. Another point is that a small 
number (0.3% of all cancers detected in screens 2 and 3 in this study) of potentially aggres-
sive PCs might be missed at a still curable stage. In a population-based screening setting, 
the risk of missing a few potentially aggressive cancers should be weighed carefully against 
preventing unnecessary biopsies in numerous men.
In general, the added value of DRE in conjunction with the PSA cut-off of 3.0 is limited, 
since a suspicious DRE does not modify the biopsy indication. However, in men with a suspi-
cious DRE, the risk of harbouring high-grade disease is greater than in men with a normal 
DRE, a finding that can be implemented in future risk calculators for high-grade PC. Secondly, 
in the selective group of men with a previous negative biopsy, a normal DRE can possibly 
prevent unnecessary biopsies.
ConClusIons
In men who underwent their first biopsy (indication, PSA level ≥3.0 ng/ml), an abnormal DRE 
contributed to the predictive value (in addition to the chance based on an elevated PSA) in 
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detecting prostate cancer and in the selective detection of potentially aggressive cancers. 
Overall, in men with and without an abnormal DRE, the predictive value decreased in sub-
sequent screening rounds because of increasing proportions of previously biopsied men. 
In participants with a previous cancer-negative biopsy, there was no additional value of an 
abnormal DRE to detect cancer; however, relatively more prostate cancers with a Gleason 
score >7 were detected. A suggestion for the use of DRE in subsequent screens in previously 
biopsied men may be that in case of a normal DRE, biopsy can be postponed to a subsequent 
visit, without missing a substantial number of potentially aggressive prostate cancers, in or-
der to reduce the number of unnecessary biopsies and overdiagnosis.
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AbstrACt
Background
Evidence indicates that an abnormal digital rectal examination (DRE) is a risk factor for high-
grade prostate cancer.
Objective
To determine whether men with an initially suspicious DRE, a prostate-specific antigen (PSA) 
level ≥3.0 ng/ml, and a benign prostate biopsy are at higher risk for detecting (significant) 
prostate cancer at rescreening than men with an initially normal DRE, and whether an adap-
tation of the rescreening interval is warranted for this group.
Design, setting and participants
Within the ERSPC Rotterdam 2,218 men underwent biopsy of the prostate (from 1993-2000) 
with a benign result at initial screening. The serum PSA was determined every 4 years. A PSA 
level of ≥3.0 prompted a DRE and lateralised sextant biopsy.
Measurements
Number and characteristics of prostate cancers found at repeat screenings and as interval 
cancers were compared between men with or without a suspicious DRE result at initial 
screening. Multivariate logistic regression analyses were performed to evaluate if an initially 
suspicious DRE was a significant predictor for detecting cancer at consecutive screenings.
Results and limitations
After 4 years, the total number prostate cancers detected in men with and without an ini-
tially suspicious DRE was, respectively, 27 (6%) versus 103 (6%) (p=0.99). After 8 years these 
numbers increased, respectively, to 45 (10%) versus 167 (10%) (p=0.88). The proportion of 
clinically significant prostate cancers was 2% and 3%, respectively, for the group with initially 
normal and abnormal DRE after 8 years. Having a suspicious DRE result at initial screening was 
not a significant predictor for detecting prostate cancer after 4 years (odds ratio (OR)=1.15, 
p=0.59) or 8 years (OR=1.41, p=0.43). A limitation of this study is the relatively short follow-up 
of 8 years.
Conclusions
During a follow-up of 8 years after initial cancer-negative biopsy, an initially suspicious DRE 
did not influence the chance for detection of cancer or significant cancer at later screens. 
An adaptation of the rescreening interval on the basis of the initial DRE outcome is not war-
ranted in future population-based screening for prostate cancer.
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IntroDuCtIon
In December 1993 the European Randomized Study of Screening for Prostate Cancer (ERSPC) 
was initiated to evaluate the influence of screening on prostate cancer (PC) mortality. The ERSPC 
Rotterdam started with a screening protocol using a serum prostate-specific antigen (PSA) cut-
off of 4.0 ng/ml and/or an abnormal digital rectal examination (DRE) or transrectal ultrasound 
(TRUS) as indication for a lateralised sextant prostate biopsy. Halfway through the first screen-
ing it was decided to discontinue the use of DRE and TRUS as screening tests for the detection 
of PC12, 13, 16, 34, 56. Instead, from May 1997, the PSA cut-off for recommending biopsy was lowered 
to 3.0 ng/ml. This decision was made because at PSA levels <4.0 ng/ml the positive predictive 
value (PPV) and sensitivity of DRE were low16, and obtaining a biopsy in all participants with PSA 
levels from 3.0-3.9 ng/ml increased the overall PPV and improved false-positive biopsy rates 
significantly at equal detection rates14. Repeat screening was offered after 4 years in all men 
with PSA levels <3.0 ng/ml and in men with PSA levels ≥3.0 ng/ml with a benign biopsy result.
Nowadays the use of DRE as screening tool is controversial. However, there is evidence that an 
abnormal DRE is a risk factor for high-grade disease47, 61. Men who have had a cancer-negative 
biopsy and continue to have an elevated PSA level are candidates for repeat biopsies in later 
screens. The objective of this study was to analyse whether in men with an initially negative biopsy 
result and an elevated PSA level (≥3.0 ng/ml), the initial DRE result is a risk indicator for detecting 
(significant) PC at subsequent screenings and whether an adaptation of the rescreening interval 
is warranted in men with an initially abnormal DRE in population-based screening programs.
PAtIents AnD methoDs
Study population
Our study cohort consisted of men participating in the first screening round of the ERSPC 
Rotterdam. Men with a PSA level ≥3.0 ng/ml, a benign biopsy result, and a normal or suspi-
cious DRE result at initial screening were included in the study population (N=2,218).
We assessed the number and characteristics of PCs detected in these participants at repeat 
screenings after 4 years (screen 2) and 8 years (screen 3), and of interval cancers (ICs; i.e., clini-
cally detected PCs between screening rounds or in men who refused further screening after 
the initial biopsy). Men with a suspicious DRE result were compared to men with a normal 
DRE at first screening. To assess the number of ICs, the total cohort of 2,218 men was linked 
to the Cancer Registry. In this way we noticed the cancers detected outside the study cen-
tre. Unfortunately the exact reason for undergoing another prostate biopsy and the biopsy 
method used outside the study were not known. A more detailed description of the study 
design has been published previously154.
Ch
ap
te
r 8
92
Techniques
Screening entailed a determination of serum PSA concentration (Beckman-Coulter Hybritech 
Tandem-E Assay, CA, USA). In case of nodularity or induration DRE was considered suspicious. 
After rectal examination TRUS was performed using a Bruel-Kjaer model 1,846 mainframe and 
a 7-MHz biplanar endorectal transducer, with the patient in a left lateral decubitus position. 
Lateralised sextant prostate biopsy121, 145 was performed using a Bard spring-loaded biopsy 
gun (C.R. Bard, Convington, GA, USA) and an 18-gauge biopsy needle. If present, a hypoechoic 
lesion on TRUS was an indication for an additional biopsy core; a palpable nodule on DRE was 
not. Clinical stage was defined as the most advanced stage based on DRE and TRUS.
Pathological examination
Biopsy specimens were analysed histopathologically, and PC was graded according to the 
Gleason score (GS) system. Significant PC was arbitrarily defined as clinical stage >T2a (ac-
cording to the TNM classification 1992) or GS≥7, or both. The threshold of clinical stage >T2a 
for significance was based on former evidence that prognosis of cT2b tumours and higher is 
worse than for cT2a and cT1c155-158.
Statistical analyses
The chi-square test was used to assess differences for binary variables. For continuous variables, 
the Student’s t-test and Mann-Whitney U test were used. All tests were two-sided. A p-value 
of <0.05 was considered statistically significant. Two separate logistic multivariate regression 
models were created. These evaluated the relationship between the DRE result at screen 1 and 
the likelihood of detecting cancer at screen 2 and screen 3 correcting for other initial round 
predictors. This analysis determined whether an abnormal DRE at initial screening (in men 
with a PSA≥3.0 ng/ml and a negative biopsy) led to a higher risk of detecting PC in subsequent 
screenings. In addition to the initial DRE result, other participant-related characteristics at ini-
tial screening were used in this model to correct for their influence on the detection of PC: 
log-transformed PSA level (in ng/ml), age (in years), logtransformed prostate volume (in ml), a 
hypoechoic lesion on TRUS, and previous biopsy (in addition to the negative biopsy at initial 
screening). For the OR, a p-value <0.05 was considered statistically significant.
The ERSPC was approved by the institutional board of the Erasmus MC, University Medical 
Center in Rotterdam, and by the Minister of Health of the Dutch government.
results
Number of cancers detected
At initial screening 2,218 men had a PSA≥3.0 ng/ml and a negative biopsy result. Of these 
men, 462 (21%) had a suspicious DRE and 1,756 (79%) had a normal result (figure 1). On the 
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basis of this initial DRE result the included subjects were evaluated in subsequent screenings. 
The descriptive variables at first screening are displayed in table 1. Some men discontinued 
screening after each round owing to crossing the age limit of 75 years, comorbidity, death, 
moving or refusal. Consequently, 1,156 participants were eligible for screening after 4 years 
Figure 1: Consort diagram. The results of three screening rounds have been summarised, and the number of interval cancers (ICs) is shown. 
Screening 2 was performed between January 1998 and June 2004 and screening 3 was performed between March 2002 and August 2007.
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(screen 2), of whom 937 (81%) had a normal DRE at initial screening and 219 (19%) initially 
had suspicious DRE findings. In 70% (739 of 937) of the men with an initial normal DRE and 
in 78% (170 of 219) of the men with an abnormal DRE, a biopsy was performed at the second 
screening. The total number of PCs detected in men with and without an initially abnormal 
DRE was 27 (6%, among which were 5 ICs) and 103 (6%, among which 19 ICs), respectively 
(p=0.9935). After 8 years, 332 (83%) of the 399 men screened at screen 3 had an abnormal 
DRE and 67 (17%) men had a normal DRE at initial screen. The numbers of cancers detected 
amounted to 45 (10%, among which 14 ICs) in men with an initially abnormal DRE and 167 
(10%, among which 50 ICs) in men with an initially normal DRE (p=0.8841). The proportion 
ICs (number of ICs divided by total number of men with benign biopsy at first screening) 
was 1.1% after 4 years in both groups. After 8 years this proportion amounted to 2.8% for 
men with an initially normal DRE and 3.0% for men with a suspicious DRE. During an 8-year 
follow-up, in total 167 PCs were detected in men with an initially normal DRE and 45 PCs in 
men with an abnormal DRE.
Tumour characteristics
The tumour characteristics of all cancers detected at screen 2 and 3, depicted by initial DRE 
result, are displayed in table 2. Tumour characteristics of ICs, assessed by linking the whole 
study population of 2,218 men to the Cancer Registry, are shown in table 3. The GS was un-
known in about 50% of the ICs because pathological analysis was undertaken outside the 
study centre.
Ten (2%) significant PCs (all screen-detected) were detected in men with an initially ab-
normal DRE after 4 years. In men with an initially normal DRE, 23 (1%) significant cases were 
detected, of which 2 were detected as ICs. Eight years after initial screening (screen 3) these 
numbers amounted to 13 (3%) significant cancers detected in men with an initially abnormal 
DRE, of which 2 ICs. Thirty-seven (2%) significant cases, of which 11 were ICs, were diagnosed 
in participants with a normal initial DRE.
Table 1: Descriptive variables at time of the initial biopsy, given as the mean (median, interquartile range) age, PSA value and prostate 
volume and TRUS outcome, given as number (proportion) with a hypoechoic lesion.
Variable
(at initial screen)
DRE normal DRE suspicious for PC P-value (two-
sided)
N (%) 1,756 (79.2) 462 (20.8)
Age, years 65.4 (65.7, 61.2-69.8) 67.0 (67.9, 63.1-71.3) <0.001*
PSA level, ng/ml 5.9 (4.8, 3.9-6.6) 5.5 (3.6-6.1) <0.001**
Prostate volume, ml 54.0 (48.2, 38.2-62.7) 50.5 (45.4, 36.3-60.1) 0.009**
Hypoechoic lesion on TRUS, N (%) 275 (15.7) 133 (28.8) <0.001***
*Student’s t-test; ** Mann-Whitney U-test; ***Chi-square test
Participants were included in the study if they had a PSA level ≥3.0 ng/ml and a benign biopsy result at initial screening
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Logistic regression analysis
At second screening (screen 2), 909 men underwent biopsy and were included in the regres-
sion analysis with the presence of PC as the dependent variable (table 4). When correcting for 
all other variables that could have influenced the detection of PC, there was no indication that 
an abnormal DRE at initial screening influenced the odds of detecting PC at second screening 
(p-value was non-significant). A larger prostate volume was associated with a lower risk of 
cancer detection (OR=0.085, p=0.001). All remaining predictors had no significant influence. 
At screen 3, 281 men were biopsied and included in the analysis. Again, a suspicious DRE 
at first screening did not significantly influence the detection of PC at screen 3, and initially 
Table 2: Tumour characteristics of screen-detected prostate cancers (based on biopsy specimen) in screening round 2 and 3 (respectively, 4 
and 8 years after the initial screening).
screen 2 screen 3
DRE result at first screening normal abnormal normal abnormal
Clinical stage (%) T1c 53 (63.1) 8 (36.4) 22 (66.7) 6 (66.7)
T2a 17 (20.2) 5 (22.7) 8 (24.2) 2 (22.2)
T2b and c 14 (16.7) 6 (27.3) 3 (9.1) 1 (11.1)
T3 - 3 (13.6) - -
Total 84 22 33 9
Gleason score (%) <7 72 (85.7) 18 (81.8) 30 (90.9) 9 (100)
7 9 (10.7) 3 (13.6) 3 (9.1) -
>7 3 (3.6) 1 (4.5) - -
Total 84 22 33 9
Table 3: Tumour characteristics of interval cancers. 
Interval 1 Interval 2
DRE at first screening normal abnormal normal abnormal
Clinical stage (%) T1a, b and c 13 (68.4) 2 (40) 19 (61.3) 4 (44.4)
T2a 4 (21.1) 3 (60) 4 (12.9) 4 (44.4)
T2 b and c - - 4 (12.9) 1 (11.1)
T3 1 (5.3) - 1 (3.2) -
T4 1 (5.3) - 2 (6.5) -
missing - - 1 (3.2) -
Total 19 (100) 5 (100) 31 (100) 9 (100)
Gleason score (%) <7 8 (42.1) 1 (20) 10 (29.0) 5 (55.6)
7 - - 2 (6.5) 1 (11.1)
>7 2 (10.5) - 2 (6.5) 1 (11.1)
missing 9 (47.4) 4 (80) 17 (54.8) 2 (22.2)
Total 19 (100) 5 (100) 31 (100) 9 (100)
The first interval comprised the 4 years between screens 1 and 2, and the second interval the 4 years between screens 2 and 3
For interval 1, 54% (13/24) of GSs were unknown for interval 2, 47.5% (19/40) of GSs were unknown
Ch
ap
te
r 8
96
having a larger prostate volume decreased significantly the risk of detecting PC at screen 3 
(OR=0.016, p=0.005). The influence of other variables was not significant (table 4).
DIsCussIon
Within ERSPC Rotterdam, all men with a benign biopsy result were invited for repeat screening 
4 years later. The current study analysed whether men with a benign prostate biopsy and an 
initially abnormal DRE were at higher risk for the detection of significant of PC in the follow-
ing years and whether an adaptation of the rescreening interval is warranted in this group. 
Therefore, participants with a PSA level ≥3.0 ng/ml, a benign biopsy, and either an initially 
normal (group-1) or abnormal DRE (group-2) were followed for 8 years, during which they 
were screened for the second time (after 4 years) and third time (after 8 years). The two groups 
were evaluated for the number of cancers detected (found at screening or clinically detected 
as ICs), and tumour characteristics were compared. During the follow-up period no significant 
difference was found in the total number of cancers detected in both groups. Moreover, the 
proportion of ICs, which gives an indication of the effectiveness of the screening program and 
the appropriateness of the length of the screening interval152, was similar as well.
Table 1, however, shows significant differences in parameters that influence the risk for de-
tection of PC. The prostate volume was significantly larger in men with a normal DRE at initial 
screening. A larger prostate volume lowers the chance of detecting PC55, and, furthermore, can 
lead to understaging as well, as in a large-volume prostate a nodus is more difficult to palpate. 
However, during the 8-year follow-up in the current study these missed and understaged can-
cers would most probably have been detected (as ICs or as higher stage). In addition, the older 
age of patients and the more frequently found hypoechoic lesions on TRUS in the group with 
abnormal DREs, increased the risk for detection of PC in this group, although we know TRUS 
Table 4: Odds ratios for predictor variables assessed at round 1 for detecting prostate cancer at screen 2 and screen 3 studied by 
multivariate logistic regression analysis. 
Predictor Prostate cancer at screen 2 Prostate cancer at screen 3
Odds ratio (95% CI) p Odds ratio (95% CI) p
Digital rectal examination* 1.151 (0.687-1.928) 0.594 1.411 (0.597-3.331) 0.433
Log-PSA level* 0.904 (0.229-3.567) 0.885 0.702 (0.055-9.026) 0.786
Age* 1.044 (0.993-1.098) 0.093 0.997 (0.899-1.106) 0.959
Log-prostate volume* 0.085 (0.020-0.368) 0.001 0.016 (0.001-0.291) 0.005
Transrectal ultrasound* 0.793 (0.439-1.434) 0.443 0.658 (0.267-1.622) 0.363
Previous biopsy (in addition to first 
round biopsy)
- - 0.905 (0.326-2.508) 0.847
* at time of initial screening; CI, confidence interval
In these analyses all men biopsied were included (respectively N=909 for screen 2 and N=281 for screen 3). A p-value <0.05 was 
considered statistically significant
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is a poor predictor9, 11, 55-57. Likely a clinical bias of the investigator who tends to see suspicious 
lesions on TRUS when palpating an abnormality may explain this observation. On the other 
hand, the higher PSA levels in the group with normal DRE increased the risk of finding PC in 
men with a normal DRE. To correct for all these predictor variables and to analyse the effect of 
DRE on the risk of finding PC, multivariate logistic regression analyses were performed. The re-
sults showed that DRE was not a significant predictor for diagnosing PC on repeat screenings.
Considering the tumour characteristics, one must realise that in general the detection 
rate of significant PC, defined as a cancer with clinical stage >T2a or biopsy GS≥7, is low in 
men with a previous cancer-negative biopsy result. Using this definition of significant PC 
means that a cancer with biopsy GS<7 but clinical stage >T2a was considered significant. 
This arbitrary classification seems, however, justified, as undergrading of biopsy specimens 
is frequently reported35, 109, 110. The comparison of tumour characteristics showed no distinct 
differences in the detection of significant disease in men with an initially abnormal or normal 
DRE result, although we had to base our conclusions on a small sample with a substantial 
part of the ICs with unknown Gleason scores.
In a previous study on screening results of ERSPC Rotterdam it was concluded that DRE 
as screening test for PC might be replaced by screening using the PSA cut-off of 3.0 ng/
ml only62. Simultaneously, it was shown that DRE might pick up aggressive cancers more 
selectively than screening by serum-PSA alone, especially in the PSA range 3.0-4.0 ng/ml. 
However, the absolute number of moderately and poorly differentiated cancers was similar 
in the PSA-based protocol (biopsy indication, PSA≥3.0 ng/ml) and in the old protocol (biopsy 
indication, PSA≥4.0 and/or DRE/TRUS abnormal). Furthermore, only a small proportion of 
men with a suspicious finding on DRE were eventually diagnosed with a PC with GS 7-10. In 
addition, coincidence should not be denied as an important factor: a substantial proportion 
of cancers detected by abnormal DRE/TRUS showed tumour volumes <0.5 ml and were not 
likely to be palpated. Those should be considered as false-positives62. On the contrary, Bor-
den et al.61 found, using a multivariate logistic regression analysis, that an abnormal DRE was 
an independent predictor for PC and for high-grade PC on initial biopsy in a referral popula-
tion. Likewise, other studies that retrospectively examined radical prostatectomy specimens 
showed that palpable tumours (cT2) were significantly more likely than nonpalpable (cT1c) 
tumours to have a higher GS in referral populations157-159, and in a screening cohort47.
Apparently, in the selective cohort for our study, an initially abnormal DRE was not predic-
tive of a higher risk for detection of significant PC at repeat screenings. It was already known 
that a previous negative biopsy lowers the risk of detecting PC at later screenings30. The cur-
rent findings are useful for the management of patients with a negative biopsy result who 
continue to have an indication for biopsy. It is not necessary to rescreen men with an initial 
suspicious DRE earlier or more frequently than men without palpable abnormalities.
However, this study concerns a screening setting and does not consider the undeniable 
value of DRE in individual patients in urological daily practice.
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Although we believe that our study results are of value for determining a screening interval 
that is of sufficient duration to protect men from unnecessary biopsies and short enough 
to prevent the occurrence of advanced disease at subsequent screenings or large numbers 
of ICs, there are some shortcomings to our study. First, the study population is a selective 
screening cohort of men with an initially negative biopsy and a PSA level ≥3.0 ng/ml. The 
conclusions drawn apply for this setting only. Second, we have followed these men for 8 
years; we have to await, however, the final conclusions of ERSPC to relate our findings to PC 
mortality. Third, the results were possibly biased because of using two previously mentioned 
two different protocols at first screening. Some participants were biopsied for an abnormal 
DRE/TRUS and others were biopsied for an elevated PSA level only. However, to minimise the 
possible bias, all included subjects were selected for an initial PSA of ≥3.0 ng/ml and only 
5.7% (127 of 2,218) of men were biopsied for an abnormal DRE/TRUS. Another limitation is 
that the lateralised sextant biopsy technique misses PCs compared to more extensive biopsy 
schemes. However, data from the ERSPC Rotterdam show a stage shift to more favourable 
tumour characteristics at subsequent screens35, 151 and a low IC rate152, which suggest, with 
the follow-up time available, that the lateralised sextant technique does not miss a substan-
tial number of potentially aggressive cancers. Finally, the number of biopsied men in the two 
groups influences the chance to detect PC: the more men biopsied, the more cancers could 
be detected. The overall proportion of biopsied men in the two groups analysed is 56% (975 
of 1,756) versus 47% (215 of 462) for normal and abnormal initial DRE, respectively. However, 
the identical proportion ICs diagnosed in both groups (3%), which is a measure of the sensi-
tivity of screening and thus for biopsy rate, is suggestive of a minor influence of the difference 
in proportion of men biopsied. Furthermore, if the proportion of men biopsied in the group 
with initially abnormal DRE was extrapolated to 56% (equal to the proportion in men with 
initially normal DRE), a total of 259 men would have been biopsied and 37 PCs instead of 
31 PCs would have been detected (according to the PPV of 14.4% (31 of 215) in this group). 
Analysis of the extrapolated total number of cancers diagnosed in both groups did not show 
a statistically significantly difference between men with an initially normal or abnormal DRE 
(Pearson chi-square 0.92, p=0.35; data not shown).
ConClusIons
During an 8-year follow-up, the current study found no evidence that men with an initial PSA 
level ≥3.0 ng/ml, a cancer-negative prostate biopsy, and an abnormal DRE are at higher risk 
for the detection of prostate cancer or clinically significant prostate cancer as compared to 
men with an initial PSA level ≥3.0, a negative biopsy and an initially normal DRE. An adapta-
tion of the rescreening interval on the basis of DRE outcome is not warranted in this particular 
group of men in future population-based screening for prostate cancer.
Chapter 9
The interobserver 
variability of digital rectal 
examination in a large 
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screening of prostate 
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AbstrACt
Background
To analyse to what extent the percentage of suspicious digital rectal examination (DRE) find-
ings vary between examiners and to what extent the percentage of prostate cancers detected 
in men with these suspicious findings varies between examiners.
Methods
In the first screening round of the European Randomized study of Screening for Prostate 
Cancer (ERSPC) Rotterdam, 7,280 men underwent a PSA determination and DRE of whom 
2,102 underwent prostate biopsy (biopsy indication PSA≥4.0 ng/ml and/or suspicious DRE 
and/or TRUS). Descriptive statistics of DRE outcome per PSA range were used to determine 
the observer variability of six examiners. Because this analysis did not correct properly for 
other predictors of a suspicious DRE (PSA level, biopsy indication, TRUS outcome, prostate 
volume and age), a logistic regression analysis controlling for these explanatory variables 
was performed as well.
Results
In 2,102 men biopsied, 443 prostate cancers were detected (PPV=21%). For all PSA levels 
the percentage suspicious DRE varied between examiners from 4% to 28% and percentage 
prostate cancer detected in men with a suspicious DRE varied from 18% to 36%. Logistic re-
gression analysis showed that three of six examiners considered DRE significantly more often 
abnormal than others (ORs 3.48, 2.80, 2.47, p<0.001)). For all examiners the odds to have 
prostate cancer was statistically significantly higher in case of a suspicious DRE (ORs 2.21-
5.96, p<0.05). This increased chance to find prostate cancer was not significantly observer-
dependent.
Conclusions
Three of six examiners considered DRE significantly more often suspicious than the others. 
However, under equal circumstances a suspicious DRE executed by each examiner increased 
the chance of the presence of prostate cancer similarly.
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IntroDuCtIon
In the setting of early detection of prostate cancer (PC) the digital rectal examination (DRE) is 
used as a test to indicate prostate biopsy. The result of the DRE is usually expressed as abnor-
mal, that is, nodularity or induration is felt which is suspicious for PC, or as normal. The DRE 
is in this setting generally believed to be a highly subjective test. However, very few studies 
are known which analyse the subjectivity of DRE in more detail. Smith et al.132 concluded that 
the findings within the same prostate on the same day by two different examiners were often 
divergent. On the other hand, there is also a study that found a good correlation between 
different observations of examiners when the prostate was assessed in a systematic way160. 
At present, serum PSA testing is mostly used as screening test for prostate cancer. PSA is, 
however, not a specific test for cancer of the prostate as a considerable overlap between PSA 
levels exists in men with normal prostates, benign prostate hyperplasia and localised pros-
tate cancer. Some researchers suggested the use of DRE to screen more selectively in order to 
lower the risk of unnecessary biopsies and overdiagnosis by showing evidence that the rectal 
examination can be used to detect aggressive prostate cancers more selectively47, 61, 157-159.
In the current study we examined within the European Randomized Study of Screening 
for Prostate Cancer (ERSPC, section Rotterdam) the interobserver variability of DRE. The best 
way to evaluate interobserver variability is to digitally examine participants more times at the 
same day by different examiners. This type of analysis would however have meant an undesir-
able burden to the participant and would have interfered with the logistics of the screening 
procedure. We describe an alternative method to compare the digital findings of different 
examiners that is not hampered by these drawbacks. The aim of this study focused on the 
following issues. Firstly, to what extent does the percentage of suspicious DRE findings vary 
between examiners in a prostate cancer screening setting and, secondly, to what extent does 
the cancer detection rate in men with these suspicious findings vary between examiners.
mAterIAls AnD methoDs
Study population
In the Rotterdam area men aged 55-75 years between December 1993 and May 1997 were 
identified by the population registry and asked to participate in the ERSPC. Men who re-
sponded by returning the signed informed consent form were randomised either to the 
screening or to the control arm. Men in the former arm were screened by serum PSA assay, 
a DRE, and a transrectal ultrasound (TRUS). Initially in the first screening round, lateralised 
sextant biopsy was proposed in participants with a PSA level ≥4.0 ng/ml and/or a suspicious 
DRE/TRUS finding at a low PSA value (0.0-3.9 ng/ml). Later, the biopsy protocol changed, but 
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this was not relevant for the data of the current study. The study population is displayed in 
figure 1. A more detailed description of the study design has been published previously120.
Techniques
Screening entailed a determination of serum PSA concentration (Beckman-Coulter Hybritech 
Tandem-E Assay; CA, USA). Examiners who examined more than 400 participants at initial 
screening were included in this study (N=6). These examiners, who performed the DRE and 
TRUS after comprehensive training, were resident urologists (four out of six; examiners num-
bered 1, 2, 4 and 5) or ultrasound technicians (two out of six; examiners numbered 3 and 6).
Nodularity and induration were considered abnormal (suspicious for PC) on DRE. TRUS was 
performed using a Bruel & Kjaer® model 1,846 mainframe and a 7-MHz biplanar endorectal 
transducer, with the subject in the left lateral decubitus position. Hypoechoic lesions were 
considered suspicious (abnormal). Lateral sextant transrectal prostate biopsy was performed, 
in line with the findings of Stamey et al.145 and Eskew et al.121, using a Bard  spring-loaded 
biopsy gun (Convington, GA, USA) and an 18-gauge biopsy needle. An additional biopsy core 
was taken from a suspicious area on TRUS, if present. At the time of performing DRE/TRUS, 
the members of the screening team were not aware of the PSA value. 
Pathological examination
Biopsy specimens were histopathologically analysed by a single uropathologist.
Statistical analyses
The study focused on two issues: 1) To what extent does the percentage of suspicious DRE 
findings vary between examiners and 2) to what extent does the percentage of cancers de-
tected in men with these suspicious findings vary between examiners.
Both issues were studied on the basis of descriptive statistics. This approach, however, did 
not control properly for possible differences in the patient mix. Therefore, multivariate logis-
tic regression was used in addition (amongst others in order to correct for the PSA ranges 
in which PCs were found). In the first setting, the outcome of the DRE (suspicious or not) 
served as the dichotomous dependent variable. The predictors used in this model were 2log 
transformed PSA and 2log transformed prostate volume, TRUS outcome (coded as 1 for suspi-
cious and zero otherwise), an indicator variable for biopsy indication used (PSA threshold; 1 
for PSA≥4 ng/ml, 0 otherwise), age and indicator variables for the individuals carrying out 
the digital rectal exam. Arbitrarily, examiner 2 was chosen as reference. A likelihood ratio 
test was carried out to test whether a model including indicator variables for the examiners 
yielded a better fit to the data than an otherwise identical model without these indicators. 
In the second setting, the outcome of the biopsy (cancer or no cancer) served as the depen-
dent variable. The same predictors were used as in the initial setting augmented with DRE 
(coded as 1 if suspicious, 0 otherwise). In this setting, all indicator variables for the examiners 
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were entered into the regression, thus making a not-suspicious rectal exam the reference 
for the odds-ratios estimated for the different examiners in this setting. Again, a likelihood 
ratio test was used to check whether including the examiner into the model (by means of 
indicator variables for each examiner) led to a model that significantly better described the 
observations. For the Odds-ratios, a p-value <0.05 was considered statistically significant. 
The goodness-of-fit Hosmer-Lemeshow statistics of the logistic models for DRE and PC were 
calculated, and the model was considered acceptable if this test had a p-value >0.05.
Figure 1: Consort diagram of the studied population of the ERSPC Rotterdam.
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The ERSPC was approved by the institutional board of the Erasmus MC, University Medical 
Center and by the Minister of Health (required by Dutch law for population screening studies).
results
Descriptive statistics
At initial screening 7,280 men underwent a PSA test and a DRE (figure 1). Of these men, 2,102 
underwent prostate biopsy (biopsy indication: abnormal DRE/TRUS and/or PSA≥4.0 ng/ml) 
and 443 PCs were detected (positive predictive value 21%), of which 246 (56%) were diag-
nosed in men with an abnormal DRE. Baseline characteristics are displayed in table 1. The 
variation between the six examiners in the proportion of abnormal DRE results for all PSA 
levels as well as for PSA ranges <4.0, 4.0-9.0, and ≥10.0 ng/ml is summarised in table 2. The 
higher the PSA range, the more abnormalities were felt. The differences in proportion abnor-
mal DRE between examiners were comparable throughout the PSA ranges. Higher PSA levels 
correlated with higher PC detection rates (given an abnormal DRE; table 3). At PSA levels <4.0 
ng/ml on average 13% of men with an abnormal DRE had PC (averaged between six examin-
ers). The cancers found with normal DRE and PSA<4.0 ng/ml were detected by TRUS. The 
proportion PC in men with a suspicious DRE were on average 46% for PSA 4.0-9.9 and 81% for 
PSA>10.0 ng/ml. The differences in this proportion between the six examiners became larger 
with rising PSA (18% difference at PSA<4.0 ng/ml, 22% at PSA 4.0-9.9 and 28% at PSA≥10.0). 
Having an abnormal DRE led more often to the detection of PC compared to men with a nor-
mal DRE (table 3). This finding was more obvious in the higher PSA ranges (proportion PC in 
men with abnormal DRE versus proportion PC in men with normal DRE was 13% versus 10% 
for PSA<4.0, 46% versus 17% for PSA 4.0-9.9 and 81% versus 38% for PSA≥10.0 ng/ml).
Table 1: Baseline characteristics of participants included in this study.
Men who underwent DRE N=7,280
Age (years)* 64.0
PSA value (ng/ml)* 2.7
Prostate volume (ml)* 36.3
% abnormal DRE
(N/men who underwent DRE)
14 (1,006/7,280)
% abnormal TRUS
(N/men who underwent DRE)
13 (937/7,280; 0.4% unknown)
% men with Bx indication
(N/men who underwent DRE)
29 (2,102/7,280)
% men with PC
(N/men who underwent DRE)
 (443/7,280)
*mean values are displayed
DRE, digital rectal examination; TRUS, transrectal ultrasound; Bx, biopsy
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A shortcoming of analysing the data by descriptive statistics was that the distribution of 
patients with PSA levels in the ranges <4.0, 4.0-9.9, and ≥10.0 ng/ml was significantly differ-
ent between the six examiners (p<0.001, Kruskal-Wallis test). Tables 2 and 3 illustrate that 
if more men had a higher PSA in the patient mix, the chance was greater that men had an 
abnormal DRE and were diagnosed with PC. For this reason logistic regression analyses were 
used in order to correct for possible differences in patient mix.
Table 2: Number of abnormal DRE results per examiner per PSA range.
PsA range (ng/ml) examiner Abnormal Dre (%) total participants
All PSAs 1 162 (28) 570
2 44 (6) 696
3 53 (5) 1,004
4 447 (18) 2,449
5 20 (4) 465
6 280 (13) 2,096
Total 1,006 (14) 7,280
<4.0 1 77 (22) 345
2 31 (5) 602
3 37 (4) 869
4 257 (14) 1,864
5 12 (3) 407
6 273 (13) 2,037
Total 687 (11) 6,124
4.0-9.9 1 67 (36) 186
2 8 (10) 78
3 10 (9) 117
4 152 (31) 493
5 5 (11) 46
6 4 (8) 50
Total 246 (25) 970
≥10.0 1 18 (46) 39
2 5 (31) 16
3 6 (33) 18
4 38 (41) 92
5 3 (25) 12
6 3 (33) 9
Total 73 (39) 186
Total number of participants included in analysis was 7,280
DRE, digital rectal examination; PSA, prostate-specific antigen
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Table 3: Proportion of prostate cancers in men with a suspicious DRE result and in men with a normal DRE result per PSA range and per 
examiner.
PsA range examiner Proportion PC in men 
with sDre
Proportion PC in men 
with nDre
bx indication: PsA≥4.0 ng/ml and/or Dre and/or trus abnormal
All PSAs 1 35.5 (54/152) 21.5 (40/186)
2 26.8 (11/41) 18.6 (16/86)
3 22.4 (11/49) 14.5 (25/172)
4 29.3 (120/410) 15.3 (80/522)
5 35.0 (7/20) 18.3 (11/60)
6 18.4 (43/234) 14.7 (25/170)
Total 27.2 (246/906) 16.5 (197/1,196)
bx indication: Dre and/or trus abnormal
<4.0 ng/ml 1 20.6 (14/68) 13.5 (7/52)*
2 10.3 (3/29) 22.2 (2/9)*
3 2.9 (1/34) 1.6 (1/61)*
4 9.4 (21/223) 10.7 (15/140)*
5 8.3 (1/12) 0*
6 16.7 (38/227) 10.8 (14/130)*
Total 13.2 (78/593) 9.6 (39/406)*
bx indication: PsA≥4.0 ng/ml
4.0-9.9 ng/ml 1 40.9 (27/66) 20.4 (23/113)
2 62.5 (5/8) 16.2 (11/68)
3 44.4 (4/9) 18.2 (18/99)
4 46.3 (69/149) 15.2 (50/330)
5 60.0 (3/5) 16.2 (6/37)
6 50.0 (2/4) 25.7 (9/35)
Total 45.6 (110/241) 17.2 (117/682)
bx indication: PsA≥4.0 ng/ml
≥10.0 ng/ml 1 72.2 (13/18) 47.6 (10/21)
2 75.0 (3/4) 33.3 (3/9)
3 100.0 (6/6) 50.0 (6/12)
4 78.9 (30/38) 28.8 (15/52)
5 100.0 (3/3) 55.6 (5/9)
6 100.0 (3/3) 40.0 (2/5)
Total 80.6 (58/72) 38.0 (41/108)
Total number of participants who underwent a biopsy was 2,102 (906 with suspicious DRE and 1,196 with normal DRE)
Bx, biopsy; sDRE, suspicious digital rectal examination; nDRE, normal digital rectal examination; PSA, prostate-specific antigen; PC, prostate 
cancer
* According to the study protocol, the biopsy indication of these men was based on an abnormal TRUS result
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Logistic regression on DRE result
The DRE result was known in 7,280 participants, of which 7,105 men were included in the 
analysis (of 175 men predictor information was incomplete). Table 4 shows odds ratios for 
five examiners and the other explanatory variables (arbitrarily, examiner 2 was used as refer-
ence examiner). Examiners 3 and 5 considered DRE abnormal approximately as often as the 
reference examiner (odds ratio (OR) approximately 1, p-value not significant). The others (ex-
aminers 1, 4 and 6) judged the DRE suspicious for cancer significantly more often under equal 
circumstances than the reference examiner (OR>1, p-value significant). Including the exam-
iners into the logistic regression model with a suspicious DRE as the output variable led to a 
significantly better fit (LR test, p-value < 0.01). This implies that apparently different examin-
ers have significantly different thresholds for calling a finding suspicious. Furthermore, if the 
PSA level doubled, the odds of an abnormal DRE increased 1.25 times (OR=1.25). The biopsy 
indication used (referred to as PSA level ≥4.0 ng/ml), TRUS outcome (normal or abnormal) 
and age also significantly increased the odds of finding an abnormal DRE, whereas prostate 
volume decreased these odds significantly (if the prostate volume doubled, the odds of an 
abnormal DRE changed by 0.67).
Logistic regression on the presence of PC
Of 2,102 participants who underwent a prostate biopsy the DRE result was known. Of these 
men 2,084 were included in the analysis (of 18 predictor information was incomplete). Table 
5 shows the odds ratios for having PC in case of an abnormal DRE for all examiners and other 
explanatory variables. The reference situation was the situation that DRE was normal. It was 
assumed that a normal DRE was independent of the examiner who performed the DRE. This 
Table 4: Odds ratios for predictors for an abnormal result of the digital rectal examination (suspicious for prostate cancer) studied by 
multivariate regression analysis.
Parameter Odds ratio (95% confidence interval) p-value
Examiner 1 3.48 (2.38-5.08) <0.001
Examiner 3 0.84 (0.55-1.29) 0.424
Examiner 4 2.80 (2.00-3.93) <0.001
Examiner 5 0.716 (0.39-1.28) 0.265
Examiner 6 2.47 (1.74-3.50) <0.001
2log PSA level 1.25 (1.14-1.37) <0.001
PSA≥4.0 ng/ml* 1.42 (1.09-1.85) 0.009
TRUS 4.08 (3.45-4.82) <0.001
2log prostate volume 0.67 (0.57-0.78) <0.001
Age 1.06 (1.04-1.07) <0.001
Examiner 2 was used as reference-examiner. Odds ratios for all other examiners must be interpreted in relation to examiner 2. In this 
analysis 7,105 of the 7,280 participants with known DRE result were included. A p-value <0.05 was considered statistically significant.
Hosmer-Lemeshow test p-value 0.0851
* used as an indicator variable for biopsy indication
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presumption was confirmed in a separate logistic regression model (data not shown). For 
all examiners, the odds for PC were statistically significantly (p<0.05; p-value for examiner 5 
was 0.049) higher than the reference odds (non-suspicious DRE). Examiner 5 seemed to pre-
dict the presence of cancer best (odds ratio 5.96), however the uncertainty in this estimate 
was considerable. PSA value and TRUS outcome also significantly increased the odds to find 
cancer, whereas prostate volume significantly decreased these odds. The biopsy indication 
used (PSA level ≥4.0 ng/ml) and age were non-significant. Including all six examiners into 
the logistic regression model with cancer detected as the output variable did not lead to a 
Table 5: Odds ratios for predictors for the chance to find prostate cancer if participants had an abnormal digital rectal examination, studied 
by multivariate regression analysis.
Parameter Odds ratio (95% confidence interval) p-value
DRE by examiner 1 2.21 (1.42-3.45) <0.001
DRE by examiner 2 2.53 (1.03-6.23) 0.043
DRE by examiner 3 2.61 (1.00-6.77) 0.049
DRE by examiner 4 2.56 (1.85-3.54) <0.001
DRE by examiner 5 5.96 (1.37-25.86) 0.017
DRE by examiner 6 3.13 (1.98-4.97) <0.001
2log PSA level 3.16 (2.59-3.86) <0.001
PSA≥4.0 ng/ml* 1.20 (0.77-1.89) 0.420
TRUS 2.78 (2.13-3.63) <0.001
2log prostate volume 0.26 (0.20-0.33) <0.001
Age 1.02 (1.00-1.04) 0.051
The reference situation is the situation in which the digital rectal examination is normal. Of the 2,102 men who underwent a biopsy, 2,084 
were included in this analysis. A p-value <0.05 was considered statistically significant.
Hosmer-Lemeshow test p-value 0.0653
* used as an indicator variable for biopsy indication
Table 6: Odds ratios for predicting the presence of prostate cancer in case of an abnormal DRE for examiner 5 compared to the other 
examiners.
Parameter Odds ratio (95% confidence interval) p-value
DRE suspicious 2.57 (1.97-3.34) <0.001
DRE suspicious according to examiner 5 2.27 (0.53-9.73) 0.270
2log PSA level 3.17 (2.61-3.87) <0.001
PSA≥4.0 ng/ml* 1.12 (0.73-1.71) 0.608
TRUS 2.72 (2.09-3.53) <0.001
2log prostate volume 0.26 (0.20-0.33) <0.001
Age 1.02 (1.00-1.05) 0.052
Odds ratios for the other explanatory variables are mentioned as well. Of the 2,102 men who underwent a biopsy, 2,084 were included in 
this analysis. A p-value <0.05 was considered statistically significant.
Hosmer-Lemeshow test p-value 0.155
* used as an indicator variable for biopsy indication
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significantly better fit (LR test, p-value 0.8). This implies that apparently different examiners 
have a comparably increased probability to detect cancer given a suspicious finding. A final 
logistic regression analysis in which the indicator variables for all the examiners except for 
examiner 5 were pooled showed that examiner 5 did not significantly better predict the pres-
ence of cancer in case of an abnormal DRE (table 6).
DIsCussIon
The best way to analyse interobserver variation in the assessment of the prostate by DRE is 
to digitally examine participants several times on the same day by different examiners and 
using kappa statistics (Cohen161) in order to quantify the interrater agreement. Two studies 
on this subject using kappa statistics showed contradictory results132, 160. This type of analy-
sis would however have meant an undesirable burden to the participant and would have 
interfered with the logistics of the screening procedure. Therefore we have used descriptive 
statistics and multivariate logistic regression analyses as alternative methods.
Although the descriptive statistics analysis gave an indication of the variability of the DRE 
result between examiners, no straightforward conclusions could be drawn because the PSA 
level influenced the probability of finding an abnormal DRE and finding PC in case of an 
abnormal DRE. Other predictors for a suspicious DRE (PSA level, TRUS outcome, biopsy in-
dication, prostate volume and age) varied per examiner as well and therefore the raw DRE 
performance data per examiner had to be controlled for the examined patient population 
of each examiner to allow a proper interpretation. This was achieved by using a multivariate 
logistic regression model.
Between-examiner variation of the percentage of men with a suspicious DRE
Logistic regression analysis showed that DRE is a subjective test (table 4, likelihood ratio test 
for the logistic model with DRE as dependent variable, see results section). Some examiners 
(odds ratio larger than 1 with p-value <0.05) found DRE significantly more often suspicious 
for cancer than others (odds ratio near to 1 with p-value ≥0.05). None of the examiners diag-
nosed a statistically significantly disproportionably low percentage of men with a suspicious 
DRE (i.e. odds ratio <1, p<0.05).
Between-examiner variation of the detection of PC given a suspicious DRE
Although there apparently existed a considerable variation in the frequency of suspicious 
findings on DRE between examiners, a suspicious finding on DRE was, however, consistently 
associated with an increased PC detection probability (see odds ratios in table 5). An exam-
iner that considers DRE more often abnormal than others generates more biopsy indications 
(at PSA levels <4.0 ng/ml) and detects more cancers. This is compatible with the knowledge 
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that in men in the age group involved a large reservoir of small PC is present138, 139. More bi-
opsies find more PCs. A larger number of insignificant cancers might be detected because of 
performing more biopsies on the basis of a suspicious DRE. If it is desirable to detect and treat 
these cancers is a debatable issue. The current article cannot give an answer to the question 
whether doing more or less DRE-driven biopsies will contribute to lowering PC mortality.
Interpretation of the multivariate logistic regression model
As indicated above our data showed that the odds to detect PC were approximately 2.5 (table 
6) times higher if an examiner felt abnormalities at DRE when compared to the situation of a 
non-suspicious DRE (assuming all other variables equal). This observation was not examiner-
dependent (see likelihood ratio test for the logistic regression model with cancer detected 
as the dependent variable). Furthermore, the estimated odds-ratio of 2.5 was apparently not 
strongly dependent on the biopsy indication used (table 6: the odds ratio for indicator PSA≥4 
ng/ml is not significantly different from 1). This is a relevant observation as the biopsy indica-
tion was different for PSA≥4 ng/ml (all men were biopsied) when compared to PSA<4 ng/ml 
(only men with a suspicious DRE and/or TRUS were biopsied). In other words, the odds-ratio 
of 2.5 was not dependent on the frequency of DRE-driven biopsies. A constant multiplying 
effect of a suspicious DRE (2.5 times) on the odds to detect cancer implies that the increase in 
the probability induced by a suspicious DRE varies as a function of PSA (and other parameters 
such as TRUS finding and prostate volume).
As shown in table 3 the positive predictive value of DRE (proportion prostate cancer in 
men with an abnormal DRE) at PSA<4.0 ng/ml is 20% at most. Correcting for TRUS result and 
other explanatory variables in a multivariate regression analysis led to an odds ratio of 2.5 for 
a suspicious DRE to detect PC and means that a suspicious DRE multiplies the odds to detect 
cancer by 2.5. In the PPV of at most 20% (table 3) this multiplying DRE effect is included. The 
data currently evaluated for interobserver variability in the present article are based on the 
first screening round of the ERSPC Rotterdam and are similar to the data analysed by Schröder 
et al.16 which showed a positive predictive value of a suspicious DRE of  13% in the PSA range 
below 4.0 ng/ml. Because of this poor performance of DRE the ERSPC Rotterdam decided in 
May 1997 to omit DRE as a screening tool. Lowering the biopsy indication to a PSA cut-off of 
3.0 ng/ml or greater without the use of DRE as a biopsy indication improved the overall PPV 
from 18.2% (biopsy indicated if DRE/TRUS abnormal or PSA≥4.0) to 24.3% (biopsy indicated 
if PSA≥3.0). The number of biopsies necessary to detect 1 case of PC accordingly changed 
from 5.2 to 3.414. Furthermore, the cancer detection rate (proportion of PC in those screened) 
was similar for both protocols: respectively 4.7 for biopsies based on PSA≥3.0 and 5.0 for the 
protocol with DRE/TRUS. Screening became more efficient as the costly and time-consuming 
DRE and TRUS had not to be performed anymore while the CDR remained equal and the PPV 
improved. In addition, 75% of the cancers that were detected on the basis of a suspicious DRE 
at PSA<3.0 (and would not be detected with the new protocol) had a prostate cancer with a 
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tumour volume <0.5 ml in the radical prostatectomy specimen. A malignancy of the prostate 
with tumour volume <0.5 ml is unlikely to be palpated and these DREs should be considered 
as false-positives14. As suggested by Stamey et al.90 prostate cancers smaller than 0.5 ml are 
not likely to reach a clinically significant size. The cancers found as a consequence of DRE in 
this PSA range have a high likelihood of being indolent based on the mentioned 75% that 
has a tumour volume <0.5 ml. In addition, there is increasing evidence that the proportion of 
indolent prostate cancer is inversely related to PSA35, 54. Cancers in men with low PSA levels 
(PSA<3.0 ng/ml) that were missed as a result of the omission of DRE would most probably 
have been detected at subsequent screenings. The protocol change was evaluated in a re-
cent study that showed that omitting DRE and TRUS did not result in an increased detection 
of prostate cancers or interval cancers after 4 years153.
In conclusion, although the risk of detecting PC increases roughly 2.5 times in case of a 
suspicious DRE, the omission of this tool as a sole indicator for prostate biopsy is justified. In 
an optimal situation the biopsy indication should be based on a chance threshold to detect 
prostate cancer, or preferably to detect potentially aggressive disease. DRE, TRUS, PSA and 
other pre-biopsy characteristics should be included in the algorithm that defines the chance 
to detect cancer in a lateralised sextant biopsy.
After adjustment for case mix, different observers vary when comparing suspicious DRE 
rates. However, the predictive values to detect PC (PPVs) for the different examiners are com-
parable given a palpable abnormality on DRE (see likelihood ratio tests in the results section). 
An explanation for this paradoxical observation is that the proportion of disease is constant 
in the group of men with palpable abnormalities.  An examiner with a low threshold will 
detect many palpable abnormalities, an examiner with a higher threshold fewer. For both 
examiners the PPVs will be comparable since for both examiners the ratio of the number 
of abnormalities related to a malignancy and abnormalities related to a non-malignancy is 
roughly equal.
Finally, it must be noted that although variables such as DRE outcome, TRUS findings and 
(to a lesser extent) prostate volume are all subject to interobserver variability, they can play 
a role in the prediction of the chance to detect prostate cancer. Several investigators found 
that the incorporation of these so-called subjective variables next to the PSA value in predic-
tive models improved the prediction of having prostate cancer142, 162, 163. Moreover, evidence 
exists that the DRE can be used to detect aggressive prostate cancers more selectively47, 61, 
157-159. This issue will be evaluated within ERSPC Rotterdam in a future article.
ConClusIons
The digital rectal examination for diagnosing prostate cancer is a subjective test. Some ex-
aminers considered the DRE significantly more often abnormal than others. However, a suspi-
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cious DRE executed by each examiner statistically significantly increased the chance on the 
presence of prostate cancer under equal circumstances (the regression model corrected for 
the other explanatory variables). It was found that DRE increases the odds to detect prostate 
cancer roughly 2.5 times independent of biopsy indication used. This increased chance to 
find prostate cancer was not significantly observer-dependent and corroborates the fact that 
a suspicious DRE is an independent predictor for the presence of prostate cancer.
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Prostate cancer screening is currently being evaluated for the effect on prostate cancer mor-
tality in two ongoing randomised controlled trials8. In the meanwhile, these trials offer an 
opportunity to evaluate the available and new screening tests. Although using the digital 
rectal examination for the diagnosis of PC is still advised by the EAU guidelines164, applying 
DRE as a screening test is controversial. With the common use of PSA cut-offs lower than the 
arbitrarily-chosen original value of 4.0 ng/ml165 as an indication for prostate biopsy, the do-
main of the digital rectal examination is generally limited to the range below these cut-offs.
ProstAte CAnCer sCreenInG At low PsA leVels: whAt kInD of 
ProstAte CAnCers Do we fInD?
In 2004, Thompson et al. reported a 15.2% prevalence of prostate cancer in 2,950 men with a 
PSA level below 4.0 ng/ml in the placebo arm of the Prostate Cancer Prevention Trial (PCPT)91. 
The selected participants never had a PSA value of ≥4.0 ng/ml or an abnormal DRE (measured 
and examined annually) during a 7-year period. At the end of these 7 years all participants 
were offered a sextant prostate biopsy. In addition to the high prostate cancer prevalence of 
15.2%, 14.9% of these cancers had a Gleason score of ≥7. The prevalence of high-grade dis-
ease also increased with the PSA level, from 12.5% (PSA≤0.5 ng/ml) to 25% (PSA 3.1-4.0 ng/
ml). Therefore, Thompson and colleagues concluded that biopsy-detectable prostate cancer, 
including high-grade cancers, is not rare among men with PSA levels ≤4.0 ng/ml and even in 
men with PSA<2.0 ng/ml.
With this new insight, the previously used PSA cut-off points and the omission of DRE be-
came questionable because of the fear of missing a considerable number of cancers and even 
potentially aggressive disease at low PSA levels. However, several comments suggested that 
many of the PCs found in the PCPT resemble autopsy cancers with no clinical relevance92, 166. 
To analyse this suggestion in more depth, the prevalence and tumour characteristics of PCs 
found at low PSA in the PCPT were compared to those found in the ERSPC Rotterdam, in 
autopsy studies and in cystoprostatectomy series as described in chapter 4 of this thesis.
The prevalence of prostate cancer in autopsy studies, cystoprostatectomy series and two 
more recent series139, 167 was similar or higher than the prevalence in the control group of the 
PCPT. An explanation for this difference is the examination of the whole prostate specimen in 
the former series versus the biopsy specimens in the PCPT. In the most recent study, Haas et 
al.139 performed 18-core needle biopsies on autopsy prostates from 164 men who had no his-
tory of prostate cancer. Prostate cancer was present in 47 (29%) prostates. Of the 47 prostates 
20 (43%) were judged to be clinically significant. Comparison of the PCPT with the ERSPC Rot-
terdam was only possible to a certain extent. The prevalence of PC was lower in the ERSPC. 
Partially, this can be explained by the higher age of the participants included in the PCPT.
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At the moment a side study within the ERSPC Rotterdam is being performed by using the 
promising molecular marker PCA382, 83 as a biopsy indication. Preliminary results show that 
almost 85% of all participants undergoing a PSA and PCA3 test have a biopsy indication 
based on these two tests. Consequently, many men with PSA levels below 3.0 ng/ml are be-
ing biopsied. With the completion of the PCA3 analysis an improved comparison between 
ERSPC and PCPT can be made for the prevalence of prostate cancer at low PSA levels and 
their tumour characteristics.
The reviewed studies for which comparison of tumour characteristics was possible, gener-
ally contradict the findings of the PCPT. The favourable characteristics (tumour volumes <0.2 
or 0.5 ml, confinement to the prostate and Gleason score <7) of tumours detectable at low 
PSA levels68, 103, 105, 106 seem to justify the conclusion that an unknown but sizeable proportion 
of the cancers found at biopsy in apparently normal men are clinically unimportant but com-
patible with autopsy cancers. Although the proportion of GS≥7 cancers in the PCPT control 
arm is larger than in the ERSPC Rotterdam and several other studies, PCPT cancers may still 
largely resemble indolent tumours. As the cancers in the PCPT were biopsy-detected, tumour 
volume and confinement to the prostate (or not) are unknown, but may be similar as in the 
reviewed series because these cancers were also unsuspected in men with no complaints or 
an abnormal DRE or PSA findings. The higher prevalence of indolent cases, as compared to 
the significant and possibly life-threatening cases, put the value of screening in men with 
these low PSA levels (<3.0 ng/ml) in question.
In a very recent paper, Schröder et al.168 evaluated if all PCs in men with serum PSA levels 
<3.0 ng/ml should be detected. This analysis was done by comparing 12-year follow-up data 
of the ERSPC with the results of the control arm of the PCPT, in which all men with PSA<3.0 
ng/ml were biopsied91. Within the ERSPC a total of 15,852 men presented with an initial PSA 
value <3.0 and 700 cancers were detected in this population. Applying the positive predictive 
value (PPV) of the PCPT, 3,472 cancers would have been detected in the first seven years of 
the ERSPC by using the PCPT screening protocol. This means that 2,772 cancers were missed 
due to the ERSPC screening protocol (biopsy indicated if PSA≥3.0 ng/ml). Only 80 of those 
2,772 cancers which remain undetected with the use of a PSA cut-off of 3.0 ng/ml as a biopsy 
indication (in men aged 55-74 years screened every 4 years) were diagnosed after those ini-
tial 7 years at a rescreen or as interval cancers and only 6 of these 2,772 (0.22%) died during 
a 12-year observation period. Their detection within the ERSPC cohort would have required 
12,315 additional biopsies.
A 12-year follow-up period is likely to be too short. Still, one might have expected that at 
least those cases which show patterns of moderately or poorly differentiated cancers, which 
have been detected in the PCPT trial but were missed in ERSPC, would have surfaced clini-
cally in larger numbers. This is clearly not the case, suggesting that men presenting with PSA 
values of <3.0 ng/ml should not be biopsied but can be followed.
Discussion 119
the omIssIon of Dre As A sCreenInG tool
In 1998 Schröder et al. showed that the PPV of a suspicious DRE in the PSA range below 4.0 
ng/ml was only 13%16. Because of this poor performance of DRE, different screening modali-
ties were evaluated9. PSA≥3.0 ng/ml as sole biopsy indicator (without DRE and TRUS) showed 
the most favourable results: the number of biopsies was decreased by 12% while the number 
of cancers detected decreased by an acceptable 8%9 (i.e. the cancer detection rate remained 
similar). Furthermore, other studies118, 128, 169 concluded that a majority of the cancers detected 
in the PSA range 3.0-4.0 ng/ml were clearly significant and suitable for curative treatment, 
therefore providing another argument to implement a screening protocol with PSA≥3.0 ng/
ml as threshold for biopsy.
In a study by Hoedemaeker et al.68 three subsets of radical prostatectomy specimens were 
evaluated: T1c tumours, non-T1c tumours with PSA≤4.0 ng/ml and non-T1c tumours with 
PSA≥4.0 ng/ml. The group of tumours detected by DRE and/or TRUS in the lowest PSA ranges 
had the most favourable pathological stages, a considerable fraction (43%) fitting the criteria 
for ‘minimal tumour’ and 86% with a tumour volume smaller than 0.5 ml. A minimal tumour 
was defined as a tumour smaller than 0.5 ml, lacking Gleason pattern 4 or 5, and confined to 
the prostate (stage pT2). Men with low PSA levels were therefore considered most likely to 
harbour clinically insignificant tumours. Based on these findings all men in the ERSPC Rot-
terdam with a PSA≥3.0 ng/ml have received a prostate biopsy from May 1997 onwards.
The protocol change was validated with respect to detection rates and PPVs in different 
PSA ranges14. Lowering the biopsy indication to a PSA cut-off of 3.0 ng/ml without the use 
of DRE as a biopsy indication improved the overall PPV from 18.2% (biopsy indicated if DRE/
TRUS abnormal or PSA≥4.0) to 24.3% (biopsy indicated if PSA≥3.0). The number of biopsies 
necessary to detect 1 case of PC accordingly changed from 5.2 to 3.414. Furthermore, the can-
cer detection rate (CDR, proportion of PC in those screened) was similar for both protocols: 
respectively 4.7% for biopsies based on PSA≥3.0 and 5.0% for the protocol with DRE/TRUS. 
Screening became more efficient as the costly and time-consuming DRE and TRUS had not 
to be performed on all participants anymore while the CDR remained equal and the PPV 
improved. In addition, 75% of the men who were diagnosed with cancer on the basis of a 
suspicious DRE at PSA<3.0 ng/ml (and would not be detected with the new protocol) had a 
prostate cancer with a tumour volume <0.5 ml in the radical prostatectomy specimen. In fact, 
these tumours were too small to palpate. This finding was confirmed by a study of Vis et al. 
that concluded that a relatively high proportion of prostate cancers diagnosed in men with 
low PSA levels and in which a biopsy was prompted by a suspicious DRE and/or TRUS, are 
considered to be detected by chance only123.
Another justification of PSA-based screening is that this procedure detected clinically sig-
nificant disease more frequently in the PSA range 0-3.9 ng/ml than DRE/TRUS-based screen-
ing in a study that compared the tumour characteristics of cancers found by the two proto-
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cols62. This study showed that in the case that all participants with a PSA 3.0- 3.9 ng/ml were 
biopsied (biopsy indication PSA≥3.0 ng/ml), more significant cancers were detected than if 
men were biopsied in case of an abnormal DRE/TRUS in the range 0-3.9 ng/ml. In fact, at PSA 
levels below 3.0 ng/ml, 289 rectal examinations were required to find one case of significant 
prostate cancer62. The detection of a substantial proportion of these PCs at PSA levels <3.0 
ng/ml was based on serendipity only, as 72% of these cancers had a tumour volume <0.5 ml 
in the radical prostatectomy specimen. With these low tumour volumes DRE and TRUS should 
be considered false-positive.
However, without rectal examination a certain proportion of clinically diagnosable pros-
tate cancers are missed and the question of their later detection with elevated PSA values 
(≥3.0 ng/ml) at a still curable stage is unresolved. This thesis evaluated the omission of DRE as 
an indicator for prostate biopsy and the value of DRE used in addition to a PSA cut-off value 
as biopsy indication.
eVAluAtIon of the omIssIon of Dre As A bIoPsy InDICAtor
The risk of omitting DRE and TRUS, and therefore the omission of biopsies at PSA<3.0 ng/ml, 
is that potentially aggressive tumours at these low PSA levels remain undetected at screen-
ing. These could surface as interval cancers (i.e. prostate cancers detected between two 
screening rounds), or as tumours with PSA levels progressed to values above 3.0 ng/ml with 
possibly unfavourable prognostic characteristics when detected at subsequent screens. The 
omission of DRE may also lead to more prostate cancer specific deaths.
The number of missed cases with potentially aggressive tumour characteristics depends 
both on the prevalence below the threshold value for biopsy, and on the effectiveness of 
the screening tests used to detect these cases. The study described in chapter 5 compared 
the prevalence and prognostic factors of tumours found in the second screening round of 
the ERSPC Rotterdam between two groups of men who had initially (at first screening) been 
screened either with DRE/TRUS or without these tests.
Screening without DRE at low PSA levels (PSA<3.0 ng/ml) did not lead to the detection 
of significantly more PCs 4 years later as compared to screening with the use of DRE. No 
significant difference in the percentage of poorly differentiated tumours at biopsy or at radi-
cal prostatectomy was found between the ‘old’ and ‘new’ screening regimen. Furthermore, 
the prevalence and tumour characteristics of interval cancers were similar in both groups. 
However, the group initially screened without DRE showed more often extraprostatic exten-
sion at radical prostatectomy. Although this conclusion is based on a small number of radical 
prostatectomy specimens (N=75) and the difference was only just significant (p=0.035), this 
is an observation which is to be kept in mind during further follow-up.
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Based on this study it was concluded that screening without DRE and TRUS did not lead to 
the detection of more aggressive PCs after four years and that the risk of screening without 
these tools seems acceptable.
Preliminary results of the third screening round, i.e. 8 years of follow-up after the preva-
lence screen, show similar findings that justify the change to the PSA cut-off of 3.0 ng/ml as 
sole biopsy indication.
In chapter 6 the omission of DRE as a screening tool was monitored by comparing the char-
acteristics of cancers detected either by a suspicious DRE or by PSA-based screening in the 
PSA range 2.0-4.0 ng/ml. In this way, the value of DRE could be evaluated at low PSA levels, 
which is the domain of DRE since the currently used cut-offs of 2.6117, 128, 3.014, 62 or 4.0129 ng/ml. 
For PSA values below 2.0 ng/ml Beemsterboer et al. had already shown a very unfavourable 
balance between the number of biopsies performed and the number of prostate cancers 
detected, with PPVs between 2% and 5%9.
PSA-based screening using a cut-off of 2.0 ng/ml detected approximately twice the num-
ber of potentially aggressive (GS≥7) tumours per number of screened men than the regimen 
using DRE (CDRs of respectively 2.3% versus 1.2%). A considerable amount (15%) of T1c-can-
cers (detected by the PSA-based protocol) were potentially aggressive (GS≥7). At the same 
time, PSA-based screening detected a substantial number of potentially indolent (T1c, GS<7) 
cases. On the other side, DRE seemed to detect more selectively high-grade cancers, but 
also missed many of these. Considering the PSA range 2.0-4.0 ng/ml and the need to detect 
aggressive but confined disease, PSA as a biopsy indication outperformed DRE at the price of 
more biopsies and subsequently a larger number of overdiagnosed cases.
The results of this study were reassuring for the decision to omit DRE as a biopsy indication 
and to use the PSA cut-off of 3.0 ng/ml instead. In the PSA range 3.0-4.0 ng/ml the detection 
rate of potentially aggressive disease (biopsy GS≥7) was more than twice the detection rate 
in the group screened with DRE (4.7% versus 2.2%). However, the price paid was that 18 men 
had to undergo a biopsy to find 1 clinically significant cancer. Nevertheless the overall PPV, 
i.e. the proportion of cancers of any Gleason score detected all biopsied men, was acceptable 
with 22.3%.
If the currently used PSA cut-off of 3.0 ng/ml should be lowered to 2.0 ng/ml remains a 
question. To find 6 additional potentially aggressive cancers in this PSA range, another 455 
participants had to be biopsied. In other words, 1 significant cancer was detected in 80 men 
biopsied. Additionally, numerous potentially indolent cancers were detected. This imbalance 
makes the indication for prostate biopsy in every man with a PSA≥2.0 ng/ml very question-
able. As already mentioned by Schröder et al., the evaluation of men with PSA 2.0 to 2.9 ng/
ml would only be useful if screening could be more selective15. Unfortunately, until now a 
selective screening tool is not available.
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The fact that performing biopsies at PSA levels below 3.0 ng/ml is not medically acceptable 
is also illustrated by the already mentioned study that compared the outcome of the PCPT to 
12 years of follow-up of the ERSPC Rotterdam168. A very much unfavourable balance between 
the number of participants needed to be biopsied to detect one missed cancer (by using a 
PSA cut-off of 3.0) was shown.
eVAluAtIon of the Dre In men wIth eleVAteD PsA leVels
If DRE seems not valuable as a screen test to indicate prostate biopsy, is it still useful to per-
form a DRE in addition to a PSA cut-off of 3.0 ng/ml? In other words, is DRE of additional 
value in men with an elevated PSA to detect cancers or even to identify the more hazardous 
prostate cancers?
In chapter 7 was shown that the chance to detect prostate cancer at initial screening in 
men biopsied for an elevated PSA (≥3.0 ng/ml) with a suspicious DRE was approximately twice 
the chance of men with a normal DRE. This additional value of a suspicious DRE was however 
limited since the biopsy indication was not altered and all men with a PSA≥3.0 ng/ml would 
nonetheless have undergone biopsy. Nevertheless, the risk of harbouring high-grade disease 
(in this study defined as biopsy Gleason score >7) was consistently higher in men with a 
suspicious DRE result, a finding that is in line with other large prostate cancer screening trials 
indicating that an abnormal DRE is associated with having high-grade disease47, 61, 63.
This finding can be valuable for individual risk determinations of the chance to harbour 
significant disease by incorporating the DRE result in future algorithms.
Currently, prostate cancer screening becomes more common in Western countries. An 
increasing number of men want their PSA level to be determined and for this reason a con-
siderable rise in numbers of men undergoing a prostate biopsy is evident. Obviously, many 
prostate cancers are detected. However, a substantial fraction (70-80 %) of the screened men 
have a benign biopsy result. Having had a previous biopsy lowers the risk of being diagnosed 
with PC at later screens30. The additional predictive value of an abnormal DRE was marginal in 
men with a previous biopsy, but a suspicious DRE was still associated with a higher chance of 
detecting high-grade disease in these men.
Taking these two facts together, leads to a recommendation for possible use of the rectal 
examination for more selective screening in order to find a balance between the numbers 
of detected, clinically significant cancers, and the burden to the screened individual. In men 
with a previous biopsy, an elevated PSA level and a normal DRE, the chance to find pros-
tate cancer is quite low (1 out of 7-10 men biopsied was diagnosed with cancer, chapter 7). 
Ninety percent of these relatively few cancers had the characteristics of potentially indolent 
disease (T1c and GS<7) and only very few had potentially aggressive features (0.3% of all 
cancers detected at second and third screening). Therefore, it may be considered justified to 
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postpone biopsy in men with a previous biopsy, an elevated PSA and a normal DRE in order 
to lower the risk of overdiagnosis and to reduce the number of unnecessary biopsies. The 
potentially indolent cancers that are missed in this way and that will possibly become harm-
ful in the future will most probably be detected in time for curative treatment at subsequent 
screenings because of their elevated PSA level, a conversion of the DRE result or by new 
markers. However, the risk of missing the few cancers with potentially aggressive features 
by postponing biopsy in the selected men should be weighed carefully against preventing 
numerous men from an unnecessary biopsy.
Evidence exists that an abnormal DRE is a risk factor for detecting high-grade disease47, 61, 
which is also illustrated by the studies that form chapter 6 and 7 of this thesis. In order to 
detect these potentially life-threatening cancers in time, we evaluated if the DRE is useful in 
the risk assessment for diagnosing these cancers at a later moment.
In chapter 8 we analysed if men with a suspicious initial DRE, an elevated PSA level (≥3.0 
ng/ml) and a benign biopsy result were at higher risk of being diagnosed with prostate can-
cer or in particular significant (in this study defined as clinical stage >T2a or GS≥7) prostate 
cancer at later screens. The second aim of the study was to evaluate if men with an initially 
abnormal DRE should be recommended to undergo rescreening earlier than after the stan-
dard four years.
A cohort of 2,218 men with a PSA≥3.0 ng/ml and a benign biopsy result, of which 1,756 
had a normal DRE and 462 had a suspicious DRE, were followed for 8 years. During the follow-
up these two groups were evaluated for the number of cancers detected and the tumour 
characteristics of these cancers.
After three consecutive screenings (8 years) identical proportions of men with prostate 
cancer (10%) were detected in both groups. No distinct difference was detected in the num-
ber of high-grade prostate cancers (2% for the participants with an initial normal DRE and 
3% for an abnormal DRE). Additionally, multivariate logistic regression analyses showed that 
initially having a suspicious DRE was not a significant predictor for detecting prostate can-
cer during the follow-up. In conclusion, rescreening earlier than the established four years 
seemed not necessary for men with an initially suspicious DRE, an elevated PSA and a benign 
biopsy result.
As already mentioned, the proportion of men with a previous cancer-negative biopsy result 
is increasing. At this moment the management of men with a previous negative biopsy is un-
clear. This thesis gave two suggestions for an eventual adaptation of the screening protocol 
in these men. In chapter 7 it was concluded that it was justified to postpone biopsy to a later 
screening in men with a previous cancer-negative biopsy, an elevated PSA level and a normal 
DRE. To the contrary, in chapter 8 it was pointed out that men with an initially normal DRE, 
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an elevated PSA and a previous benign biopsy did not have a decreased risk for diagnosing 
prostate cancer or potentially aggressive disease at subsequent screens.
At first sight, these two conclusions seem to contradict each other. However, when look-
ing at both study populations carefully, the apparently contradictory conclusions become 
comprehensible because of differences in the populations and study methods. The most im-
portant difference is that in chapter 7 three consecutive screening rounds were separately 
evaluated. Some participants included in screenings 2 and 3 in chapter 7 had undergone 
a previous biopsy, others had not. The population for which the postponement of a subse-
quent biopsy was suggested, was a selection of men with a previous biopsy and a present 
PSA level ≥3.0 ng/ml. Furthermore, in these selected men, the PSA at earlier screens was not 
necessarily elevated to levels above 3.0 ng/ml, as in earlier screens biopsy could be indicated 
by an abnormal DRE or TRUS while the PSA level was below 4.0 ng/ml. In addition, some men 
had rapidly increasing PSA levels influencing the chance to detect PC.
Contrary to the three separately analysed screening rounds in chapter 7, the population 
analysed in chapter 8 was followed from initial screening for 8 years and three screenings. 
All included participants had at first screen a PSA≥3.0 ng/ml and were subsequently biopsied 
at later screens if the PSA had remained above 3.0. However, as in this study the initial DRE 
result was evaluated, participants could have a conversion from for example a normal DRE at 
initial screening to an abnormal at second or third screening. In the second screening round 
23% (210 of 909 biopsied) had a conversion of the DRE result and in the third round this 
proportion was 31%. Conversion of the outcome of DRE can explain the fact that the initial 
DRE is not of value for the risk assessment of detecting cancer later screens. Unfortunately, 
virtually no information is available on the phenomenon DRE conversion over time and fur-
ther research on this subject is needed.
Considering the conclusions of both studies, the initial DRE result seemed not predictive 
for the diagnosis of cancer at later screenings (in men with an initial PSA≥3.0 ng/ml and a 
benign biopsy), whereas an abnormal DRE result at the time of biopsy in men with a previous 
negative biopsy and an elevated PSA (thus neglecting the initial DRE result) did lead to a 
higher risk of the diagnosis prostate cancer compared to men with a normal DRE. The lat-
ter conclusion suggests the use of a longer screening interval in the selected population of 
participants with a normal DRE, a previous biopsy and an elevated PSA.
the DIGItAl reCtAl exAmInAtIon Is subjeCtIVe, but PreDICtIVe for 
CAnCer
One of the major criticisms on the digital rectal examination used as a screening test for 
prostate cancer is its subjectivity. Only two studies that analyse the subjectivity of DRE are 
known132, 160, and show contradictory results. In chapter 9 the interobserver variability of DRE 
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within the first screening round of the ERSPC Rotterdam was investigated. At that time DRE 
was still used as a screening test for prostate cancer in Rotterdam.
Six examiners were evaluated for their variability in DRE outcome (normal or abnormal) 
and for the variability in the proportion prostate cancers detected in case of an abnormal 
DRE result in a study population of 7,280 men. As expected, DRE was shown to be a subjec-
tive test: some examiners considered the DRE significantly more often abnormal than others. 
However, a suspicious DRE executed by each examiner statistically significantly increased the 
chance on the presence of prostate cancer under equal circumstances. A suspicious DRE was 
shown to be an independent predictor for the presence of prostate cancer, as a suspicious 
DRE increased the odds to detect prostate cancer approximately 2.5 times independent of 
the biopsy indication used. Clearly, the different examiners had different thresholds for call-
ing a DRE suspicious. But in case of a suspicious DRE, each examiner consistently showed 
increased odds for diagnosing prostate cancer as it was actually not possible to discriminate 
between cancer and no cancer and the proportion of disease is constant in the group of men 
with palpable abnormalities.
The increased risk of diagnosing prostate cancer for men with a suspicious DRE is in accor-
dance with the conclusions of chapter 7, which showed a higher chance to detect prostate 
cancer at initial screening in men with a suspicious DRE biopsied for an elevated PSA (≥3.0 
ng/ml). However, these results concern data from the first screening round of the ERSPC Rot-
terdam and the additional predictive value of an abnormal DRE became less at later screen-
ings, especially in men with a previous biopsy (chapter 7).
Furthermore, the data evaluated for the interobserver variability of DRE (finding a 2.5 times 
increased risk of detecting PC if the DRE was suspicious) are similar to the data analysed by 
the study that concluded that the predictive value of DRE was poor at PSA levels below 4.0 
ng/ml16. Although the risk of detecting PC increases roughly 2.5 times in case of a suspicious 
DRE in the current study, the omission of DRE as a sole indicator for prostate biopsy is still 
justified because of its poor positive predictive value at low PSA levels. Moreover, Bozeman et 
al. showed that DRE is an inferior screening tool for prostate cancer. However, they concluded 
also that an abnormality on DRE in patients diagnosed with prostate cancer was most likely 
to represent cancer and thus, in most patients, cancer was not diagnosed serendipitously170. 
Although not useful as a biopsy indicator on its own, DRE can play a role in the prediction 
of the chance to detect prostate cancer by incorporation in predictive models next to other 
variable such as serum PSA142, 162, 163, 171, 172.
Is Dre seleCtIVe for hIGh-GrADe DIseAse?
Several researchers suggested the use of DRE to screen more selectively in order to lower the 
risk of unnecessary biopsies and overdiagnosis by showing evidence that the rectal examina-
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tion detects aggressive prostate cancers more selectively than PSA-based screening. Borden 
et al. concluded that an abnormal DRE was an independent predictor for high-grade prostate 
cancer on initial biopsy in a referral population61. Others showed that palpable tumours (cT2b) 
were significantly more likely to have a higher Gleason score than non-palpable tumours by 
retrospectively examining radical prostatectomy specimens in referral populations157-159 and 
in a screening cohort47.
Recently, the study group of Catalona has published a paper that stated that a substantial 
proportion of prostate cancers detected by DRE at PSA levels less than 4.0 ng/ml have fea-
tures associated with clinically aggressive tumours63. They suggested that the omission of 
DRE from screening protocols might compromise treatment outcomes as omitting DRE at 
PSA levels less than 3.0 ng/ml would have detected 14% fewer prostate cancers overall and 
7% fewer prostate cancers with a Gleason score of 7 or higher.
Unfortunately, bias in this report does not allow proper comparison with our data. The 
study is based on the data of participants who underwent radical prostatectomy. How did 
this selection influence the outcome? A number of 1,335 screen-detected cancers were not 
radically operated. Within this group, a considerable number could probably have had pal-
pable abnormalities. Moreover, the investigators did not mention how many participants had 
to undergo a biopsy to find the cancers. Next to the bias mentioned above and the fact that 
this study concerns non-randomised volunteers instead of a randomised controlled popula-
tion, another important problem of this report is that the study groups (i.e. prostate cancer 
detected by DRE alone, PSA alone, or by DRE and PSA) included several statistically relevant 
parameters that influenced the chance of detecting prostate cancer or high-grade disease. 
For example, the PSA level was significantly higher in the group with elevated PSA and ab-
normal DRE compared to the group with elevated PSA alone. This likely increased the risk of 
detecting (high-grade) prostate cancer in the first group. Another unexplained issue is the 
reported PPV of an abnormal DRE of 18% in men with PSA levels below 4.0 ng/ml that is in 
sharp contrast to the findings of an earlier report of the same study group13, in which a PPV of 
10% was reported for an abnormal DRE and a PSA level below 4.0 ng/ml.
In line with the findings of the Catalona group, chapter 6 and 7 of this thesis showed that 
DRE seemed to detect high-grade prostate cancers more selectively than screening with a PSA 
cut-off alone. However, the protocol using DRE missed also numerable significant cancers.
DRE as screening tool is not being reconsidered within the ERSPC Rotterdam. An evaluation 
four years after the omission of DRE showed that this did not result in an increased interval 
cancer rate or PC detection at subsequent screening (chapter 5). As mentioned previously, 
this finding was confirmed by the recent paper of Schröder et al.168. Is was shown that, using 
the PSA cut-off 3.0 ng/ml, a very unfavourable number of participants would be needed to 
be biopsied to detect one cancer in the PSA range below 3.0. Together with the low PPV of 
DRE at low PSA levels16, it does not seem necessary to reconsider the renewed use of DRE as 
a biopsy indicator at PSA<3.0.
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the trAnsreCtAl ultrAsounD As A sCreenInG tool
This thesis deals with digital rectal examination. However, within the ERSPC Rotterdam tran-
srectal ultrasound (TRUS) was evaluated and omitted at the same time. The performance 
of DRE and TRUS was similar as illustrated by a study of Rietbergen et al.173. In a study that 
evaluated 3,963 men undergoing a PSA test, a DRE and a TRUS, 173 prostate cancers were 
detected. DRE alone would have diagnosed 47.1% of all cancers and TRUS alone would have 
detected 45.3% of the cancers.
In general, the value of TRUS is considered limited as a screening test for prostate can-
cer9, 11, 55, 56. Defining a lesion suspicious on TRUS is highly investigator-dependent and hy-
poechoic lesions, which are considered suspicious for prostate cancer, are not very specific57. 
Next to hypoechoic lesions, prostate cancers can have iso-echoic or hyperechoic character-
istics58-60.
Nevertheless, TRUS is very useful in performing systematic prostate biopsies. For this rea-
son the TRUS-guided systematic prostate biopsy is the gold standard in obtaining prostatic 
tissue in men indicated for prostate biopsy.
Still, an additional biopsy core is taken if a hypoechoic lesion is visible. If active screening 
for prostate cancer will prove to be beneficial in terms of prostate cancer mortality reduction, 
the first question that arises will be what the appropriate screening algorithm should be.
For this reason we have recently investigated the value of taking an additional hypoechoic 
lesion directed biopsy in addition to a systematic, lateralised, sextant biopsy for the detection 
of prostate cancer150.
The performance of TRUS as a screening tool was poor. The value of the additional biopsy 
core was limited since only 3.5% of the visible cancers were detected solely by the 7th biopsy 
core at first screening. However, a substantial part of these cancers were clinically relevant 
and would have been missed without the additional biopsy. This finding was less clear in 
subsequent screenings (round 2 and 3), even in men who were not previously biopsied. 
Therefore, only in men screened for prostate cancer for the first time, an extra lesion-directed 
biopsy core in addition to the lateralised sextant biopsy is advisable.
further reseArCh
Whether screening for prostate cancer has a beneficial effect on prostate cancer mortality 
will become clear after the completion of the ERSPC and PLCO. At that time the effect of 
having a suspicious DRE on prostate cancer-specific mortality will become clear as well. And 
the question if it was indeed beneficial to omit DRE as a screening test for prostate cancer will 
be answered definitively.
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The genuine performance of DRE at low PSA levels can only be evaluated if all men in this PSA 
range are biopsied as was done in the control arm of the Prostate Cancer Prevention Trial91. 
With the current use of low PSA cut-offs there is a considerable amount of overdiagnosis 
and many unnecessary biopsies are performed. As there are indications that DRE can detect 
significant cancers selectively, the potential usefulness of DRE should be further established. 
Currently, the PCA3 urine test is being evaluated within the ERSPC Rotterdam screening arm 
as an indicator for prostate biopsy, independent of the PSA value. Until now, 85% of the entire 
study group that underwent the PSA and PCA3 test had a biopsy indication, including a large 
number of men with a PSA<3.0 ng/ml. In the near future enough data will be available to 
investigate the selectivity of DRE for significant disease at very low PSA levels in the ERSPC 
Rotterdam.
Another interesting question can be answered with the completion of the PCA3 analysis. As 
explained in chapter 4, prostate cancer prevalence at PSA levels beneath 4.0 ng/ml is lower 
in the ERSPC compared to the PCPT14, 16, 55, 91, 138. However, within our study cohort not every 
participant was biopsied and the results were partially extrapolated. With the completion of 
the PCA3 analysis an improved comparison between ERSPC and PCPT will become possible 
for the prevalence of prostate cancer at low PSA levels and their tumour characteristics.
The development of more selective screening procedures in order to lower the number of un-
necessary biopsies and overdiagnosis has high priority. Targets of future research are promis-
ing molecular markers that selectively detect high-grade disease. But also the development 
of risk calculators65, 66, in which DRE can be incorporated, to predict the chance on significant 
prostate cancer is being investigated. By using a risk calculator, the biopsy indication will be 
defined by a certain chance threshold for having prostate cancer.
If population-based screening for prostate cancer will proof to decrease the number of men 
that die from prostate cancer, the optimal screening algorithm has to be formulated. Next to 
the decision to omit DRE as a screening test, optimal values for the lower and upper age limit, 
the PSA threshold and the screening interval152, 174 have to be defined. Alternatively, a risk 
calculator65, 66 to determine the risk of prostate cancer in an individual can be used. Passing 
a certain risk threshold indicates a prostate biopsy (see www.uroweb.org for the developing 
risk calculator based on ERSPC data).
ConClusIons
From the results combined in this thesis, the following conclusions can be drawn and practi-
cal implications can be given:
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•	 Omitting DRE as a screening test in men with low PSA levels did not lead to missing a 
relevant number of cancers. PSA-based screening with a 3.0 ng/ml cut-off remains ad-
equate.
•	 Choosing a cut-off for PSA-based screening is arbitrary. However, the balance between 
numbers of participants needed to be biopsied to detect one cancer is very unfavour-
able at PSA levels between 2.0 and 3.0 ng/ml. Therefore, a PSA threshold of 2.0 ng/ml is 
not advisable without additional modifications.
•	 At first screening, men with a suspicious DRE are at higher risk of being diagnosed with 
prostate cancer compared to men with a normal DRE.
•	 The additional predictive value of a suspicious DRE for the detection of prostate cancer 
in men with an elevated PSA is lost in previously biopsied men.
•	 At PSA levels above the cut-off value for prostate biopsy, an abnormal DRE increases the 
chance to detect high-grade disease in men undergoing their first or repeat biopsy.
•	 Used as a screening test at low PSA levels DRE however missed a considerable number 
of significant cases, which is unacceptable in a screening situation. Therefore, the use 
of DRE will be predominantly in the setting of risk-calculators, algorithms that calculate 
individual risks of prostate cancer or particularly high-grade disease.
•	 The number of men actively asking for prostate cancer screening increases. Consequent-
ly, the proportion of men with a benign biopsy result and a continuous biopsy indication 
is growing. Biopsy can generally be postponed to a later screening without an important 
chance of missing a significant prostate cancer in men with a previous benign biopsy, an 
elevated PSA and a normal DRE.
•	 In contrast, the initial DRE result in men with a negative biopsy and an elevated PSA at 
first screening is not predictive for diagnosing prostate cancer at subsequent screens.
•	 In case of an initially suspicious DRE result there is no need to shorten the screening 
interval of 4 years.
•	 DRE is a subjective test.
•	 This thesis evaluated the DRE as a screening test, and it was shown that an abnormal DRE 
at low PSA levels led in only 10% to the diagnosis of prostate cancer in a screening set-
ting. However, the unquestionable value of DRE in individual patients in urological daily 
practice is not considered. Every urologist has to keep in mind the exceptional patient 
who presents with a very low PSA value and locally advanced cancer.
Finally, the question that is posed in the title of this thesis should be answered: is DRE out-
dated or still a valuable test? The answer to this question is two-sided.
As a screening test to indicate a prostate biopsy the DRE is outdated. It has been proven 
that DRE has a low PPV at low PSA levels. The trend has been to lower the cut-offs in PSA-
based screening which reduced the domain of DRE to lower PSA ranges and consequently 
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resulted in even lower PPVs. Furthermore, the number of previously biopsied men is increas-
ing, in whom the value of DRE is less clear.
However, DRE is still valuable on a more individual basis when incorporated into algo-
rithms that function as calculators for the risk of finding prostate cancer at biopsy or the risk 
of harbouring significant disease. Instead of performing a biopsy for an elevated PSA level 
or suspicious DRE outcome alone, a risk threshold would form the indication, calculated by 
using several clinical and laboratory variables. For this reason DRE should still be carried out 
in population-based screening programs, but not as a sole indicator of prostate biopsy.
Importantly, we need to await the final conclusions of the ERSPC to evaluate the value of 
DRE in the light of prostate cancer specific mortality.
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Summary
The first part of this thesis includes in short the history of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC, chapter 1) and an introduction (chapter 2) in prostate 
cancer screening in general. The prostate-specific antigen (PSA), corner stone in prostate 
cancer screening, is addressed and its limitations are evaluated. Several suggestions for 
improving screening procedures are mentioned and the potential role of the digital rectal 
examination (DRE) for this purpose is suggested. The scope of this thesis (chapter 3) entails 
the role of DRE in screening for prostate cancer. It aims to evaluate whether the omission of 
the DRE in 1997 in the ERSPC Rotterdam is still justified considering the available data from 
several screenings. Another focus of this thesis is to investigate if DRE is valuable in predict-
ing prostate cancer and, in particular, significant prostate cancer in men who are biopsied for 
an elevated PSA level.
The second part of this thesis deals with prostate cancer screening at low PSA levels and the 
types of cancers that are found in this range. It has been suggested that many prostate can-
cers found at PSA levels ≤4.0 ng/ml resemble autopsy cancers and are potentially indolent 
or insignificant cancers. In chapter 4 the prevalence and tumour characteristics of prostate 
cancers detected in this low PSA range are evaluated by comparing screening studies, cysto-
prostatectomy series and autopsy data. The favourable characteristics of tumours detectable 
at very low PSA levels seem to justify the conclusion that an unknown but sizeable propor-
tion of the cancers found at biopsy are clinically insignificant.
Until May 1997 participants were offered prostate biopsy in case of a PSA value above 4.0 ng/
ml and/or an abnormal result on DRE and/or transrectal ultrasound (TRUS). Later, the screen-
ing protocol was changed and a PSA level of 3.0 ng/ml or higher became the only indication 
for biopsy (PSA-based screening).
The omission of the DRE as a screening tool is evaluated in the third part of this thesis. The 
risk of omitting DRE and TRUS, and therefore the omission of biopsies at PSA<3.0 ng/ml, is 
that potentially aggressive tumours at these low PSA levels remain undetected at screening. 
These can surface as interval cancers, i.e. prostate cancers detected between two screening 
rounds, or as tumours with PSA levels progressed to values above 3.0 ng/ml with possibly 
unfavourable prognostic factors at a subsequent screening.
Chapter 5 compares the prevalence and prognostic factors of tumours found in the sec-
ond screening round of the ERSPC Rotterdam between two groups of men who had initially 
been screened either with DRE and TRUS (group-1) or without these tests (group-2).
Group-1 consisted of 5,957 men and in group-2 8,044 men were included, all participants 
had an initial PSA value ≤3.0 ng/ml. There was no significant difference in second round can-
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cer detection rates, positive predictive values, number of poorly differentiated tumours, and 
number of interval cancers detected.
It can be concluded that omitting DRE and TRUS did not result in an increased interval 
cancer rate or prostate cancer detection and seems therefore justified based on these 4 years 
of follow-up.
Chapter 6: comparison of the cancer detection rates (CDRs) and tumour characteristics 
of screen-detected prostate cancers either by DRE or by PSA as biopsy indication at low PSA 
levels suggests that PSA-based screening should be preferred.
Two populations of men with PSA values between 2.0 and 3.9 ng/ml were studied. Group-1 
(N=1,877) was biopsied if DRE was suspicious. In group-2 (N=801) all men were offered bi-
opsy, regardless of DRE result.
In conclusion, PSA-based screening in the PSA range 2.0-3.0 ng/ml detected 15.2% of po-
tentially aggressive (Gleason score (GS) ≥7) tumours as T1cs, but in addition large numbers 
of possibly insignificant cancers (T1c, GS=6) were diagnosed. DRE seemed to detect more se-
lectively high-grade cancers (46.7% in contrast to 15.0% with PSA-based screening), but also 
missed many of these. Furthermore, PSA-based screening detected more organ-confined 
disease (96.6% versus 77.5% for DRE-based screening).
Considering both populations and the need to detect aggressive but confined disease, PSA 
as biopsy indication outperformed DRE at the price of more biopsies.
The fourth part of the thesis investigates the additional value of DRE in predicting prostate 
cancer and in particular potentially aggressive disease in men who are biopsied for an el-
evated PSA level. DRE is known to be a subjective test. When using DRE as a part of prostate 
cancer screening, it is essential to be informed about the interobserver variability of the test.
Chapter 7 shows that men with an elevated PSA value and an abnormal DRE are at higher 
risk to harbour prostate cancer compared to men with similar PSA levels and a normal DRE. 
The additional value of a suspicious DRE for the detection of PC in men with an elevated PSA 
level in subsequent screenings and the tumour characteristics of PCs detected in men with 
a suspicious DRE were determined. A PSA value ≥3.0 ng/ml prompted a DRE and a TRUS-
guided, lateralised sextant biopsy. In three screens, a total of 5,040 biopsy-sessions were 
evaluated and the positive predictive values (PPVs) of a suspicious DRE and normal DRE were 
compared.
The conclusion was drawn that at initial and subsequent screening, the chance of having 
cancer at biopsy was higher in men with a suspicious DRE compared to men with normal 
DRE (in subsequent screenings to a lesser extent) and the combination of a PSA≥3.0 ng/ml 
with a suspicious DRE resulted in detecting significantly more PCs with a Gleason score of 8 
or higher. A suggestion for the use of DRE in previously biopsied men in subsequent screens 
may be that in case of a normal DRE, biopsy can be postponed to a subsequent visit, without 
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missing a substantial number of potentially aggressive PCs in order to reduce the number of 
unnecessary biopsies and overdiagnosis.
Chapter 8 provides insight in the value of the initial DRE result for the prediction of (sig-
nificant) prostate cancer at later screens. The goal was to investigate whether men with an 
initially suspicious DRE, a PSA≥3.0 ng/ml and a benign prostate biopsy are at higher risk of 
detecting (significant) PC at rescreening than men with an initially normal DRE (and elevated 
PSA and previous biopsy), and whether an adaptation of the rescreening interval is warranted 
for this group. Within the ERSPC Rotterdam 2,218 men were biopsied with benign result at 
initial screening. The serum PSA was 4-yearly determined and a PSA≥3.0 ng/ml prompted a 
DRE and lateralised sextant biopsy. The number and characteristics of PCs found at repeat 
screenings after 4 and 8 years, and as interval cancers were compared between men with 
or without a suspicious DRE result at initial screening. Multivariate-logistic-regression analy-
ses were performed to evaluate if an initially suspicious DRE was a significant predictor for 
detecting cancer at consecutive screens. During the follow-up of 8 years after initial cancer-
negative biopsy, an initially suspicious DRE did not influence the chance to detect cancer or 
significant cancer at later screens. An adaptation of the rescreening interval on the basis of 
the initial DRE outcome is not warranted in future population-based screening for prostate 
cancer.
Since DRE is a subjective test, the interobserver variability must be considered in deter-
mining its value as a screening test. In chapter 9 is analysed to what extent the percentage 
of suspicious DRE findings varies between examiners and to what extent the percentage of 
prostate cancers detected in men with these suspicious findings varies between examiners. 
The variability in DRE outcome and in the risk of prostate cancer in case of an abnormal DRE 
was compared between 6 examiners during the initial screening of the ERSPC by descrip-
tive statistics and multivariate logistic regression analyses. It was confirmed that DRE is a 
subjective test. Three of six examiners considered DRE significantly more often suspicious 
than the others. However, a suspicious DRE executed by each examiner increased the chance 
of the presence of PC similarly, when correcting for the other explanatory variables. It was 
found that DRE increases the odds to detect PC roughly 2.5 times independent of the biopsy 
indication used. This increased chance to find PC was not significantly observer-dependent 
and corroborates the fact that a suspicious DRE is an independent predictor for the presence 
of PC.
The fifth part of this thesis summarises and discusses the previous chapters. These studies are 
put into perspective and related to each other. Practical implications based on the conclu-
sions of this thesis are given (chapter 10).
The DRE has been shown not to be useful as a screening test. It has been proven that DRE 
has a low positive predictive value (PPV) at low PSA levels. The trend has been to lower the 
cut-offs in PSA-based screening, which reduced the domain of DRE to lower PSA ranges and 
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consequently resulted in even lower PPVs. Furthermore, the number of previously biopsied 
men is increasing. In these men the value of DRE is even less clear.
However, DRE is still valuable on a more individual basis when incorporated into algo-
rithms that function as calculators for the risk on prostate cancer or the risk of harbouring 
significant disease. Instead of performing a biopsy for an elevated PSA level or suspicious 
DRE outcome alone, a risk threshold would form the indication, calculated by using several 
clinical and laboratory variables. For this reason DRE should still be carried out in population-
based screening programs, but not as a sole indicator of prostate biopsy.
Importantly, we need to await the final conclusions of the ERSPC to evaluate the value of 
DRE in the light of prostate cancer specific mortality.
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Samenvatting
In het eerste deel van dit proefschrift wordt kort de geschiedenis van de European Rando-
mized Study of Screening for Prostate Cancer (ERSPC) besproken (hoofdstuk 1) en een in-
troductie gegeven in de vroegopsporing van prostaatkanker in het algemeen (hoofdstuk 
2). Het prostaatspecifiek antigeen (PSA) vormt de hoeksteen voor de vroegopsporing van 
prostaatkanker. De voor- en nadelen van het PSA worden belicht en suggesties gegeven voor 
verbetering van vroegopsporingsprogramma’s, waarbij de potentiële rol van het rectaal tou-
cher (DRE) aan de orde komt.
Doelstelling van dit proefschrift (hoofdstuk 3) is het onderzoek naar de rol van het DRE bij 
de vroegopsporing van prostaatkanker. In het bijzonder evalueert dit proefschrift het wegla-
ten van het DRE als screeningstest, zoals dat sinds 1997 in de ERSPC Rotterdam gebeurt, aan 
de hand van de beschikbare data van een aantal opeenvolgende screeningsrondes. Verder 
richt dit proefschrift zich op het onderzoek naar de waarde van het DRE bij het voorspellen 
van de diagnose prostaatkanker en in het bijzonder het voorspellen van significante, poten-
tieel levensbedreigende prostaatkanker bij mannen die gebiopteerd worden vanwege een 
verhoogde PSA-waarde.
Het tweede deel van dit proefschrift gaat over de vroegopsporing van prostaatkanker bij lage 
PSA-waarden en het type kankers dat daarbij ontdekt wordt. In de literatuur is gesuggereerd 
dat vele prostaatkankers bij mannen met lage PSA-waarden (≤4,0 ng/ml) overeenkomsten 
vertonen met de carcinomen in obductiestudies, die beschouwd kunnen worden als potenti-
eel indolente of insignificante tumoren. In hoofdstuk 4 worden de prevalentie en de tumor-
karakteristieken onderzocht van prostaatkankers bij mannen met deze lage PSA-waarden. 
Hiertoe worden vroegopsporingsstudies, cystoprostatectomiestudies en obductiestudies 
vergeleken. De gunstige karakteristieken van de kankers bij zeer lage PSA-waarden lijken de 
conclusie te rechtvaardigen dat een aanzienlijk deel van de kankers die gedetecteerd worden 
door middel van prostaatbiopten klinisch insignificant zijn.
Tot mei 1997 werd de deelnemers van de ERSPC Rotterdam geadviseerd om prostaatbiopten 
te ondergaan, wanneer zij een PSA-waarde van 4,0 ng/ml of hoger hadden en/of wanneer er 
een afwijking werd gevonden bij DRE of bij transrectale echografie (TRUS) van de prostaat. 
Na die tijd werd het screeningsprotocol aangepast. DRE en TRUS werden weggelaten en een 
PSA-waarde van 3,0 ng/ml of hoger werd de enige reden om prostaatbiopten te ondergaan.
Het weglaten van het DRE als screeningstest wordt geëvalueerd in het derde deel van dit 
proefschrift. Het risico van het weglaten van DRE en TRUS uit het screeningsprotocol is dat 
onder een PSA van 3,0 ng/ml geen prostaatbiopten meer worden genomen en dat kan tot 
gevolg hebben dat potentieel agressieve tumoren bij deze lage PSA-waarden onopgemerkt 
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blijven. Deze maligniteiten kunnen op twee manieren toch nog aan het licht komen. De eer-
ste mogelijkheid is dat deze tumoren worden ontdekt als intervalkankers, kankers die tussen 
twee screeningsbezoeken in aan het licht komen, meestal vanwege klinische verschijnselen. 
Ze kunnen daarnaast gediagnosticeerd worden bij een volgend screeningsbezoek vanwege 
een gestegen PSA-waarde (tot boven de afkapwaarde van 3,0 ng/ml) met inmiddels mogelijk 
ongunstige tumorkarakteristieken.
hoofdstuk 5 vergelijkt de prevalentie en de prognostische factoren van tumoren die zijn 
ontdekt tijdens de tweede screeningsronde van de ERSPC Rotterdam bij twee verschillende 
groepen mannen (allen met een eerste PSA-waarde <3.0 ng/ml). Groep 1 werd bij het eerste 
screeningsbezoek volgens het oude protocol door middel van het DRE onderzocht. Groep 
2 werd zonder DRE gescreend. Groep 1 bestond uit 5.957 mannen en groep 2 uit 8.044 
mannen. Er was geen significant verschil in de proportie gedetecteerde kankers, de positief 
voorspellende waarden (PPV), het aantal slecht gedifferentieerde tumoren en de proportie 
intervalkankers.
Het weglaten van het DRE en de TRUS resulteerde niet in een groter aantal intervalkankers 
of prostaatkankers ontdekt bij een later screeningsbezoek. Op basis van de resultaten van 
vier jaar na het eerste screeningsbezoek kan geconcludeerd worden dat het weglaten van 
het DRE gerechtvaardigd is.
hoofdstuk 6: de vergelijking van kankerdetectie en tumorkarakteristieken van kankers 
opgespoord bij lage PSA-waarden suggereert dat vroegopsporing van prostaatkanker op 
basis van de PSA-test de voorkeur heeft boven het DRE als screeningstest.
Twee populaties met PSA-waarden van 2,0-3,9 ng/ml werden bestudeerd, van wie in groep 
1 (N=1.877) mannen een biopt ondergingen in geval van een abnormaal DRE en groep 2 
(N=801) waarin iedereen een biopt onderging (PSA-afkapwaarde 2,0 ng/ml). Screening met 
behulp van de PSA-waarde detecteerde in het PSA-gebied van 2,0-3,9 15,2% potentieel 
agressieve tumoren (Gleason score ≥7) in het T1c-stadium, maar daarbij werd ook een groot 
aantal mogelijk insignificante kankers ontdekt (T1c, Gleason score = 6). Het rectaal toucher 
leek selectiever de hooggradige kankers op te sporen (46,7% vergeleken met 15,0% in het 
geval van de PSA-afkapwaarde van 2,0), maar veel van dit soort tumoren bleef ook onopge-
merkt. Bovendien werden door middel van de PSA-test meer tumoren gevonden die beperkt 
waren tot de prostaat (96.6% versus 77,5% bij de DRE-test).
Met het doel van vroegopsporing van agressieve nog te genezen kankers voor ogen, vol-
deed de PSA-afkapwaarde van 2,0 ng/ml als biopsie-indicatie beter dan het DRE. De prijs 
hiervoor was het nemen van meer biopten.
Het vierde deel van dit proefschrift onderzoekt de toegevoegde waarde van het DRE bij het 
voorspellen van het risico van prostaatkanker - in het bijzonder dat van potentieel agressieve 
tumoren bij mannen die worden gebiopteerd vanwege een verhoogde PSA-waarde. Het DRE 
staat bekend als subjectieve test. Wanneer DRE als onderdeel van de vroegopsporing van 
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prostaatkanker wordt gebruikt, is het van belang om informatie te geven over de verschillen 
tussen onderzoekers die de test uitvoeren.
hoofdstuk 7 laat zien dat mannen met een verhoogde PSA-waarde en een verdacht DRE 
een hoger risico hebben op het krijgen van prostaatkanker dan mannen met een vergelijkbaar 
PSA en een normaal DRE. De toegevoegde waarde van een verdacht DRE bij de betreffende 
groep mannen voor het opsporen van prostaatkanker in volgende screeningsrondes werd 
duidelijk, evenals de tumorkarakteristieken van de kankers die gevonden werden bij man-
nen met een verdacht DRE. Een PSA-waarde ≥3,0 ng/ml vormde de indicatie om een rectaal 
toucher en prostaatbiopten te ondergaan. Gedurende drie screeningsrondes werden 5.040 
biopsieprocedures geëvolueerd en werden de PPV’s van een verdacht en een normaal DRE 
bepaald. De conclusie was dat de kans op het hebben van prostaatkanker hoger is bij mannen 
met een verdacht DRE dan bij mannen met een normaal DRE in de eerste screeningsronde 
en, in mindere mate, in de rondes daarna. De combinatie van een verhoogd PSA (≥3,0 ng/
ml) en een verdacht DRE resulteerde in de opsporing van significant meer prostaatkankers 
met een Gleason score van 8 of hoger. Op basis van deze resultaten is het mogelijk om met 
behulp van het DRE de screeningsprocedure aan te passen voor mannen met een verhoogd 
PSA en een eerdere goedaardige biopsie-uitslag. De reden om de screeningsprocedure aan 
te passen is het verminderen van het aantal onnodige biopsieprocedures en zogeheten over-
diagnose. In het geval van een normaal DRE bij deze groep mannen kan een biopsie worden 
uitgesteld tot een volgende screeningsronde zonder het risico om een substantieel aantal 
potentieel agressieve kankers te missen.
hoofdstuk 8 geeft inzicht in de waarde van het DRE-resultaat tijdens het eerste scree-
ningsbezoek voor het voorspellen van de diagnose (significante) prostaatkanker in latere 
screeningsrondes. Het doel was om te onderzoeken of mannen met een initieel verdacht DRE, 
een PSA≥3,0 ng/ml en een benigne biopsie-uitslag een hoger risico hebben op het vinden 
van een (significante) kanker in een volgende ronde en of om die reden de tijd tussen twee 
screeningsrondes aanpassing behoeft voor hen. Binnen de ERSPC Rotterdam werden 2.218 
mannen gebiopteerd met een goedaardige uitslag in de eerste screeningsronde. De PSA-
waarde werd elke vier jaar bepaald en een waarde ≥3,0 ng/ml vormde een biopsie-indicatie. 
Het aantal kankers, met hun karakteristieken, gevonden in volgende rondes (na vier en acht 
jaar) werd vergeleken tussen mannen met een verdacht en een normaal eerste DRE. Ook het 
aantal intervalkankers werd vergeleken. Met behulp van multivariate logistische regressie-
analyses vond een evaluatie plaats over de vraag of een initieel verdacht DRE een significante 
voorspeller is voor het ontdekken van kanker bij latere screeningsronden.
Een initieel verdacht DRE bleek de kans op het detecteren van prostaatkanker of signifi-
cante prostaatkanker bij latere rondes niet te beïnvloeden gedurende een follow-up van acht 
jaar na de eerste, goedaardige biopsieuitslag. De tijd tussen twee screeningsrondes behoeft 
om deze reden dan ook geen aanpassing vanwege een initieel verdachte uitslag van het 
DRE.
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DRE is een subjectieve test. De variabiliteit tussen onderzoekers die een rectaal tou-
cher uitvoeren, moet overwogen worden bij het bepalen van de waarde van het DRE als 
screeningstest. hoofdstuk 9 onderzoekt in welke mate de proportie verdacht afgegeven 
prostaten varieert tussen onderzoekers en hoeveel verschil er zit in de proportie prostaat-
kankers die ontdekt wordt, indien een onderzoeker het DRE als afwijkend beschouwt. De 
variabiliteit in DRE-resultaat en in het risico van prostaatkanker bij een verdacht resultaat 
werd bepaald voor zes onderzoekers tijdens de eerste ronde van de ERSPC Rotterdam met 
behulp van beschrijvende data en multivariate logistische regressie. Bevestigd werd dat DRE 
een subjectieve test is. Drie van de zes onderzoekers beschouwden het DRE significant vaker 
afwijkend. Een verdacht DRE verhoogde de kans op kanker echter op eenzelfde manier bij 
iedere onderzoeker, wanneer werd gecorrigeerd op overige factoren die van invloed zijn op 
de detectiekans van prostaatkanker. Het DRE verhoogde de odds om kanker op te sporen 2,5 
keer, onafhankelijk van de gebruikte biopsie-indicatie. Deze verhoogde kans om prostaat-
kanker te vinden was niet significant afhankelijk van de onderzoeker die het DRE uitvoerde. 
Hiermee wordt het feit bevestigd dat een verdacht DRE een onafhankelijke voorspeller is 
voor de aanwezigheid van prostaatkanker.
Het vijfde deel van dit proefschrift vat voorgaande hoofdstukken samen. Deze onderzoeken 
worden in een breder perspectief bediscussieerd en aan elkaar gerelateerd. Praktische impli-
caties gebaseerd op de conclusies van het proefschrift komen aan de orde.
Het is aangetoond dat het gebruik van DRE als screeningstest niet nuttig is. Uit literatuur 
blijkt dat het DRE een lage PPV heeft bij lage PSA. De trend om de PSA-afkapwaarden te ver-
lagen beperkt het domein van DRE tot nog lagere PSA-waarden met lagere PPV’s. Bovendien 
groeit het aantal mannen die eerder gebiopteerd zijn. Bij hen is de waarde van het DRE zelfs 
nog onduidelijker.
DRE is echter wel waardevol op een meer individuele manier. Het DRE kan samen met 
andere klinische en laboratoriumvariabelen worden ingebouwd in algoritmes die de kans op 
prostaatkanker of significante prostaatkanker kunnen berekenen. In plaats van het uitvoeren 
van prostaatbiopten op indicatie van een PSA-afkapwaarde of een abnormaal DRE-resultaat 
vormt een bepaalde kans op kanker de reden om biopten te ondergaan. Hierom zou het DRE 
op deze manier moeten worden uitgevoerd in een bevolkingsonderzoek voor prostaatkan-
ker.
Het is belangrijk om de uiteindelijke resultaten van de ERSPC af te wachten om definitief de 
waarde van het DRE te kunnen bepalen in het licht van prostaatkankerspecifieke mortaliteit.
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Dankwoord
Een promotie is iets onwerkelijks totdat het boekje daadwerkelijk voor je ligt. En dan nog 
voelt het surreëel. Op de weg ernaartoe heb ik met plezier onderzoek gedaan, maar ben ik 
ook de nodige hobbels tegengekomen. Gelukkig heb ik het doel bereikt en rest mij alleen 
nog iedereen te bedanken die mij heeft geholpen dit proefschrift tot stand te brengen.
Beste professor Schröder, u wil ik bedanken voor de mogelijkheid bij u en de ERSPC, begrip-
pen op het gebied van prostaatkanker, te promoveren. Ik sta versteld van uw urologische 
kennis en kunde. Ik ben heel blij dat ik u dit boekje kan overhandigen. Des te meer omdat u 
de realisatie van mijn proefschrift somber inzag: een promovenda die snel achter elkaar twee 
kinderen krijgt en ook nog eens parttime gaat werken…
Monique, mijn begeleider, mijn vaste co-auteur en mijn co-promotor. Bedankt voor alles: 
voor het wegwijs maken in de ERSPC en het screeningsbureau, voor je ideeën, je raad en 
daad. Je bent een vrouw van weinig woorden, maar dat je me altijd duidelijk hebt gemaakt in 
mijn promotie te geloven, heeft me veel steun gegeven.
De overige leden van de kleine commissie, professor Bangma, professor Horenblas en profes-
sor Assendelft wil ik bedanken voor hun beoordeling van het manuscript en voor het zitting 
nemen in de kleine commissie.
De kleine commissie wordt aangevuld met doctor van Moorselaar, John Rietbergen en Harry 
de Koning. Heel hartelijk dank voor het zitting nemen in de commissie.
Natuurlijk wil ik de mannen bedanken die deelnamen aan het screeningsonderzoek. Het wa-
ren er velen: vriendelijk of nors, grappig of serieus, zenuwachtig of zelfverzekerd, oud of nog 
ouder, enthousiast of timide, havenarbeider of geleerde, BN-er of gewone Rotterdammer. 
Allen waren persoonlijk overtuigd van de zin van hun deelname aan het onderzoek.
Stijn, jij bent het langst mijn kamermaatje geweest. We hebben samen heel wat ‘hoge toppen 
en diepe dalen’ (citaat dr. Roemeling) van het wetenschappelijk onderzoek beleefd. Gelukkig 
was het in ieder geval gezellig en waren we meestal vol goede moed. Dank!
Stijn de Vries, Tineke en Roderick: mijn andere, directe collega-promovendi. Bedankt voor 
de goede sfeer die er met jullie was. Geintjes, goede gesprekken, koffietjes, kletspraatjes en 
gezelligheid zijn zoooo belangrijk ter afwisseling van de spreekuren en het denkwerk!
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Bedankt ook, Ries, voor het meedenken en filosoferen. Jouw inzichten zijn verfrissend en 
vaak verrassend!
Alle overige co-auteurs, dankjewel voor jullie bijdrage aan mijn papers.
Lakshmi, Conja, Marlies, Bianca, Naomi, Maaike, Ellen van den Berg en Monique van der Linde, 
jullie wil ik graag bedanken voor al het werk op het screeningsbureau. En Lakshmi, veel dank 
voor het assisteren van de screeningsspreekuren. Fijn dat jullie mijn collega’s waren.
En nu mijn paranimfen, Tineke en Pauline.
Tien, de vele gesprekken, over koetjes en kalfjes, maar ook diepzinnig, en de raad en daad 
van jou tijdens het werk en onderzoek waren nuttig en fijn. Succes met je eigen promotie, die 
vast niet lang meer op zich laat wachten.
Plien, we begonnen onze studie en carrière samen in Leiden, waar jij me wegwijs maakte 
bij Biomedische Wetenschappen (welke microscoop heb je eigenlijk nodig?). Naast een hele 
lieve vriendin ben je mijn sportmaatje en volgen we nu beiden de opleiding waar we erg 
gelukkig van worden: de opleiding tot huisarts! Dankjewel dat je me bij wilt staan bij de 
verdediging van mijn proefschrift.
Dankjewel voor al jullie inhoudelijke, praktische en psychische steun! Ik ben blij dat jullie 
naast mij staan op 5 november.
Lieve vrienden en vriendinnen, bedankt voor de gezelligheid, de afleiding, het oppassen, 
en, Annelies en Edu, voor de zolder waar ik rustig kon werken. Fijn dat jullie begrepen dat ik 
het druk had en tijdelijk minder tijd voor afspraken, wandelingen op het strand, etentjes en 
sport. Gelukkig kan dat nu weer volop!
Het belangrijkst van allen die mij hielpen bij de verwezenlijking van mijn proefschrift is mijn 
familie. Door een liefdevolle basis en een gelukkig leven kun je namelijk bergen verzetten!
Lieve mam, Oop en Oom bedankt voor het veilige, warme nest dat jullie me gaven, waar ik 
nog steeds met zeer grote regelmaat land en vertoef met mijn eigen kuikens en met Jor. Jullie 
hebben me altijd gesteund en gestimuleerd in wat ik doe, en wil doen.
Lieve pap, het is zo fijn dat je me steeds goede moed ingesproken hebt op de momenten 
dat ik dat echt even nodig had.
Lieve Frans en Mir, bedankt voor jullie warmte, interesse en goede raadgevingen voor het 
tot stand komen van dit boekje.
Lieve Jor, grote liefde van me, ik ben heel blij dat het gelukt is om mijn proefschrift te verwe-
zenlijken. Bedankt voor het motiveren en faciliteren. Zonder jou was het niet gelukt. Ik ben 
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er erg trots op dat ik dit boekje geschreven heb in deze drukke periode van ons leven. Het 
valt echter compleet in het niet bij de komst van Wies en Pelle die geboren zijn in dezelfde 
periode. Ze zijn onze liefste schatten en bronnetjes van intens geluk. Ik ben erg gelukkig met, 
en door jullie.
Door het geluk en de liefde binnen ons gezin kon ik de promotiestress altijd makkelijk re-
lativeren en werd ik erg goed in het overschakelen van een ingewikkelde statistische kwestie 
naar een vuile broek of hongerige baby. Ik ben van mening dat een beetje afleiding alleen 
maar een goede invloed heeft op het verloop van denkprocessen.
Claartje Gosselaar, 2008
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